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Abstract 
Natural product derived nanotherapeutics  are currently in the lime light of cancer research, due 
to their enhanced multifunctional therapeutic abilities, in terms of target specific drug delivery by 
utilization of aptamers, locked nucleic acid conjugates and also imaging strategies such as 
magnetic resonance imaging, positron emission tomography. Published findings from our 
laboratory demonstrated that iron saturated bovine lactoferrin (FebLf) and polymeric based 
calcium phosphate nanocarriers encapsulated with FebLf showed significant in vitro and in vivo 
anti - tumour activity in colon and breast cancer models. The present study aimed at development 
of multimodal iron saturated lactoferrin (FebLf) Nanocapsules (FebLf NCs) and evaluation of 
anti - cancer abilities in an in vitro (breast cancer - MDA-MB-231) and in vivo (colon cancer ± 
Caco2 and breast cancer - MDA-MB-231) human xenograft cancer models. Physical 
characterisation of nanocapsules: scanning electron microscopic observations confirmed a 
consistent size range of 60 to 80 nm with spherical morphology. Fourier transform infrared 
spectrum and x-ray diffraction studies indicated characteristic peaks for lactoferrin (NH3 and OH 
bonding patterns) in FebLf NCs. FebLf NCs magnetometric analysis demonstrated 
superparamagnetic behaviour in the range of 60 emu/g saturation magnetization. In vitro studies: 
Immunocytochemistry observations confirmed successful cellular localisation and 80 - 90% of 
cellular internalisation was observed within one hour duration as revealed in confocal 
microscopic observations(p<0.005). Cellular internalisation of  FebLf NCs was observed  in a 
time dependent manner  at 12, 24 and 48 hours was receptor mediated via lactoferrin (Lf), 
transferrin (TFR, TFR 1, TFR 2), low density lipoprotein receptor-related protein (LRP 1 and 
LRP 2), divalent metal transporter 1 (DMT 1), ferroportin, ferritin receptors (p<0.005) as 
observed in quantitative real time polymerase chain reaction (qRT PCR) analysis. Apoptotic 
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
mechanism of action of FebLf NCs involved down regulation of anti - apoptotic signalling 
molecules - survivin, livin, phosphatidylinositol 3-kinase (PI3K)) pathway (p<0.005). 
Furthermore, a decrease in mitochondrial potential (p<0.005) was noted and caused cytochrome 
C (p<0.005) release. In vivo studies: In vivo nude mice (Balb C nu/nu) breast and colon cancer 
human xenograft model studies revealed excellent biocompatibility of FebLf NCs, when 
administered via oral route and tumour reduction was observed over a time period of 90 days. 
Haematoxylin and eosin staining showed no toxicity of FebLf NCs in the mice tissues. In vivo 
internalisation of FebLf NCs was mediated by following receptors - lactoferrin (Lf), transferrin 
(TFR, TFR 1, TFR 2), low density lipoprotein receptor-related protein (LRP 1 and LRP 2), 
divalent metal transporter 1 (DMT 1), ferroportin, ferritin receptors (p<0.005). Further, Near 
infrared fluorescence live mice imaging studies showed selective localisation of FebLf NCs at 
tumour site and reduction in tumour was estimated in terms of radiant efficiency and area of the 
fluorescent signal obtained.  In the light of current observations, future directions of the study 
includes uncovering multimodal imaging abilities by employing imaging techniques such as 
magnetic resonance and fluorescence based multimodal imaging strategies to uncover 
multifunctional ability of FebLf NCs nanoformulation. 
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ApobLf = Apo lactoferrin (iron free form) 
 
B 
BBB = Blood brain barrier 
bLf = Bovine lactoferrin 
C 
CDK4 = Cyclin dependent kinase 4  
CD2 = Cluster of differentiation 2 
CDK = Cyclin dependent kinases 
CML = Chronic myelogenous (or myeloid) leukaemia 
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CD28 = Cluster of differentiation 28  
CTLs = Cytotoxic T cells 
CTCL = Cutaneous T-cell lymphoma 
Cyt C = Cytochrome C 
Chk2 = Check point kinase 2 
CDF -1 = Cycle dependent factor 1 
D 
DLS = Dynamic light scattering spectroscopy 
DC = Dendritic cells 
DMEM = Dulbecco's modified eagle medium 
DMT 1 = Divalent metal ion transporter protein 1 
E 
EGFR= Epidermal growth factor receptor 
ErbB2 = Erythroblastic leukaemia viral oncogene homolog 2  
EPCAM = Epithelial cell adhesion molecule 
F 
FebLf = Iron saturated lactoferrin 
FTIR = Fourier transformed infrared spectroscopic analysis 
FSH = Follicle stimulating hormone 
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FTS = Farnesylthiosalicylic acid 
FAK = Focal adhesion kinase 
FBS = Fetal bovine serum 
G 
GM-CSF = Granulocyte macrophage±colony-stimulating factor 
GTP = Guanosine-5'-triphosphate 
GrB = Granzyme B 
GA = Geldanamycin 
 
H 
HSP90 = Heat shock protein 90  
HIF-Į = Hypoxia-inducible factor-1Į 
HREs = Hypoxia responsive elements 
HER2 = Human epidermal growth factor receptor 2 
HL = Hodgkin lymphoma 
HNSCC = Head and neck squamous cell carcinoma 
hTERT = Human telomerase reverse transcriptase 
HDAC = Histone deacetylases 
HLA = Human leukocyte antigen 
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HRPC = Human refractory prostate cancer cell 
I 
IAP = Inhibitor of apoptosis 
INCENP = Interacting subunits inner centromere protein 
Id1 = Inhibitor of differentiation 1 
IR =Infrared 
IGFR = Insulin growth factor receptor 
K 
kBr = Potassium bromide 
L 
LPD = Liposome polycation 
LNA = Locked nucleic acid 
LRP = Lipoprotein polysaccharide receptors 
Lf = Lactoferrin 
M 
mTOR = Mammalian target of rapamycin 
MEK = Mitogen-activated protein kinase 
MGMT = Methyl guanine methyl transferase 
MAPK = Mitogen activated protein kinase activation 
MRI = Magnetic resonance imaging 
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mdRNA = Meroduplex ribonucleic acid molecule 
MTD = Maximum tolerated dose 
N 
NF- Nȕ = Nuclear factor kappa-lightchain-enhancer of activated B cells 
NH2SiNPs = Amino silica nanoparticles 
NP = Nanoparticle 
NO = Nitric oxide 
NSLC = Non-small lung cancer  
NTA = Nitrilotriacetate acid disodium salt 
NK = Natural killer 
O 
ODN = Oligonucleotides 
P 
PI3K = Phosphatidylinositol 3-kinase 
PTEN = Potential tumour suppressor gene 
PPAR-g = Peroxisome proliferator activated receptor ± g 
PEDF = Pigment epithelium derived factor   
PPP = Picropodophyllin 
PET = Positron emission tomograpy  
PDT = Photodynamic laser therapy 
PI = Propidium iodide 
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Q 
qRTPCR = Quantitative real time polymerase chain reaction analysis 
R 
RNAi = RNA interefence 
RTK = Receptor tyrosine kinase  
Rb = Retinoblastoma 
RT ± PCR = Reverse transcriptase polymerase chain reaction 
REG = Regenerating gene 
RPMI = Roswell park memorial institute 
ROS = Reactive oxygen species 
S 
SEM = Scanning electron microscopy analysis 
shRNA = Short hairpin RNA 
STAT = Signal transducer and activator of transcription 
Src = Sarcoma gene 
SP = Specificity proteins 
SIP1 = Survivin interacting proteins 1 
SPECT = Single photon emission computed tomography 
SPIONS = Super paramagnetic iron oxide nanoparticles 
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T 
TRAIL = Tumor necrosis factor-related apoptosis-inducing ligand 
TNF-Į  7XPRUQHFURVLVIDFWRUĮ 
TGZ = Troglitazone 
TPR1 = Tetratricopeptide repeat 1 
TNFR = Tumor necrosis factor receptor 
TFR = Transferrin receptor  
V 
VEGF = Vascular endothelial growth factor 
 
W 
Wnt = Wingless and int homologue 
X 
XRD = X - ray diffraction analysis 
Y 
Y2H = Yeast - two ± hybrid 
Z 
ZFP = Zinc finger proteins 
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Chapter 1: Introduction  
1.1 Background and significance of the proposed study 
Cancer is caused due to uncontrolled growth patterns of the normal cells, resulting in abnormal 
proliferation, resulting in the disease(Kanwar, Kamalapuram & Kanwar 2011a). Current focus of 
the research has been  critical to understand the increasing ways of the tumour cells to hinder 
currents therapeutic drugs and thereby leading to tumour drug resistance(Kanwar et al. 2012a). 
The most common way to combact cancer is by utilising conventional chemotherapeutic, 
immunological based and radio resistance therapies for management of cancer(Kanwar, 
Mahidhara & Kanwar 2011c). The above mentioned therapeutic regimes have been administered 
to patients as a single regime or in a combinatorial therapy(Kanwar et al. 2012b). Nevertheless, 
the evolving cancer cell signalling mechanism have viciously designed themselves to remain 
untouched by the conventional treatments, causing cancer progression (Yang et al. 2009). The 
most promising tool for the devising of novel cancer therapeutics is by utilising of 
nanotechnological based platforms(Kanwar 2012). These platforms utilising the concepts of 
nanotechnology based concepts for fabrication of new drugs and can be targeted with utmost 
precision at the tumour site(Kanwar et al. 2012a). The science dealing with the nanotechnology 
based drug formulations for the medical field is aptly termed as nanomedicine(Baratchi et al. 
2009a). The most advanced and upcoming development in the field of of nanomedicine is the 
multifunctional nanomedicine based drugs(Wong, Wu & Bendayan 2012). These multifunctional 
nanomedicines are aptly designed to target the tumour site with the molecular precision (Kanwar, 
Roy & Kanwar 2011b). The breakthroughs of the medicine and biology such as RNA interefence 
mediated technology, microRNA technology, aptamer technology and nanobody based platforms 
ϯ

have been utilised for improvement of current exisiting nanobased drug delivery concepts, that 
help these nanomedicines to selectively target the tumour area, rendering the whole body devoid 
of the drug. This form of drug delivery is most promising as it enables very less toxicity for the 
human body by exact drug targeting (Soundararajan Vijayarathna et al. 2014) (Kanwar, 
Mahidhara & Kanwar 2011c).  
Another significant milestones in the field of drug discovery has been the thirst of scientists in 
search of natural product derived medicines that can offer exceptional therapeutic benefits when 
compared to chemo and radio therapeutic drugs(Kanwar et al. 2008a). The most important 
natural products identified are lactoferrin, curcumin, neem and herbal drug compounds. The 
above mentioned molecules have shown their exceptional capability in regressing the tumour 
growth and most interestingly these compounds showed nil cytotoxicity, remarkable tumour 
growth inhibition mechanisms and they also help in the boosting of natural immune defense 
mechanisms(Kanwar et al. 2008a). Current focus of the project work has been to develop 
lactoferrin based multifunctional nanomedicine drugs that can be utilised for cancer imaging and 
therapy. Lactoferrin is a well known multifunctional therapeutic molecule offering exceptional 
multimodal therapeutic benefits such as selective targeting of cancer cell and stem cell growth 
signalling mechanisms, activating the immune cells such as interleukins, cytokines and 
macrophages, which inturn help in combating cancer cell growth(Kanwar, Mahidhara & Kanwar 
2012b; Kanwar et al. 2008a). Keeping in mind the myriad of therapeutic possibilities offered by 
lactoferrin, the project was designed for fabrication of multifunctional iron saturated lactoferrin 
nanocapsules for cancer imaging and therapy.   
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1.2  Project hypothesis  
The project work deals with the development of lactoferrin based nanotherapeutics for targeted 
cancer therapy and imaging application. Lactoferrin, a multifunctional therapeutic molecule 
extensively characterized at our laboratory is well known for its myriad of therapeutic properties 
including anticancer, antimicrobial, antiviral, antifungal and modulates human immune 
system(Kanwar et al. 2008a). Lactoferrin molecule has the property to bind to the iron molecules 
at the C and N terminal of its globular structural confirmation. Iron binding capacity of 
lactoferrin helps to accelerate its anticancer therapeutic ability(Kanwar et al. 2008a). 100% iron 
saturated lactoferrin (FebLf) prepared at our laboratory was found to have a promising anticancer 
action by modulation of critical apoptotic signalling mechanisms including survivin, PI3K, AKT 
and MAPK pathways(Kanwar et al. 2012b; Varadhachary et al. 2004). Furthermore, FebLf 
exerted its functional activation of immune system cells that in turn help to combat cancer by 
promoting accelerating production of interleukins, cytokines and recruitment of macrophages at 
the tumour site(Kanwar et al. 2008a). FebLf enclosed ceramic nanodrug formulations showed 
promising in vivo anticancer activity with improved half life of drug, sustained release over time 
period leading to prolonged drug action in both colon and breast human xenograft 
models(Kanwar, Mahidhara & Kanwar 2012b).  
Hypothesis: The alginate coated chitosan nanogel encapsulated FebLf nanocapsules (FebLf NCs) 
would exhibit anti tumour efficacy in both in vitro and in vivo human colon and breast cancer 
xenograft models. FebLf NCs would also act as multimodal therapeutic imaging agent by laser 
based fluorescence imaging technology, thereby acting as a multivariant nanotheranostic agent 
for simultaneous drug delivery and disease monitoring in in vivo conditions. Research question: 
(a) To unravel the in vitro and in vivo antitumour efficacy of multimodal FebLf NCs 
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
nanocapsules in human breast (MDA-MB-231) and colon (Caco2) cancer models.(b) To monitor 
nanotheranostic ability of multimodal FebLf NCs by employing near infrared flouroscence live 
mice imaging and cancer therapy.         
1.3 Project aims and objectives 
The main objective of the project work is to develop nanoformulated encapsulated iron saturated 
bovine lactoferrin for antitumour activities in oral feeding experiments: 
x Fabrication of alginate coated chitosan nanogel encapsulated iron saturated lactoferrin 
nanocapsules (FebLf NCs), physiochemical characterisation of nanodrug.  
x Evaluation of cellular and molecular biology functions in an in vitro breast cancer 
(MDA-MB-231) model and study the cellular internalisation mechanisms, cytotoxic 
action in 2D and 3D cancer cell model.  
x Investigate the ex vivo mice intestinal loop assay to understand the biocompatibility, 
intestinal transport mechanism and absorption patterns. These studies aimed to prospect 
the iron saturated lactoferrin as an oral anticancer nanotherapeutic. 
x Investigate the antitumour efficacy of FebLf NCs in in vivo human xenograft breast and 
colon cancer models and real time imaging in live mice by fluorescence imaging strategy 
to monitor the drug localisation, disease condition over a time period.  




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Chapter 2: Literature Review 
2.1 Bovine lactoferrin (bLf): a multifunctional therapeutic molecule 
Introduction and functional role of lactoferrin: Lactoferrin, a naturally derived multifunctional 
molecule from milk components, is currently in the lime light of anti cancer research(Kanwar et 
al. 2008a). Lactoferrin is well known to have prominent anticancer, antimicrobial, antifungal and 
antiviral therapeutic properties, along with immunomodulatory functions(Gibbons, Kanwar & 
Kanwar 2011). Immunomodulatory capability of lactoferrin is manifested by its ability to 
activate various immune cells including natural killer (NK) cells, T lymphocytes, monocytes, 
macrophages, cytokines(Kim et al. 2012a). Anti apoptotic signalling mechanisms of lactoferrin is 
mediated via upregulation of caspase (3 & 8) signalling cascades, pro-apoptotic molecules ± 
BCL2, BAX and Bid. Studies revealed lactoferrin abrogated growth factors including vascular 
endothelial growth factor (VEGF), fibroblast growth factor (FGF), etc signalling mechanisms, 
thereby blocking growth factor mediated tumourigenesis(Gibbons, Kanwar & Kanwar 2011).   
Cellular internalisation mechanisms of lactoferrin: Lactoferrin employs vivid internalisation 
mechanisms majorly through the receptor mediated endocytosis. An array of receptors including 
± Lf, LRP1, LRP2, TFR, TFR1,TFR2, DMT-1, ferroportin, ferritin ± heavy chain, and ferritin 
light chain are known to play a crucial role in transhipping of lactoferrin across cell 
membrane(Grey et al. 2004; Herbison et al. 2009). Lactoferrin has remarkable iron binding 
ability in its structural confirmation at C and N terminal ends, hence, transforming itself into iron 
saturated lactoferrin, expressing promising therapeutic efficacies. Due to the presence of  iron 
component in its structural confirmation, lactoferrin plays a critical role in maintaining iron 
metabolism and homeostasis in the body(Latorre et al. 2010). Therefore, iron specific receptors, 
metal ion transporter proteins involve critically in transcytosing iron across the cell membrane. 
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Due to enhanced internalisation mechanisms involving membrane receptors, lactoferrin 
pronouncingly expresses its anti-apoptotic ability and immunomodulation effect, thereby 
promoting itself as multifunctional therapeutic molecule(Theurl et al. 2009).      
 
 
Figure 2.1 Schematic illustration of structure of lactoferrin molecule. The diagrammatic 
representation shows the N and C terminal globular lobes of lactoferrin molecule with ĮKHOL[
DQG ȕ VKHHW GRPDLQV. Iron binding sites (Fe3+) are represented as red dots in the pocket like 
configuration in the deep cleft located in N and C terminal lobes (Reference: Baker et al 2009). 
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Lactoferrin targeting cancer signaling and cancer stem cell signaling mechanisms: Lactoferrin is 
known for its ability to critically modulate stem cell mechanisms and plays a key role in shunting 
the nodal stem cell signaling molecules leading to angiogenic inhibition. Studies conducted at 
our laboratory confirmed the prominent anti stem cell signaling role of iron saturated lactoferrin 
(FebLf) via downregulation of CD44, CD133, CD166 stem cell markers in colon cancer model. 
Furthermore, FebLf inhibited EPCAM and survivin expression, these observations warrant the 
metastatic inhibition capability of iron saturated lactoferrin, as EPCAM and survivin are nodal 
molecules in promoting metastasis. Hence, these promising findings confirm the stem cell 
growth and metastatic inhibition ability of iron saturated lactoferrin(Kanwar et al. 2014).  Anti 
metastatic ability of lactoferrin was studied in athymic mice (Balb/c strain) bearing metastatic 
colon carcinoma (Co 26Lu). Investigations showed lactoferrin induced enhanced CD8+ cell 
expression in combination with anti-asialo GM1 antibody treatment leading to inhibition of lung 
metastasis(Iigo et al. 1999). Studies were conducted to decipher lactoferrin mediated apoptosis in 
leukemia. Results confirmed c-Jun N-terminal kinase (JNK) mediated apoptosis mechanism via 
regulation of ERK pathway, further leading to activation of caspase - 3 and caspase ± 9(Lee et al. 
2009). Immunological mediated anticancer activity of lactoferrin was noted with oral 
administration of lactoferrin in association with cis-platinum chemotherapeutic regime. 
Lactoferrin induced increased production of interleukin - 18 in the intestinal enterocytic cells, 
enhanced NK cell activity and circulating CD8+ T cells against squamous cell carcinoma and 
mammary adenocarcinoma (Varadhachary et al. 2004). In vivo studies were conducted in 
azoxymethane (AOM) - induced colon cancer tumours. Investigations showed an increase in Fas 
ligand, Bax upregulation mediated antitumour action of lactoferrin, triggering inhibition of rat 
colonic tumour growth(Fujita et al. 2004). Cellular internalisation mechanism of lactoferrin via 
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clathrin-mediated endocytosis was examined in colon cancer cells (Caco2).Research findings 
showed prominent role of lactoferrin receptor signalling mediated via ERK pathway(Jiang et al. 
2011). Lactoferrin, a prominent inflammatory biomarker is studied for its combinatorial 
therapuetic effects with oxaliplatin in colorectal cancer. Research findings confirmed 
upregulation of lactoferrin and c-reactive protein expression levels leading to growth inhibition 
in response to oxaliplatin treatment delivered via polymeric chitosan/alginate 
microspheres(Urbanska et al. 2012). Antitumour property of novel lactoferrin peptide 
(RRWQWR) delivered by liposomes to Jurkat T-leukemia cells was investigated. Observations 
proved that anticancer nature of novel lactoferrin peptide was mediated by modulation of 
cathepsin B and caspase signalling mechanism (Richardson et al. 2009). Immunological 
retaliative property of lactoferrin was studied in erythroleukemia. Findings showed that 
lactoferrin critically modulated Ik-ȕ VLJQDOOLQJ PHFKDQLVPV OHDGLQJ WR HQKDQFHG % FHOO
proliferation (Kim, Chang & Kim 2011). Studies were conducted in in vivo mice model with 
EMT6 breast cancer to understand the apoptosis mechanism of human lactoferrin. Results 
showed that lactoferrin triggered downregulation of Bcl2, causing mitochondrial apoptosis 
leading to upregulation of Bax and caspase-3 signalling mechanism (Wang et al. 2011). Anti-
inflammatory property of human lactoferrin was investigated in human umbilical endothelial 
cells (HUVECs). Lactoferrin triggered transcriptional downregulation of TNF - Į mediated 
intercellular adhesion molecule - 1 (ICAM-1) expression, further, leading to inhibition of NF-Nȕ
binding to ICAM-1 (Kim et al. 2012a). Experimental investigations showed the critical role of 
lactoferrin mediated cell growth inhibition via nuclear accumulation of SMAD-2 in human 
epithelial cancer cell line HeLa (Zemann et al. 2010). 
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2.2. Overview of cancer growth mechanisms and therapeutic approaches 
2.2.1 Introduction 
Member of inhibitor of apoptosis proteins are critically involved in both cell division and 
apoptosis suppression (Cheung et al. 2010a; Johnson & Howerth 2004; Kanwar et al. 2001). 
Regulation of anti apoptotic genes (survivin etc) is very complex involving multiple key cell 
signalling pathways at both transcriptional and post transcriptional level. Transcriptionally,  anti 
apoptotic gene expression is tuned by cell cycle dependent and independent mechanisms(Altieri 
2008). During the post transcriptional effects, anti apoptotic genes (survivin etc) are modulated 
by stimulation of growth factors like protein kinases and insulin growth factor that are mainly 
associated with the stabilisation and translation mechanism of survivin messenger RNA 
(mRNA), relying on mammalian target of rapamycin (mTOR) complex regulation that mediates 
cell growth in phosphatidylinositol 3-kinases/serine/threonine protein kinase (PI3K/AKT) 
pathway (Oh et al. 2008; Vaira et al. 2007). Apart from the above noted mechanisms, 
ubiquitylation and de ± ubiquitylation reactions are known to regulate anti apoptotic molecule 
expression and function by both degradative and non degradative pathways. However, multiple 
phosphorylation events in cell cycle have a profound effect on anticancer signalling that are 
mainly mediated by protein kinases and cell cycle dependent kinases (Kanwar et al. 2001). 
Survivin is known to regulate apoptosis, cytokinesis followed by interaction with heat shock 
protein (HSP90), second mitochondria ± derived activator of caspases (Smac/Diablo), cyclin 
dependent kinase 4 (CDK4), cluster of differentiation 2 (CD2), retinoblastoma /E2F complex, 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), p53 (Kanwar et al. 
2001). 
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Studies conducted on survivin promoter activity and its increased expression during tumour 
proliferation is mainly attributed to increased loss of tumour suppressor genes (p53) and due to 
activation and increased expression of oncogenes (RAt Sarcoma (Ras)). Cellular localisation of 
survivin observed in nuclei during interphase stage of mitosis is mainly associated with 
microtubules during spindle apparatus formation and also in mitochondria(Altieri 2008). 
Interestingly, hypoxia condition has a profound effect on survivin expression. It was reported 
that increase of survivin levels was exponentially correlated with hypoxia condition (Kanwar et 
al. 2001). Survivin plays a key regulatory role in organisation of chromosomal passenger 
complex through its interacting subunits inner centromere protein (INCENP) and borealin / dasra 
B that leads to the spindle apparatus formation during anaphase. Studies conducted at our 
laboratory successfully showed interaction of aurora B kinase with  survivin baculovirus IAP 
Repeat (BIR) motif mutant can lead to accelerated G0/G1 growth phase arrested differentiated 
neuronal cells during  mitosis (Baratchi, Kanwar & Kanwar 2010d). Survivin is known to be 
particularly expressed in a wide range of cancers with multiple functions which include cell 
division, apoptosis, cellular stress response and role in maintaining genome integrity(Kanwar et 
al. 2010b). 
This section will examine the state of art knowledge reporting the recent developments in cancer 
growth mechanisms including survivin and its interaction with heat shock protein 90 (HSP90) 
chaperone, hypoxia condition and prominent cell signalling pathways (PI3K/AKT, mTOR, Extra 
cellular signal regulated kinases (ERK) signalling, tumour suppressor genes (p53, phosphatise 
and tensin homologue (PTEN), oncogenes (B ± cell lymphoma 2 (Bcl2), Ras) in promoting 
tumour angiogenesis. In addition, role of current molecular inhibitors (dominant negative 
survivin mutants, natural product derived therapeutics, nanodelivery systems and synthetic 
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inhibitors - geldanamycin and derivatives, YM 155) in targeting prominent anti cancer molecules 
are reported. Furthermore, recent scenarios of cancer chemo and radio resistance are 
summarised.  
 
Figure 2.2 Flow chart describing interaction of cancer growth mechanisms. Figure 
Legends: Flow chart outlines the interaction between the three nodal molecules - survivin, 
HSP90 and hypoxia. Cancer and chronic inflammation are mainly characterized by uncontrolled 
cell proliferation, following aberrant expression of anti apoptotic proteins (ex: survivin), 
activation of oncogenes, growth factors and heat shock proteins (ex: HSP90) and hypoxia 
condition. Survivin promotes tumour proliferation by regulation of tumour suppressor genes, cell 
division and cell stress response that is mediated by heat shock proteins, which in turn stabilise 
hypoxia condition leading to activation of enhanced survivin expression, ultimately promoting 
tumour progression.(Figure reference: Kanwar et al; Drug discovery today 2011). 
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2.2.2 Role of angiogenesis in cancer growth 
Hypoxia-inducible factor-1Į (HIF-Į) is central transcription factor, activated during hypoxia 
condition and modulates the expression of many genes involved in cell metabolism, 
proliferation, apoptosis and angiogenesis. HIF-Į and hypoxia responsive elements (HREs) 
directly interact with the survivin promoter up regulating survivin gene expression. Positive 
correlation was observed in terms of increased HIF-Į and survivin expression along with 
angiogenic factors in a wide range of cancer cell lines (colon, pancreatic and breast cancer cell 
lines). Antisense oligo nucleotides targeting HIF-Įcaused marked down regulation of survivin 
in pancreatic cancer (BxPc-3 cell line). Over expression of survivin was mediated by oxygen-
independent HIF-ĮXSUHJXODWLRQLQHQGRWKHOLDOJURZWKIactor-treated breast cancer cell line (Fan 
et al. 2008).  
Transcriptional increase in survivin mRNA expression was observed in the presence of hypoxia 
and anti cancer drugs in hepatocellular carcinoma (Mamori et al. 2007). Exposure of cervical 
cancer cells (HeLa cell line) to hypoxia condition caused a dramatic upregulation of survivin 
levels exclusively in the mitochondrial compartments, having minimal effect in cytosolic 
survivin levels. Hence, this significant feature of dynamic upregulation of mitochondrial survivin 
levels in response to cellular stress plays a prominent role in cellular adaptation to stress 
conditions (Dohi et al. 2004).  In vivo mice studies revealed survivin expression in the brain 
tissues is induced by hypoxia conditions is partially independent of HIF-Į and vascular 
endothelial growth factor (VEGF).  Conversely, enhanced expression of survivin was noted in 
the absence of HIF-Į, this suggests that alternative mechanisms involving angiogenic growth 
factors may be functional to regulate survivin levels, in vivo. Therefore, HIF-Į factor can also 
down regulate survivin. Since, HIF-Į can stabilise or upregulate p53 during hypoxic conditions, 
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in turn p53 suppresses survivin.  These findings collectively signify that under hypoxia 
conditions, HIF-Į can modulate gene expression in terms of promoting or inhibiting apoptosis 
based on the specific conditions (Conway et al. 2003). Our laboratory studies conducted on HIF-
Į and survivin expression in a combinatorial approach revealed effective inhibition of these 
molecules when targeted with anti angiogenic agents like angiostatin or  VEGF blocking peptide 
along with antisense inhibition strategy that ultimately triggered efficient survivin 
downregulation causing inhibition of tumour angiogenesis(Kanwar, Kamalapuram & Kanwar 
2010; Krissansen, Sun & Kanwar 2005).  Survivin expression induced by epidermal growth 
factor receptor (EGFR) signalling is mediated by transcriptional activation of HIF-Į in an 
oxygen independent manner.  Studies conducted on breast cancer cell line during normoxia 
conditions revealed that levels of survivin and HIF-Į are increased in an EGFR dependent 
manner.  Hence, the cross talk between HIF-Į and EGFR signalling pathways can cause 
upregulation of survivin expression, leading to increased apoptotic resistance (Peng et al. 2006b).  
Surprisingly, no relationship was observed between the survivin expression and HIF-Į RI
advanced cervical carcinoma of patients treated by radiotherapy (Bache et al. 2007). 
Collectively, these studies clearly indicate that HIF-1Įmight be a key transcription factor for 
apoptotic gene (survivin) expression and function (Chen & Huang 2008; Fan et al. 2008). (Figure 
1, 2, 3).  
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2.2.3 Role of cell stress mechanisms for cancer growth   
HSP 90 associated with survivin is over expressed in cancers with roles in mitotic control and 
apoptosis inhibition. The cytoprotection mechanism of survivin ± HSP90 association is centred 
on the mitochondrial pathway, where survivin has a role in regulation of mitochondrial 
apoptosis. Disruption of survivin ± HSP 90 interaction destabilizes survivin, initiating 
mitochondrial apoptosis and suppressing cell proliferation (Fortugno et al. 2003). HSP 90 is 
abundantly present in mitochondria with subcellular localisation to organelle intermembrane 
space and matrix, which is differentially expressed in tumour cells, but undetectable or expressed 
at very low levels in the organelles of normal tissues(Cheung et al. 2010b). The upregualtion of 
HSP90 levels in mitochondria is associated with deregulation of cancer signalling pathways 
AKT (Kang et al. 2009). Experimental findings reported the subcellular localisation of survivin 
to mitochondria is mediated by physical association with HSP90 chaperone complex in the 
cytoplasm. The survivin ± HSP90 complex is then imported to the mitochondria via 
mitochondrial Tom 70 receptor ± interacting protein and during cellular stress by immunophilin 
aryl-hydrocarbon receptor ± interacting protein via Tom20 receptor ± dependent recognition to 
mitochondria(Altieri 2008; Kang et al. 2009). However, possible disruption of survivin ± HSP90 
complex destabilizes survivin protein leading mitochondrial apoptosis and ultimately cell growth 
suppression (Fortugno et al. 2003). HSP90 interaction with survivin enables stabilisation of 
cofactors like AKT, human epidermal growth factor receptor (Erb-2) and HIF-Į that leads to 
tumour progression(Cheung et al. 2010b).  
 
2.2.4 Cancer signal transduction mechanisms through prominent cell signalling pathways:
Anti apoptotic proteins including Ɛurvivin are nodal proteins involved in multiple signalling 
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mechanisms coordinating various cellular molecules, transcriptional networks and modifiers that 
directly or indirectly promote tumour proliferation by regulating cancer cell homeostasis (Altieri 
2008). We discuss about the interaction of prominent cell signalling pathways ± PI3/AKT 
pathway, mTOR pathway, ERK Pathway, tumour suppressors (p53, PTEN) and oncogenic (Ras, 
Bcl2) signalling pathways.(Figure 2.3).  
  
 
Figure 2.3: Interaction of cancer cell  signal transduction mechanisms. Figure Legend: The 
diagram illustrates about the interaction of cytoplasmic survivin ± HSP 90 complex with HIF and 
cell signalling molecules. Survivin ± HSP90 complex is activated by PI3K/AKT/mTOR 
pathway, further stabilised by NF-kB and HIF (Hypoxia inducible factor) activated via Ras / Erk 
pathway leading to tumour proliferation. Tumour suppressor gene - PTEN is deregulated and p53 
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functional inactivation is caused by cell signalling molecules ± mTOR, HIF, Bcl2 and also 
survivin ± HSP90 complex. Collectively, the above mentioned events further stabilise survivin ± 
HSP90 complex promoting tumour proliferation. (Figure reference: Kanwar et al; 2011). 
 
2.2.4.1 PI3K/AKT pathway: Phosphatidylinositol 3-kinase (PI3K) phosphorylates 
phosphatidylinositol ± 4, 5 bis phosphate (PIP2) on plasma membrane to generate 
phosphatidylinositol ± 3,4,5-triphosphate (PIP3). PI3 is comprised of heterodimers, with a 
regulatory subunit - P85 and catalytic subunit P110. Regulation of P85 subunit is mediated by 
receptor tyrosine kinase (RTK) signalling pathway that can lead to functional activation of 
PI3K/AKT pathway and its downstream signalling cascades that are crucial for oncogenic 
activity. A potential tumour suppressor gene PTEN encodes enzyme PIP3 - ase to stop PI3K 
VLJQDOOLQJ6WXGLHVH[DPLQLQJWKHHIIHFWRIVKRUWKDLUSLQ51$¶VWDUJHWLQJ3EHWDVXEXQLWKDYH
reported, efficient down regulation of PI3K/AKT signalling pathway in PTEN deficient cancer 
cell lines. Hence, these findings validate P110 isoforms as potential therapeutic target (Liu et al. 
2009).    
EGFR is also known to regulate PI3K and ERK signalling in lung cancers. Experimental 
findings in treatment of cancer cells with EGFR inhibitors caused inhibition of these pathways 
and triggered apoptosis(Engelman 2009). PI3K/AKT pathway is activated via EGFR signalling 
leading to up regulation of HIF-Į, which transcriptionally activates survivin gene expression by 
binding to its promoter region (Debatin, Wei & Beltinger 2008; Peng et al. 2006b). Follicle ± 
stimulating hormone (FSH) is known to promote neovascularisation of tumours by inducing 
expression of vascular endothelial growth factor (VEGF) and upregulating survivin expression, 
principally activated by PI3K/AKT pathway (Huang et al. 2008). Similar results were also 
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reported in human neuroblastoma cell lines with increase in survivin expression and 
phosphorylated AKT (Beierle et al. 2005). Studies conducted in acute myeloid leukemia cells 
demonstrated that PI3K pathway mediated survivin expression is induced by haematopoietic 
cytokines (Carter et al. 2006). Human epidermal growth factor receptor 2 (HER2) mediated 
survivin upregulation in breast cancer cell line revealed the role of PI3K/AKT pathway and 
herceptin. However, HER2 specific inhibitor efficiently downregulated survivin by inhibiting 
PI3K pathway (Asanuma et al. 2005; Melillo 2007). The functional mechanism involved HER 2 
over expression leading to phosphorylation of 4EBP-1 molecule, a repressor of translation, 
allowing translational activation of survivin expression involving PI3K/AKT pathway (Lu et al. 
2009). PI3K /AKT pathway is attributed for its mechanism in inducing apoptotic resistance by 
increasing survivin expression(Altieri 2008), one such studies conducted on head and neck 
squamous cell carcinoma and non small cell lung cancer cell lines proved that PI3K/AKT 
pathway in combination with insulin growth factor like receptor (IGF-IR)  caused apoptosis 
resistance to a  farnesyltransferase inhibitor, SCH66336. Inhibition of AKT molecule or 
knockdown of survivin expression, subsequently induced apoptosis in response to this inhibitor 
(Oh et al. 2008). Investigations carried out in head and neck squamous cell carcinoma revealed 
that PI3K/AKT pathway in conjugation with a transcription factor - inhibitor of 
differentiation(Id1), promotes cell proliferation and differentiation leading to survivin up 
regulation (Lin et al. 2010). Studies conducted in prostate cancer cells showed apoptotic 
resistance to anti- androgens by upregulation of survivin via insulin ± like growth factor / 
PI3K/AKT pathway(Pennati, Folini & Zaffaroni 2007). 
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2.2.4.2 mTOR pathway:  Mammalian target of rapamycin (mTOR), a member of 
phosphatidylinositol kinase family of proteins is attributed to promote tumorogenesis by 
activating various growth promoting factors and  phosphorylation of cellular kinases, that lead to 
translation of mRNA encoding cell cycle regulators (cyclin dependent kinases (CDK), 
transcription factor - Myk) (Engelman 2009). Experimental studies conducted in non small lung 
cancer cell lines reported that mTOR ± AKT pathway mediated survivin expression leading to 
malignant progression caused by tobacco carcinogens - nicotine and 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK). However, siRNA knockdown of survivin expression suppressed 
tumour progression (Jin et al. 2008). Studies conducted on pharmacological inhibition of  mTOR 
complex by rapamycin in chronic lymphocyctic leukaemia proved mTOR pathway mediated 
survivin expression. Rapamycin induced G1/S cell cycle arrest in cell lines and subsequently 
caused downregulation of survivin. Similiar results were obtained in plasma cell myeloma cell 
line leading to translational inhibition of survivin(Drakos, Rassidakis & Medeiros 2008). 
Immunoregulatory function of mTOR complex in association with survivin protein involves 
critical regulation of the G1/S cell cycle check point in T cells by a kinase aurora B, that exists as 
a complex with survivin and mTOR(Song et al. 2007; Thomson, Turnquist & Raimondi 2009). 
mTOR complex in conjugation with survivin expression has shown to promote chemoresistance 
in cisplatin based therapy. Studies conducted on ovarian cancer proved down regulation of AKT 
molecule by triciribine, a drug compound or short hairpin RNA (shRNA) transfection disrupted 
the mTOR and survivin signalling, sensitising cells to cisplatin (Zhang, Zhang & Sun 2009). 
mTOR complex in combination with insulin growth factor receptor ± 1 modulates translational 
expression of survivin levels. Experimental studies conducted on prostate cancer cells proved 
that downregulation of mTOR complex by rapamycin and simultaneous suboptimal taxol 
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treatments in cell lines inhibited cell proliferation (Vaira et al. 2007). Survivin expression is also 
known to be mediated via Ras signalling pathway based activation of mTOR complex (Shinjyo 
et al. 2008)  
2.2.4.3 ERK pathway: Survivin is known to be extensively expressed in acute myeloid 
leukaemia (AML) cells via ERK pathway and hematopoietic cytokines. Experimental studies 
conducted on these cell lines with mitogen-activated protein kinase (MEK) inhibitor PD98059 
proved the effective inhibition of ERK pathway in both normal AML cells and granulocyte 
macrophage±colony-stimulating factor (GM-CSF) AML cells, suggesting the role of 
hematopoietic cytokine mediated ERK pathway in regulating survivin expression at mRNA and 
protein level (Carter et al. 2006). ERK pathway in conjugation with AKT pathway showed taxol 
mediated upregulation of survivin expression. Studies conducted on taxol resistant cell lines 
proved that cis-acting DNA element upstream of 1430 survivin promoter region is responsible 
for survivin upregulation during taxol treatment. Antisense inhibition of survivin and 
pharmacological inhibition of AKT and ERK pathway, increased taxol induced cell death(Ling 
et al. 2004). Ras dependent ERK pathway activation induced survivin expression in human 
glioblastoma cell line. Studies conducted using Ras inhibitor, farnesylthiosalicylic acid (FTS) 
caused efficient downregulation of Ras dependent ERK pathway activation leading to decreased 
survivin expression (Blum et al. 2006). Research studies on chronic myeloid leukemia cell lines 
proved consistent up regulation of survivin via ERK pathway. The mechanism involves 
activation of ERK pathway by BCR-Abl, a activated tyrosine kinase specifically present in 
chronic myelogenous (or myeloid) leukemia (CML), acts as an upstream regulator of ERK 
pathway thereby causing increased survivin expression. Efficient downregulation of survivin 
reduced ERK activation and subsequently sensitised cells to imatinib in both sensitive and 
Ϯϭ
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resistant cell lines (Carter et al. 2006). Studies conducted on prostate cancer cells on survivin 
expression by quercetin caused tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) 
± induced apoptosis. Experimental findings suggest that quecertin promoted ERK ± mediated 
deacetylation of histone H-3 region of SP1, a transcription factor that binds to survivin promoter. 
This leads to downregulation of survivin by inhibiting SP1 binding activity, simultaneously 
enhancing TRAIL cytotoxicity (Kim et al. 2008). 
 
2.2.4.4 Tumour suppressor genes:  
p53: p53, a prominent tumour suppressor gene accelerates its activity through p21 target gene 
and stops cell cycle progression via multiple signalling pathways that transactivate various 
apoptotic factors like Bcl-2±associated X protein (Bax), Puma, Noxa and p53 ± regulated-
inducing protein 1 (p53AIP1). It is also known to regulate the expression of anti apoptotic 
proteins Bcl-2 and survivin(Burz et al. 2009). Mutations associated with p53 have a potential 
role in development of cancers and in aberrant expression of anti apoptotic proteins like survivin. 
Studies conducted revealed the transcriptional repression of survivin gene by wt-adenomatous 
polyposis coli protein (Khan et al. 2009)  or by wild type p53 interaction with survivin promoter 
at p53 binding site via E2F-1 transcription factor. This repressive effect may be indirect and 
dependent on synthesis of a repressor protein through p53/p21/retinoblastoma (Rb)/E2F 
transcription pathway and also independent of apoptosis. Survivin is expressed in cell cycle 
dependent manner at G2/S phase during cell proliferation and downregulated at G1 phase by cell 
cycle arrest. Increased survivin expression was associated with p53 mutations and loss of 
heterozygosity in breast cancer cells. Point mutations occurring in p53 are known to exert 
ϮϮ
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oncogenic functions by transactivation of survivin variant expression with their loss of tumour 
suppressor function (Vegran et al. 2007). 
Putative p53 ± responsive elements or indirect promoter squelching events are involved in direct 
transcriptional silencing of survivin in a negatively regulated fashion. p53 dependent apoptosis 
and G2 ± M phase cell cycle check point functions, cooperatively inhibit mitotic survinin gene 
expression resulting in abundant cell death. Cell cycle independent mechanisms in combination 
with functional loss of p53 gene are involved in deregulation of survivin gene in vivo via ablation 
of cell cycle check points and conferring resistance to apoptosis, thereby traversing mitosis (Xia 
& Altieri 2006). Studies conducted in oral cancers demonstrate the over expression of survivin 
and p53. Mutated p53 genes cooperate with other oncogenes facilitating enhanced tumour 
progression. A significant correlation between the expression of survivin and p53 was observed 
in squamous carcinoma, oral cancers, gastric cancers, lung cancer, colorectal cancers, breast 
cancer (Khan et al. 2009).  
Hypoxia induced p53 acts as a transrepressor activating the production of anti apoptotic proteins 
like Bcl2 and survivin. During low oxygen concentrations, HIF-1Į  factor is known to 
transactivate genes needed to adopt hypoxic conditions by competitive binding to available 
coactivators such as p300/CBP and thus inhibiting p53 binding and subsequent 
activation(Hammond & Giaccia 2005). p53AIP1, a newly discovered potential mediator of p53 
dependent apoptosis, is induced during the p53 phosphorylation at Ser ± 46 in severe DNA 
damage conditions and not expressed in normal cells expect in thymus. Studies conducted in non 
small lung cancer cells, proved the role of p53AIP1 on survivin expression same as p53. 
Therefore the p53 AIP1, a derivative of p53 can also have an inhibitory effect on survivin 
expression. Very few studies are undertaken on p53AIP1 molecule and thus exploring the 
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combination of p53AIP1 along with survivin expression may be a potential improvement in 
prognosis of cancer(Yamashita et al. 2009). 
Transcriptional inhibition analysis of survivin gene was shown to be mediated through the 
stabilisation of p53 proteins by chemotherapeutic agent, doxorubicin by an indirect mechanism 
involving stabilised p53 proteins that bind to p53 binding site in survivin promoter region and 
hence suppressing its activity via drug trans ± acting mechanism. However, studies on survivin 
promoter activity in terms of sequence selective DNA ± binding anticancer agents that can 
modulate survivin expression and also their role in drug action mechanism can lead to novel 
incentives to watch survivin transcription in anti cancer strategies (Wu et al. 2005). Increased 
expression of survivin in endometrial tumours was correlated with hypermethylation that lapsed 
the binding of p53, a prominent repressor of survivin and PTEN, inactivation of DNA repair 
enzymes and O6-methylguanine DNA methyltransferase (MGMT). Later, demethylation of gene 
promoter by decitabine resulted in p53 dependent transcriptional survivin repression. Results 
suggest the fact that demethylation induced by a chemotherapeutic agent is active in cancers by 
allowing the functional reactivation of tumour suppressor genes like p53 etc. These findings 
validated with gel shift assays warrant that DNA methylation based approach to trigger p53 
dependent apoptosis and anti apoptotic protein repression i.e. survivin are highly tissue/ context 
specific approach(Nabilsi, Broaddus & Loose 2009). 
Survivin interacts with RAS-related nuclear protein, guanosine-5'-triphosphate (Ran ± GTP) 
pathway, involved in formation of spindle apparatus during cell division, which is specifically 
present in tumour cell mitotic signalling network with downstream effector molecules 
functioning as cancer genes. Ablation of Ran ± GTP pathway in tumours resulted in loss of 
survivin levels, mitotic defects i.e. disruption of spindle apparatus and increased p53 or Bcl2 
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independent apoptosis, simultaneously no such observations were noted in normal cells. This 
data represents the differential sensitivity of tumour cells for Ran ± GTP pathway with novel 
therapeutic interventions(Altieri 2008). From the investigations described above, it is clear that 
tumour suppressor gene like p53 has an important role in regulation of tumour proliferation. 
Moreover, loss of p53 function can be a good prognostic indicator.   
PTEN: PTEN, a prominent tumor suppressor gene, is located on chromosome band 10q 23.3. 
PTEN gene encodes products that could inhibit cell growth, promoting cell apoptosis by 
dephosphorating PIP3, thereby deactivating PI3K/AKT pathway (Deng et al. 2006). PTEN gene 
is known to acutely silence survivin expression to undetectable levels in normal cells(Guha et al. 
2009). PTEN  is known to indirectly regulate survivin expression via downregulation of 
PI3K/AKT pathway, by removal of phosphate group from inositol ring of PIP3 molecule, 
consequently disrupting PI3K/AKT pathway(Sui et al. 2006).  PTEN directly decreases survivin 
via FOXO1 and FOXO3a transcription factors, in the survivin promoter region. In vivo and in 
vitro studies in prostate cancer cells demonstrated that PTEN tumour suppression is inversely 
correlated with survivin expression. Hence, it was suggested that disruption of constitutive 
expression of survivin is essential for  function of endogenous PTEN tumour suppression(Guha 
et al. 2009). PTEN  is a most commonly mutated tumour suppressor gene in gastric carcinoma 
malignancies(Schulze-Bergkamen et al. 2009). Studies conducted in gastric cancer patient 
samples showed positive correlation between PTEN and survivin expression. Surprisingly, Dong 
et al reported negative correlation in terms of survivin expression in gastric cancer (Deng et al. 
2006). Studies conducted in endometrial adenocarcinoma revealed increased survivin expression 
along with decreased activity of PTEN gene. However, a correlation was not established between 
survivin and PTEN, which suggest that survivin exerts in proliferative activity by different 
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mechanisms in development endometrial cancer (Erkanli et al. 2006). Although research findings 
reported that PTEN and survivin expression can be considered as a prognostic marker in ovarian 
cancer cells, but negative correlation was observed in association of these molecules(Sui et al. 
2006).  
2.2.4.5 Oncogenes: 
Bcl 2 Oncogene: BCL±xL is known to be anti apoptotic protein of Bcl -2 family and mainly a 
hypoxia responsive element over expressed in prostate carcinoma. Hence, HIF-Į factor 
constitutively promotes tumourigenesis by binding directly at the BCL-xL promoter region and 
also at survivin promoter region, subsequently increasing survivin promoter activity leading to 
HIF-Įdependent proliferation (Chen et al. 2009). Nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-kB) activation is known to play a prominent role in activating extrinsic 
apoptotic pathway mediated by tumor necrosis factor (TNF-Į) , by critically regulating the 
expression of survivin and Bcl-2, thereby maintaining cellular proliferation(Lin et al. 2010). 
Quercetin, a bioflavonoid investigated for its anti proliferative effects in human liver carcinoma 
cell line (HepG2) and known to induce apoptosis in dose and time dependent manner.  
Mechanism of quercetin induced apoptosis is mediated by downregulation of survivin and Bcl-2 
protein expression, possibly by a p53 independent manner directly regulated by p53 or due to 
G2/M cell cycle arrest dependent regulation of survivin(Tan, Wang & Zhu 2009). 
Pharmacological inhibition profile of curcumin was examined for its mechanism in promoting 
apoptosis in ovarian carcinoma cells. Curcumin exhibited cytotoxic activity in ovarian cancer 
cells by a p53 independent pathway involving p38 mitogen ± activated protein kinase (MAPK) 
activation, followed by ablation of AKT signalling and leading to decreased expression of anti 
apoptotic proteins - Bcl- 2 and survivin (Watson et al. 2010). The principal mechanism behind 
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mitochondrial dysfunction involves  aberrant expression and function of anti apoptotic 
mechanisms mainly coordinated by expression levels of Bcl-2 and survivin, which further 
antagonises caspase activity(Guha et al. 2010). Studies were conducted to decipher the novel 
mechanisms of action by peroxisome proliferator activated receptor ± g (PPAR-g) ligand induced 
apoptosis on myeloid leukaemia - K562 and HL-60 cell lines. 15-deoxy-delta(12,14)-
prostaglandin J2 (15d-PGJ2) and troglitazone (TGZ), molecular antagonists were examined for 
their apoptotic inducing mechanisms leading to upregulation of bax, moreover effective 
downregulation of survivin and Bcl-2 expression was observed. Therefore, these findings 
warrant PPAR-g ligands as potential therapectic targets in myeloid leukemia cells (Liu et al. 
2005). Studies were conducted using TW -37, a small molecule inhibitor of Bcl-2 family proteins 
in pancreatic cancer cells. Mode of action of TW-37 involved inhibition of cell cycle related 
genes, S- phase cell cycle arrest which was further determined with decreased survivin 
expression (Wang et al. 2009b).  Research studies were conducted using ABT-737, a molecular 
inhibitor of Bcl- 2 family of proteins in refractory hodgkin lymphoma (HL) cell line. This 
molecule exhibited concentration and time dependent cytotoxicity with possible mechanisms 
involving downregulation of Bcl-2, Bcl-xL, survivin protein and also NF-kB. Hence, these 
results provide a background to further improve the pharmacological profile of the inhibitor 
(Jayanthan et al. 2009). Signal transducer and activator of transcription (STAT)3 protein, a 
recently studied novel cell survival regulator is known to exhibit its cytoprotective mechanisms 
against apoptosis via upregulation of antiapoptotic proteins such as Bcl-xL and survivin, 
followed by inactivation of caspases(Uckun et al. 2010). 
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Ras Oncogene: The oncogenic activity of c-H- Ras is attributed for its mechanisms of 
upregulation of survivin expression via functional activation of PI3K and ERK/MEK. MAPK 
signalling pathways are independent of cellular proliferation. Experimental findings depicted that 
downregulation of C-H-Ras expressions led to reduction in survivin levels. Hence, it is a general 
notion that wide expression of survivin in majority of cancers can be activated by Ras ± 
signalling pathways(Sommer et al. 2007). Recent studies demonstrated that Ras induced survivin 
activation plays as prominent role in hematopoietic cells. Ras is known to mediate transcriptional 
expression of survivin via MAPK, PI3K and mTOR pathways (Shinjyo et al. 2008). 
Experimental findings reported in hepatocarcinoma - HeLa cell line and HeLa DiR cell line 
proved consistent expression of survivin was due to induction of c-H-Ras during all cell cycle 
phases and hence protected from apoptotic effects of drug molecules. However, siRNA mediated 
silencing of survivin in presence of c-H-Ras reversed the condition, sensitising cells to apoptosis. 
Therefore, it has been a well established fact that Ras ± survivin pathway is a crucial for 
oncogenic activity leading to survivin upregulation (Sommer et al. 2007). Research studies 
undertaken in DLD-1 cell line (human colon cancer cell lines) with activated k-Ras oncogene 
showed endogenous expression of survivin. Furthermore, siRNA mediated survivin targeting 
resulted in cell death, majorly due to G2-M phase arrest in cell cycle, leading to increase in 
polyploidy and ultimately cell death. Hence, it is suggested that inhibitors that antagonise the 
association between K-Ras and survivin can pronounce cell apoptosis in K-Ras activated cancer 
cells (Sarthy et al. 2007). Investigations were conducted on SW480 (colon cancer cell line) using 
lovastatin (3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (HRIs) ) that block 
cholesterol synthesis pathway.  Results suggested survivin expression was reduced by this 
compound leading to apoptosis. Mechanism of action of lovastatin on survivin inhibition 
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involved inhibition of Ras mediated PI3 ±Kinase activation via blockage of Ras isoprenylation, 
mechanism that activates biological function of Ras proteins (Kaneko et al. 2007). Studies were 
conducted on human tumour cells using Ras inhibitor S-farnesylthiosalicylic acid (FTS; 
salirasib) that reregulated Ras pathways by suppression of survivin expression and transcription 
factors, stress responses that control aberrant cell proliferation. FTS caused transcriptional 
suppression of survivin. Therefore, it can be noted that FTS can be a prominent treatment regime 
for Ras deregulated tumours (Blum et al. 2007). Similar studies were conducted using FTS in 
U87 glioblastoma multiforme cell lines and results were in accord with previous studies as 
discussed. However, forced expression of survivin resulted in FTS functional inhibition restoring 
Ras tumour pathways (Blum et al. 2006). Investigations conducted on immortalized human 
pancreatic epithelial cells demonstrated that K-Ras promotes angiogenesis through MAPK 
signalling pathways leading to enhanced survivin expression (Matsuo et al. 2009). Experimental 
studies conducted in pro-B cell acute lymphoblastic leukemias (ALLs) showed E2A-HLF, is a 
transcription factor that promotes leukemogenesis and is regulated by Ras pathways. E2A-HLF 
is also known to directly or indirectly enhance survivin transcription. Hence, further studies in 
deciphering E2A-HLF functional mechanisms can help us to understand the regulation of 
survivin and involvement of Ras pathways in promoting leukemogenesis (Okuya et al. 2010). 
2.2.5 Prominent inhibitors targeting cancer growth 
Wide spectrum of molecular inhibitors are available to counteract anti apoptotic molecular 
expression and function for decreasing tumour growth potential and enhancing tumour cell 
apoptotic response to the drug molecules used. In this section, prominent therapeutic strategies 
employed in targeting anticancer signalling mechanism are discussed (Cheung, Kanwar & 
Krissansen 2006; Kanwar et al. 2010b) (Table 1, 2).   
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2.2.5.1 Dominant negative survivin mutants and gene therapy:  Our laboratory developed a 
recombinant cell permeable dominant negative survivin, fused with a poly ± arginine (R9) cell 
penetration domain to R9 peptide (SurR9-C84A). This construct successfully penetrated inside 
tumour cells abrogating survivin function and thereby causing caspase independent and 
dependent apoptosis in cancer cells. Furthermore, it was discovered that SurR9-C84A activates 
TNF-Į signalling in three dimensional prostate and cervical cancer cell models, followed by 
marked downregulation of survivin expression(Cheung et al. 2010a). B7 -1 an important factor 
which is expressed on antigen presenting cells (APC) interacts with cluster of differentiation 28 
(CD28) cells and thereby promotes T cell mediated immune response against cancer cell growth. 
Studies were conducted to decipher the role of survivin in enhancing immunosuppressive effect 
in tumours by prompting immune resistance to cytotoxic T cells (CTLs). In vivo mice studies 
were conducted with a combinatorial treatment approach involving B7-1 molecule in association 
with dominant negative survivin or anti sense survivin and results obtained showed prominent 
downregulation of survivin causing increase in production of CTLs, further leading to growth 
inhibition. Thus, investigations for the first time prove that survivin expression in relation with 
B7-1 factor is a promising diagnostic and prognostic marker for therapeutic manipulation of 
tumours (Kanwar et al. 2001). 
2.2.5.2 Natural product derived compounds: Curcumin, a potent natural compound having 
anti cancer activity is now being widely studied to decipher its anti cancer mechanisms. In vivo 
pancreatic cancer cell model investigations revealed the inhibitory of effect of curcumin on SP 
transcription  factors causing functional inactivation of  NF - kB pathway,  leading to regression 
of downstream targets ± survivin, VEGF and cyclin D molecules along with posing a decrease in 
mitochondrial membrane potential uneveiling its mitochondriotoxic effect (Jutooru et al. 2010). 
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The mitochondriotoxic effect of curcumin is mainly due to functional activation of caspases - 8, 
9, 3, PARP cleavage and BH3 interacting domain death agonist (BID) domain truncation causing 
release of cytochrome C, downregulation of factors such as survivin, AKT, FOXO, GSK3 
ultimately leading to mitochondrial apoptosis(Hussain et al. 2006). Further, clinical trails on 
cutaneous T-cell lymphoma (CTCL) patients indicated that curcumin induced downregulation of 
survivin, Bcl2 was majorly due to functional LQDFWLYDWLRQ RI 67$7 DQG 1) Nȕ signalling 
followed by caspase activation induced apoptosis (Zhang et al. 2010). The anti cancer 
mechanism of limonoids, a derivative of neem (azadirachta indica) investigated on Hela cell line 
revealed its action in a dose dependent manner causing GO/G1 cell cycle arrest subsequently 
triggering decreased cyclin B, D1, PCNA expression and mitochondrial potential leading to 
functional inactivation of NF- kȕ, caspase-2 signalling mechanism that ultimately showed a 
suppressive effect on survivin (Priyadarsini et al. 2010). However, further in vivo mice studies 
undertaken in oral cancer cell model to decipher the inhibitory effect of limonoids on survivin 
expressed showed that increase in nuclear survivin was noted with decrease of its cytoplasmic 
counterpart (Harish Kumar et al. 2010).   
2.2.5.3 Nanodelivery systems : Nanoscale devices, when coupled with functional biological 
molecules like receptor mediated tumour specific ligands, antibodies, anticancer drug 
combinations, drug encapsulations and also imaging probes, are much smaller than cancer cells 
and can be aptly utilised for targeted drug delivery with enhanced selectivity (Baratchi et al. 
2009b; Kanwar, Mahidhara & Kanwar 2009; Mohanty C et al. 2010; Mohanty et al. 2011; Wang 
et al. 2008). siRNA based targeting of survivin is well established, although conventional 
delivery of siRNA  reported nonspecific delivery, degradation of naked siRNA by cell endo and 
exonucleases, immune stimulation etc. (Oh & Park 2009). Hence, nanotechnology based 
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strategies are evolving to comprehend these issues and enable targeted therapeutic approach 
(Table 2). 
Our laboratory research studies undertaken in human colon cancer cells (Caco-2 and HT-29) to 
assess activity of alginate-coated nanocarriers (ACNC)  nanocarriers loaded with covalently 
cross linked CPP (R9 and Tat peptides) complexed with antisense survivin exhibited enhanced 
anti tumour activity with increased bioavailabity and sustained release of the drug molecules 
(Kanwar, Mahidhara & Kanwar 2011b; Mahidhara, Kanwar & Kanwar 2010 ). Furthermore, 
investigations carried out in human breast cancer cells (MDA-MB-231 and MCF-7) with alginate 
gel-encapsulated, chitosan ceramic nanocore nanocarriers (ACNC-NPs) loaded with (DNSurR9) 
and shepherdin  along with oncogenic antisense miRNA-27a caused marked downregulation of 
survivin along with angiogenic factors -VEGF receptor. The mechanism of action involved 
promotion of apoptosis by enhanced antisense activity followed by disintegration of 
mitochondrial compartments in cancer cells. Hence, these studies illustrate a novel therapeutic 
mechanism with our nanodelivery system and can be placed in the radar of pharmacological 
inhibition strategy for anti survivin treatments (Baratchi, Kanwar & Kanwar 2010c; Bawa 2009; 
Cheung et al. 2010a; Kanwar, Mahidhara & Kanwar 2011b; Kanwar et al. 2010 ). (Figure 4).   
 
Polyamidoamine (PAMAM) dendrimer ± conjugated MPNs were designed to delivery antisense 
survivin oligonucleotides (asODN) to tumour cells. The nanoparticulate system, designed with 
more positive charges on the surface were highly internalized across the cell membrane and had 
a profund inhibitory effect on survivin gene and protein expression(Byrne, Betancourt & 
Brannon-Peppas 2008; Jabr-Milane et al. 2008; Pan et al. 2007; Park et al. 2009). Liposome 
polycation (LPD) - DNA nanoparticle formulation with anisamide as a component that binds 
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specifically to sigma receptors which are highly expressed in lung cancer cells, was developed 
by Li and Huang for specific delivery of survivin siRNA.  In vitro studies demonstrated 
improved gene delivery efficiency suppressing survivin expression, thereby sensitising cancer 
cells to chemotherapeutic drug, Cisplatin and promoting apoptosis(Byrne, Betancourt & 
Brannon-Peppas 2008; Chen & Huang 2008; Oh & Park 2009). Similar nanoparticulate system 
was developed, with additional PEGylated lipid tethered to the ligand, which improves 
nanoparticle stabilisation. In vitro studies conducted, revealed greater transfection efficiency 
with improved downregulation of survivin mRNA and protein, decreased cellular proliferation 
and enhanced sensitisation of cancer cells to anti cancer drugs (Li & Huang 2006a, 2006b). 
Investigations using anti- survivin amino silica nanoparticles (NH2SiNPs) proved enhanced gene 
delivery efficiency in HeLa and epithelial carcinoma cells (A549), inhibiting survivin expression 
and cell proliferation. Furthermore, the results when compared with liposomal delivery system, 
anti survivin oligonucleotide  - (NH2SiNPs) were more biocompatible and exhibited nil 
cytotoxicity, with more improved transfection(Peng et al. 2006a). Locked nucleic acid (LNA) ± 
oligonucleotide ± nanoparticle (NP) (LNPs) conjugates were developed by utilisation of gold 
nano particles tethered with thiol ± terminated locked nucleic acid oligonucleotides, enabling to 
form remarkable stable duplexes and effective binding with the complementary nucleic acids in 
the cells for promoting  gene silencing. In this study, LNA ± anti survivin oligonucleotide ± NP 
conjugates were incubated with lung carcinoma cell line, A549 and survivin expression was 
examined. Results suggested that LNPs significantly down regulated survivin protein levels in a 
dose dependent manner as confirmed by western blot analysis, in comparision with control 
samples(Seferos et al. 2007). Dual purpose magnetic iron oxide nanoparticles were designed for 
in vivo targeting of survivin expression in tumour mice models. These magnetic nanoparticles 
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were covalently linked to survivin siRNA for therapeutic targeting and simultaneously labelled 
with a infrared dye to enable near ± infrared in vivo optical imaging and high resolution magnetic 
resonance imaging (MRI). Furthermore, these nanoparticles were also coupled with a membrane 
translocation peptide for efficient intracellular delivery. Experimental results reported drastic 
inhibition in survivin levels verified by reverse transcriptase ± polymerase chain reaction (RT ± 
PCR), leading to enhanced tumour apoptosis and necrosis in comparison with controls(Medarova 
et al. 2007; Nan 2007; Wang et al. 2008).  
 
 
Figure 2.4: Nanomedicine mediated cancer drug delivery. Figure legend: The diagram 
illustrates compartmentalised oriented nanotechnology based drug delivery against cancer. 
Intracellular uptake of (A) Alginate-coated nanocarriers (ACNC)  nanocarriers complexed with 
antisense survivin - cross linked CPP (R9 and Tat peptides) and (B)  Alginate gel-encapsulated, 
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chitosan ceramic nanocore nanocarriers (ACNC-NPs) loaded with (DNSurR9) ± complexed with 
antisense miRNA-27a  are mediated by endocytosis mechanism. ACNC ± antisense survivin ± 
CPP peptide delivery system counteracts the action of cytosolic survivin triggering apoptosis. 
ACNC-NP - DNSurR9) ± antisense miRNA-27a delivery system exhibited multifunctional 
nature inhibiting cytosolic survivin, oncogenic  miRNA-27a, VEGF receptor and causing 
disintegration of mitochondria leading to angiogenic inhibition and mitochondrial apoptosis. 
(Figure reference: Kanwar et al; Drug Discovery Today 2011).   
2.2.5.4 Synthetic inhibitors for targeting cancer 
Geldanamycin and derivatives: Exposure of sarcoma cell line to 17 ± AAG, caused down 
regulation of survivin protein leading to enhanced apoptotic response and also radio 
sensitisation(Pennati, Folini & Zaffaroni 2007). Studies conducted on glioma cells with 17 ± 
AAG, showed disruption of HSP90 ± HIF-ĮLQWHUDFWLRQFDXVHGWKHGHFUHDVHRIFHOOPLJUDWLRQ
via focal adhesion kinase (FAK) phosphorylation(Graner & Bigner 2005). Investigations 
conducted on Hela cells demonstrated loss of survivin expression in a dose dependent manner of 
GA (geldanamycin), with growth arrest at G2 ± M phase transition with consistent inactivation 
of p53 / Rb complex (Fortugno et al. 2003).  It was shown that geldanamycin and 17-AAG 
treated human cancer cell lines - A549, HONE-1 and HT-29 caused increase in survivin 
expression at translational level and therefore, HSP90 inhibitors regulate survivin expression in 
different stages in a vivid manner. Hence, further studies need to be conducted to decipher the 
exact mechanism of action of these inhibitors on survivin(Cheung et al. 2010b). 
1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-
naphtho[2,3-d]imidazolium bromide (YM155) : Gene reporter assays were performed with 
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transformed cells expressing stable survivin gene promoter region ± driven by luciferase reporter 
gene(Nakahara et al. 2007a) to screen the potent inhibitors of survivin promoter and a 
imidazolium based compound known as YM155 seemed to be effectively targeting survivin 
expression, at a very low sub nano molar concentrations. YM155 molecule exhibited its activity 
both in vitro and in vivo, by escalating caspase mediated apoptotic mechanisms and inhibition of 
DNA repair with increased radiosensitivity by downregulation of survivin in a time dependent 
manner (Nakahara et al. 2007a), which in turn can sensitise the tumour cells to conventional 
chemotherapeutic strategies(Iwasa et al. 2008). Investigations undertaken to evaluate the effect 
of YM155 on various anti apoptotic proteins resulted in effective decrement in survivin and 
conversely having no effect on c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, a-actin, and h-tubulin 
proteins, mitotic mechanisms, G2-M phase cell cycle check point and alteration of the 
phosphorylated form of AKT showing differential selectivity of YM155 on survivin expression 
independent of functional p53 gene status in tumours(Nakahara et al. 2007a). Preclinical studies 
have proven the activity of YM155 in suppressing survivin expression both at protein and 
mRNA level. The increased sensitivity of human refractory prostate cancer was established, In 
addition to this, pharmacokinetic analysis showed profound concentrations of YM155 was in 
tumours tissue than in plasma(Mita et al. 2008). Phase 1 clinical studies indicated potential use 
of YM155 as a drug candidate for non ± hodgkin lymphoma, hormone ± refractory prostate 
cancer and non small cell lung cancer. Decreased prostate serum antigen level was observed in 
subjects treated with YM155 and studies are underway to test the efficiency of YM155 molecule 
in combination with a chemotherapeutic drug, docetaxel in hormone refractory prostate 
cancer(Tuma 2009). Elucidation of YM155 activity and cell signalling pathways involved, in 
ϯϲ

combination with conventional radio and chemotherapeutic treatment platforms can provide a 
rationale for effect anticancer therapies (Iwasa et al. 2008). 
 
2.2.6  Cancer chemoresistance and radioresistance: 
Chemoresistance: NF- kȕ, a transcription factor is known to promote chemoresistance in 
multiple myeloma cells, along with its downstream effectors like survivin. Studies were 
conducted using curcumin compound on chemoresistant cell lines. Curcumin showed enhanced 
apoptosis effect by downregulating NF- Nȕ function and associated downstream molecule 
survivin attributing to its chemosensitive effects on cancer cells (Sung et al. 2009). Studies 
conducted on pancreatic cancer cell lines showed chemoresistant behaviour to gemcitabine 
treatment followed by enhanced survivin expression. Emodin, a medicinal herb was used in 
combinatorial therapy with gemcitabine to suppress cancer cells by downregulation of survivin 
and also ȕ- catenin which is known to interact with survivin promoting chemoresistance (Guo et 
al. 2009). Survivin is known to promote chemosresistance by stabilising microtubule 
organisation. Studies conducted using BPR0L075, a tubulin depolymerising agent on a 
BPR0L075 resistant KB cell line showed enhanced survivin expression. Therefore, conditional 
deletion of survivin gene with a specific siRNA molecule markedly induced sensitivity for 
BPR0L075 compound. Hence, results suggest that administration of a microtubule destabilising 
agent in combination with survivin inhibitor can prove worthwhile for treatment of 
chemoresistance cancers (Cheung et al. 2009). Research studies were carried out using T138067, 
a drug compound active against multi drug resistant tumour cell lines. However, due to induction 
of survivin expression via PI3K/AKT and MEK/ERK pathways, the drug had less pronounced 
apoptotic effect on chemoresistant tumours.  Furthermore, a new molecule SN8, metabolite of  
ϯϳ

ironotecan known to effectively inhibit survivin was used in combination with T138067  and 
interestingly this drug formulation effectively inhibited survivin, promoting  enhanced cell 
death(Ling et al. 2009). Mohammad Saleem et al demonstrated the use of lupeol, a triterpene 
compound known to inhibit human androgen ± sensitive prostate cancer cells (CaP cells) acts as 
an microtubule destabilising agent by inducing G2/M cell cycle arrest, decreasing survivin 
expression (Saleem et al. 2009). Research findings were reported that ErbB2 mediated 
transcriptional increase in survivin expression causes taxol resistance in breast cancer cell lines. 
Downregulation of survivin gene by specific siRNA molecule sensitised cells to taxol treatment. 
PI3K/AKT and sarcoma (Src) gene activation is known to promote translational increase in 
survivin via mTOR/eukaryotic translation initiation factor 4E-binding protein 1 ;4EBP1) 
pathway. Therefore, inhibitors acting on both erythroblastic leukemia viral oncogene homolog 2 
(ErbB2) and PI3K/AKT pathway can help in modulating taxol resistance interms of survivin 
expression (Lu et al. 2009). Investigations performed with low nitric oxide (NO) levels caused 
chemoresistance against cisplatin/ taxol treatment in head and neck squamous cell carcinoma 
(HNSCC). Cytoprotective mechamism was mediated by survivin upregulation at low doses of 
NO. Furthermore, RNA interference (RNAi) studies carried out to deplete survivin levels 
completely attenuated anti ± apoptotic mechanisms of NO. Hence, results suggest that RNAi 
targeting of survivin in combination with NOs specific inhibitor can be a potential treatment 
regime for head and neck cancers (Fetz et al. 2009). Survivin is also known to promote 
chemoresistance in part by integrin mediated signalling. focal adhesion kinase (FAK), a centre 
molecule in this signalling pathway  is known to regulate survivin expression leading to intrinsic 
chemoresistance(Wu et al. 2009). Studies were carried out to investigate the mechanism of 
paclitaxel resistance in ovarian cancer cells. Lentiviral short hairpin RNA molecules were 
ϯϴ

targeted to survivin and results reported that knowndown of survivin caused reversal of 
paclitaxel resistance (Duan et al. 2008). 
Radioresistance:  Survivin expression is known to be regulated by specificity proteins (SP) and 
is linked to inducing radioresistance in tumours. Studies conducted in pancreatic cell lines with 
tolfenamic acid revealed that proteosomal degradation of SP proteins, leading to suppression of 
SP dependent survivin upregulation, thereby sensitising cancer cells to radiation and promoting 
apoptosis. The results obtained in in vivo studies were in accord with in vitro studies (Konduri et 
al. 2009). Investigations conducted using survivin siRNA  in irradiated SW480 (human 
adenocarcinoma cell line ) and HCT ± 15 (colorectal carcinoma cell line), caused marked 
attenuation of survivin  resulting in G2- M phase cell cycle arrest, causing DNA double strand 
breaks  and promoting increased caspase - 3/7 activity leading to enhanced radiation induced 
apoptosis (Rodel et al. 2005). human telomerase reverse transcriptase (hTERT) , a telomerase 
activation enzyme was targeted with survivin promoter based siRNA, experimental findings 
from these observations reported decreased proliferation of cervical cancer cells followed by 
increase in radiosensitisation effect(Ryan, O'Donovan & Duffy 2009). Investigations on HepG2 
cell line subjected to high ± linear energy transfer (LET radiation and examined the major cause 
of radiosensitive. The group used survivin specific siRNA to suppress survivin upregulation in 
radioresistant HepG2 cells. Experimental findings reported profound radiosensitivity in the cell 
lines was observed after specific inhibition of survivin mRNA by RNA interference studies(Jin 
et al. 2010). Similar kind of studies were carried out in primary human glioma cell line and in 
KB squamous cell carcinoma to examine the extent of double strand breaks caused due to 
survivin inhibition in radioresistant cell lines(Jiang et al.). However, controversial results were 
also reported in radioresistant lung cancer cell lines, with no change observed in levels of 
ϯϵ

survivin expression when the cells were treated with HIF-Į specific siRNA(Kim et al. 2009). 
Research studies carried were out by using nucleoside analogues, TAS ±  ƍ-C-
ethynylcytidine) in radioresistant tumour cells. TAS ± 106, used in combination with HIF-Į 
inhibition, in hypoxic tumour cells caused infrared radiation induced apoptosis, subsequently 
downregulating survivin expression. Furthermore, TAS -106 has reached Phase 1 / 2 clinical 
trials in anti cancer therapies(Bischoff, Altmeyer & Dumont 2009). Increased survivin protein 
expression was noted in studies conducted in irradiated colon cancer line (KM12L4a) (Pfeifer et 
al. 2009). Studies conducted on MDA- MB-231 (breast cancer cell line) showed improved 
radiosenstitisation effect, when treated with DN ± Survivin molecule leading to suppressed 
angiogenesis and decreased cell survival (Aggarwal et al. 2009). Similar kind of studies were 
performed using far infrared radiation treated cells in SK±N±MC (human neuroblastoma cell 
line) and profound survivin up regulation mediated by transcription factor NF-.ȕ was observed 
(Madhusoodhanan et al. 2009). Studies were conducted on pancreatic cancer cells - PANC-1 
(photon radioresistant) and MIA PaCa-2 (photon radiosensitive) to determine the rate of survivin 
expression. Proton irradiation coupled with gemcitabine treatment showed marked inhibition of 
survivin in MIA PaCa-2 cell line, while very less effect was observed in PANC-1(Galloway et 
al. 2009). Survivin is also known to play a prominent role in inducing radioresistance in 
progenitor cells.  Studies were conducted using COMMA ± geo cell line (mammary progenitor 
cells) to determine the rate of survivin expression following irradiation. Experimental findings 
reported increased survivin expression mediated by WNT/catenin signalling pathway (Chen et al. 
2007). Furthermore, pharmacological inhibition of WNT/catenin signalling pathway by ICG -
001, a molecular inhibitor caused downregulation of catenin via interaction with cAMP ± 
ϰϬ

responsive element binding protein. Hence, this resulted in transcriptional inhibition of 
survivin(Woodward et al. 2007). 
 
2.2.7 Conclusion and future directions: In conclusion, understanding the pharmacology of anti 
apoptotic molecules (such as survivin etc) in cancer biology can certainly lead to development of 
sustainable therapeutic approaches. Recent studies were undertaken to evaluate the sub-cellular 
localisation and functional aspects in the mitochondrial signalling network and ambiguous 
behaviour of survivin interactions with the molecular inhibitors is a topic of current debate which 
is still under consideration (Kang et al. 2009). However, the evolving complexity in survivin 
signalling mechanisms has retrograded the current therapeutics from specifically targeting 
survivin. Adhering to the knowledge generated from our research studies conducted at our 
laboratory, we illustrate a novel nanotechnological based paradigm like nanocarriers, 
multifunctional nanodevices that can selectively target sub - cellular survivin localisation and 
trigger survivin downregulation, when targeted utilising biocompatible natural product derived 
therapeutics inconjucture with RNAi, microRNA and aptamer enabled technologies (Bawa 2009; 
Kanwar, Mahidhara & Kanwar 2011b; Mahidhara, Kanwar & Kanwar 2010 )(Figure 4)(Box 1). 
The treatment strategies mentioned above contemporaneously detect and oversee anti apoptotic 
molecule expression ultimately leading to inhibition of cancer growth.  
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Table 2.1: Inhibitors and modulators of cancer growth mechanisms  
 
CSP Inhibitor Modulator Ref 
 
PI3K Herceptin  EGFR, HIF, HER2  (Asanuma et al. 
2005; Debatin, 
Wei & Beltinger 
2008; Melillo 
2007; Peng et al. 
2006b) 
PI3K SCH66336 FSH, VEGF, Haematopoietic 
Cytokines, Id1     
(Carter et al. 
2006; Huang et 
al. 2008; Lin et 
al. 2010; Oh et 
al. 2008)    
mTOR Nicotine and NNK IGFR1  (Jin et al. 2008; 
Vaira et al. 
2007)  
mTOR Triciribine  Ras  (Shinjyo et al. 
2008; Zhang, 
Zhang & Sun 
2009)  
ERK  PD98059,Imatinib , 
Quercetin   
Bcr-Abl (Carter et al. 
2006; Kim et al. 
2008; Tan, 
Wang & Zhu 
2009)    
p53 Decitabine E2F-1, APC, Hypoxia, 
p300/CBP, Ran ± GTP 
(Altieri 2008; 
Hammond & 
Giaccia 2005; 
Khan et al. 
2009; Nabilsi, 
Broaddus & 
Loose 2009; 
Vegran et al. 
2007)    
PTEN  FOXO1,FOXO3a  (Guha et al. 
2009) 
Bcl2,  NF-
ț% 
Curcumin, ABT-737  p53, p38 MAPK (Sung et al. 
2009; Watson et 
al. 2010) 
(Jayanthan et al. 
2009)    
Bcl2 TW -37 , 15d-PGJ2 & TGZ, 
STAT3     
PPAR-g  (Liu et al. 2005; 
Uckun et al. 
2010; Wang et 
ϰϮ

al. 2009b)    
Ras Lovastatin  PI3K, MEK,MAPK  (Kaneko et al. 
2007; Matsuo et 
al. 2009; 
Sommer et al. 
2007)  
Ras, ERK FTS; salirasib  E2A-HLF  (Okuya et al. 
2010) (Blum et 
al. 2007)  
 
CSP ± Cell Signalling Pathway: PI3K - Phosphoinositide 3-kinases, mTOR - Mammalian 
target of rapamycin, ERK - Extracellular signal-regulated kinases, p53, PTEN(Phosphatase and 
tensin homolog) - Tumour suppressor proteins, Bcl2,Ras - Oncogenes, NF-ț% - Nuclear factor 
kappa-light-chain-enhancer of activated B cells. 
 
Inhibitors: SCH66336 - Farnesyltransferase inhibitor, NNK  -  (4- methylnitrosamino)-1-(3-
pyridyl)-1-butanone), PD98059 - Mitogen-activated protein kinase (MEK) inhibitor, ABT-737 - 
Molecular Inhibitor, TW -37 - Molecular Inhibitor, (15d-PGJ2) - (15-deoxy-delta(12,14)-
prostaglandin J2), TGZ - Troglitazone, STAT3 - Signal transducer and activator of transcription, 
FTS: Salirasib  - (S-farnesylthiosalicylic acid), Lovastatin - ( 3-Hydroxy-3-methylglutaryl 
coenzyme A reductase inhibitors (HRIs) )  
 
Modulators: EGFR - Epidermal growth factor receptor, HIF - Hypoxia Inducible Factor, 
HER2 - Human epidermal growth factor receptor 2, FSH -  Follicle-stimulating hormone, 
VEGF -  Vascular endothelial growth factor, Id1 - Inhibitor of Differentiation, IGFR1 - Insulin 
growth factor receptor ± 1, Bcr-abl - Oncogene fusion protein, E2F-1 - Transcription factor, 
APC  -  Adenomatous polyposis coli protein,  p300/CBP - Transcriptional co-activator proteins, 
Ran ± GTP pathway - Ran (Ras-related Nuclear protein) - Guanosine-5'-triphosphate pathway, 
FOXO1 and FOXO3a - Transcription factors, p38 MAPK - P38 mitogen-activated protein 
kinases, (PPAR-g) - Peroxisome proliferator activated receptor ± g  ligands, E2A-HLF - 
Transcription factor.          
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Table 2.2: Novel nanodelivery systems targeting cancer. 
 
 
Nanodelivery system Sequence  Mechanism 
of action 
Key 
molecules 
Study 
Model 
Ref 
 
Polyamidoamine (PAMAM) 
dendrimer ± conjugated 
MPNs antisurvivin 
oligonucleotides(asODN) 
siRNA - (5-
CCCAGCCTTCCAGCTCC
TTG-3) 
Blocking 
translation 
of survivin 
mRNA 
Ribosome, 
survivin 
In vitro (Byrn
e, 
Betan
court 
& 
Brann
on-
Peppa
s 
2008; 
Jabr-
Milan
e et al. 
2008; 
Pan et 
al. 
2007; 
Park 
et al. 
2009) 
LPD(Liposome Polycation - 
DNA) ± PEGylated  
nanoparticle coupled with 
anisamide  - conjugated to 
survivin siRNA 
siRNA  
5¶-
GGCUGGCUUCAUCCAC
UGCdTdT- 
3¶;  
 
3¶- 
dTdTCCGACCGAAGUAG
GUGACG-5¶. 
sigma 
receptor-
mediated 
pathway 
Sigma 
receptors, 
survivin 
In vitro (Byrn
e, 
Betan
court 
& 
Brann
on-
Peppa
s 
2008; 
Chen 
& 
Huan
g 
ϰϰ

2008; 
Oh & 
Park 
2009) 
Anti- survivin amino silica 
nanoparticles (NH2SiNPs)   
siRNA  
 
(5V-TGT GCT ATT CTG 
TGA ATT-3V 
Antisense 
inhibition of 
survivin 
survivin In vitro (Peng 
et al. 
2006a
) 
(Locked nucleic acid)LNA ± 
oligonucleotide ± NP 
(Nanoparticle) 
 
siRNA  
 
CCCAGCCTTCCAGCTCC
TTG(OEG)SH 
Inhibiting 
gene 
expression 
survivin In vitro (Sefer
os et 
al. 
2007) 
Magnetic iron oxide 
nanoparticles coupled with  
membrane translocation 
peptide ± conjugated to 
survivin siRNA 
 
Translocation peptide - 
(Myr-Ala-(Arg)7-Cys-
CONH2) 
Enhanced 
apoptosis 
and necrosis 
survivin In vivo 
(mice 
models) 
(Meda
rova 
et al. 
2007; 
Nan 
2007; 
Wang 
et al. 
2008) 
Antisense survivin + 
Liposome 
6HQVH SULPHU ¶-
GAGTCGTCTTGGCGGA
GG-¶ 
$QWLVHQVH SULPHU ¶-
CTTAGATGTGGCATGT
CACTC- 
¶ 
Antisense 
inhibition of 
survivin 
survivin In vivo 
(mice 
models) 
(Kan
war et 
al. 
2001) 
Dominant negative survivin 
+ liposome 
Primers 
&$) ¶-
CACTCCCCGGGCGCAG
CCTTCCTCAC- 
Blocking 
endogenous 
survivin 
function by 
competitive 
binding to 
Survivin  In vivo 
(mice 
models) 
(Kan
war et 
al. 
2001) 
ϰϱ

¶ 
&$5 ¶-
GGCTGCGCCCGGGGAG
TGCTT- 
¶ 
survivin 
effectors. 
Combination of antisense + 
dominant negative survivin 
+ liposome 
Antisense strategy  
6HQVH SULPHU ¶-
GAGTCGTCTTGGCGGAGG-
¶ 
$QWLVHQVH SULPHU ¶-
CTTAGATGTGGCATGTCACT
C- 
¶ 
Dominant negative survivin 
Primers 
&$) ¶-
CACTCCCCGGGCGCAGCCTT
CCTCAC- 
¶ 
&$5 ¶-
GGCTGCGCCCGGGGAGTGC
TT- 
¶ 
 
Antisense 
inhibition 
and 
competitive 
binding to 
survivin 
effectors 
Survivin In vivo 
(mice 
models) 
(Kan
war et 
al. 
2001) 










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2.3 Molecular inhibitors targeting cancer growth mechanisms 
 
2.3.1 Introduction 
Essentially, anti apoptotic proteins play a key role in modulating cell cycle dependent 
mechanisms such as cell division, cell stress response and cell cycle checkpoints with physical 
localisation to mitotic spindle apparatus (Pennati, Folini & Zaffaroni 2008). At the mitotic level, 
anti apoptotic molecular (survivin etc) over expression is reported to have an inhibitory effect on 
centrosomal microtubule nucleation that later stabilise the microtubule functional integrity in 
causing bidirectional microtubule growth during cell division(Kanwar et al. 2010c). Non cell 
cycle dependent mechanisms of survivin involves in tissue patterning functions via wingless and 
int homologue(Wnt)/ betaȕ ± catenin signalling mechanism, cytokine activation via signal 
transducer and activator of transcription 3 (STAT3) signalling, activatory costimulatory 
molecules (OX-40) and pleiotrophic cell signal transduction  pathways such as PI3K/AKT, NF-
kȕ signalling pathways. Due to the above mentioned mechanism, inhibitor of apoptotic genes 
tend to play a major role for cell growth modulation and hence, leading to over expression in 
majority of cancers (Pennati, Folini & Zaffaroni 2008). Studies conducted in the recent past  
proved the ability of survivin to counteract with extrinsic and intrinsic mediators of apoptosis 
with affecting mechanisms such as  withdrawal of IL -3 , stimulation of ligands like FAS, 
TRAIL, functional activation of caspase ± 3, 7, 8 mechanisms. Therefore this interactive ability 
of survivin tends to increase cell proliferation of tumour cells and also mutant cancer cells. 
Survivin is known to play a prominent role in promoting angiogenesis leading to new blood 
formation in tumour vasculature. The possible mechanism of regulating angiogenesis involves 
enhancing anti apoptotic stimuli in endothelial cells leading to cell growth due to angiogenesis 
(Ryan, O'Donovan & Duffy 2009). Some of the key prominent features of cancer related 
ϰϳ

inflammatory mechanisms is manifested by leukocyte infiltration, increased expression of 
cytokines ± TNF, interleukin and chemokines, promotion of tumour angiogenesis and tissue 
modelling for proliferation. Transcription factors, cytokines and chemokines are known to 
mediate mechanisms that enhance cancer inflammation ultimately leading to tumour progression 
(Grivennikov, Greten & Karin 2010; Mantovani, Garlanda & Allavena 2010). Survivin in 
association with heat shock protein 90 (HSP90) is known to stabilise factors like AKT, Erb-2 and 
HIF -1Į that enhance tumour progression. Hence, studies designed to target survivin ± HSP90 
interaction is proven to be effective treatment strategy (Cheung et al. 2010b). Non transcriptional 
mechanisms are known to deregulate survivin expression for example ± stabilisation of survivin 
mRNA in mTOR mediated cell signalling pathway(Altieri 2010). Recent studies conducted to 
identify the regulatory role of survivin in apoptosis mechanism revealed that,  under the 
apoptotic stress, survivin is known to relocalise from cytoplasm to nucleus caused due to a 
change in RAs-related nuclear protein Guanosine-5'-triphosphate (RanGTP) pathway. During 
apoptosis stress, RanGTP is known to exhibit gradient collapse and hence leading to inefficient 
formation of RanGTP ± CRM1(nuclear export receptor) - survivin export complex that cause 
survivin relocalisation and subsequent ubiquitination facilitating survivin degradation and also 
preventing it from re entering in cytoplasm(Chan et al. 2010). Recent observations suggest that 
the key role of organelle specific survivin ± HSP90 interaction that trigger cell signalling cascade 
to activate pathways that sustain tumour growth. Tumour specific subcellular localisation of 
survivin was noticed in mitochondria that interacts with HSP90  forming complex causing an 
antagonistic effect on mitochondrial apoptosis thereby specifically activating cell signalling 
pathways(Altieri 2008). Research findings suggested that mitochondrial pool of survivin may 
inhibit apoptosis through caspase interference mechanisms(Kanwar et al. 2010c). However, the 
ϰϴ

mechanism of recruiting various key molecules by mitochondrial survivin remains to be 
elucidated (Altieri 2008). Till date, the prominent approaches that target cancer include four 
different ways namely ± utilisation of antisense oligonucleotides, ribozymes and siRNAs , 
targeting with small molecular inhibitors and peptidomimetics, gene therapy approaches by use 
of  molecule specific dominant mutants and gene  promoter driven mechanisms, immunotherapy 
based targeting of survivin(Pennati, Folini & Zaffaroni 2008). This section for the first time 
provides a state of art knowledge pertaining to the research conducted to understand the biology 
and in therapeutic targeting of  anticancer molecules. An array of targeted approaches against 
cancer involving RNAi based approach, immunotherapeutic strategies, chemotherapeutic and 
peptide based approaches are discussed in detail. This section provides an insight about recent 
developments in understanding role of anti antipoptotic molecular expression as an angiogenic 
and diagnostic markers in cancer development and also future directions pertaining to the applied 
research in therapeutic biology of cancer are elaborated. 
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Figure 2.5: Schematic representation of strategic mechanisms and signalling molecules 
involved in cancer targeting. Figure legends - Schematic representation of strategic 
mechanisms and signalling molecules involved in cancer targeting. (A) RNAi; (B) Peptide; (C) 
Chemotherapeutic drug; and (D) Immunotherapeutic based targeting molecules. 
 
2.3.2 Role of anti apoptotic proteins in cancer 
Survivin has a role in apoptosis and survival mechanisms in neutrophils belonging to myeloid 
lineage. There was decrease in survivin expression and increased apoptosis in neutrophils (Hayes 
et al. 2006a). Identification of a novel survivin interacting protein 1 namely tetratricopeptide 
repeat 1(TPR1) polypeptides was carried out that played a role in survivin controlled apoptotic 
mechanisms during mitosis and correlated with chemotherapeutic agents and immune responses. 
Yeast - two - hybrid (Y2H) technology was used to identify these proteins, where as functional 
significance of these proteins needs to be elucidated (Hentsch, Dücker & Hock 2007). 
Interestingly, dominant negative mutant of survivin (SurR9-C84A) developed at our laboratory 
showed promising results having neuroprotective ability that could open new avenues for 
therapeutic management in neurodegenerative disorders. We observed that SurR9-C84A had a 
proliferative effect in differentiated neuronal cell lines SK-N-SH and HCN-2 mediated by 
regulation of microtubule binding and stability during cell division (Baratchi et al. 2010). 
Research findings  related the elucidation of neuroprotective effect of survivin manifested by 
functional inactivation of caspase - 9 followed by activation of cytochrome C (Cyt C)and 
apoptotic protease activating factor 1 (Apaf 1) thereby inhibiting apoptosis (Sendtner, Rapp & 
Wiese 2004). The isolation of survivin interacting proteins termed as survivin binding partners  
modulate the biological and pathological mechanisms of survivin. These  binding partners are 
ϱϬ

screened and isolated by Yeast two hybrid system and hence, further can be developed as 
essential drug targets (Altieri 2005). Acute renal failure is associated with functional activation 
of caspases followed by drastic increase of pro apoptotic genes that modulate survivin 
expression. Survivin over expression protects cells from apoptosis through Fas ligand (FasL) 
interactions. Hence, antisense targeting of survivin can trigger Fas induced apoptotic 
mechanisms (Conway 2009). Survivin interacting proteins (SIP1) that modulate survivin 
expression are known to control apoptotic mechanism. These molecules are also known to 
promote drug resistance and anti aging properties, can be an attractive drug targets (Hentsch & 
Hock 2006). Studies conducted with the plant extracts derived from coleus forskolii, nostoc 
commune, scenedesmus dimorphus, curcuma longa, crocus sativus, daniellia oliveri, lepechinia 
caulescens and limnophila conferta, stimulate the survivin expression in normal human 
keratinocyte cells. Survivin is known to confer regenerative capacity in human epidermis cells 
and basal layer of stem cell epidermis (Dumas, Bonte & Renimel 2010). The invention related to 
development of eukaryotic cells with a human survivin promoter gene linked to a reporter 
molecule. This system is used to monitor the expression of survivin based on increase and 
decrease in level of reporter gene. Further, in vivo imaging studies were undertaken using SPlug 
Tg ovarian and prostate cancer mice models to detect survivin expression depending on 
luciferase reporter activity (Li 2009).  Effect of small molecule inhibitors capable of inhibiting 
histone deacetylases (HDAC) was noticed and had an effect on cell proliferation pathways. 
These HDAC inhibitors showed a decrease of pro angiogenic factors angiopoietin - 2, survivin  
in endothelial cell growth and along with downregulation of hypoxia inducible factor ± 1 (HIF - 
Į in tumour cell growth and caused suppression of  tumour angiogenesis (Cai et al. 2008).   
Prominent role of survivin in survival and apoptotic mechanisms was manifested in non dividing 
ϱϭ

cells of myeloid lineage, particularly neutrophils. Hence, survivin expression was decreased in 
neutrophil apoptosis and concomitant increase in survivin was noted in presence of granulocyte 
macrophage - colony stimulating factor (GM-CSF).However, antisense inhibition of survivin 
caused increased neutrophil apoptosis. This concept can be an effective therapeutic strategy by 
modulating survivin expression(Hayes et al. 2003). 
Phosphorylation of survivin by mitotic kinase complex and p34 cdc2 cyclin B1, that helped to 
maintain cell viability during mitotic processes. However, lack of survivin phosphorylation 
during mitosis caused dissociation of survivin - active caspase - complex leading to caspase - 9 
dependent apoptosis of cells. Furthermore, methods to identify interaction of survivin and p34 
cyclin complex were deciphered utilising various molecular agents such as peptides, small 
molecules, vitamin deravatives and carbohydrates(Altieri 2009).  
 
2.3.3 Inhibitors targeting cancer angiogenesis  
 An increase in angiogenic stimulation and endothelial cell growth was conferred with an 
increase in survivin expression. Therapeutic modulation of survivin can make an impact on 
endothelial cell growth. Furthermore, survivin along with AKT is known to activate anti 
apoptotic pathways leading to endothelial cell growth and tumour angiogenesis. Targeting the 
survivin / AKT pathway can provide with prominent therapeutic interventions to stimulate 
endothelial cell growth in tumour angiogenesis (Alteri & Sessa 2001). Survivin gene expression 
was detected in cancer cells using molecular beacon technology. Molecular beacons are dual 
labeled probes consisting of a flourophore and a quencher to detect oligonucleotides (ODN). The 
functional mechanism involves, generation of a fluorescent signal in the presence of ODNs due 
ϱϮ

to hybridisation of quencher, but in the absence of target sequence both flourophore and 
quencher exists together that prevent generation of signal. Hence, based on this concept the 
concentration of ODN can be estimated. Molecular beacons targeting survivin along with cyclin 
D1 mRNAs were introduced in the cells. A flourophore molecule was attached to detect the 
specific gene expression. This strategy can be effective for simultaneous delivery and detection 
of specific gene expression and mechanisms related (Yang 2006). Methods were developed to 
screen and identify compounds that selectively bind to target ribonucleic acid (RNA). Non 
competitive binding assays were carried out and binding efficiency was detected utilising a 
physical method. Survivin mRNA was screened and compounds that bind selectively were 
identified (Conn et al. 2005). Recombinant nucleic acid molecules encoded with an IAP gene 
family control element linked with a cytotoxic agent were devised. Herein, recombinant nucleic 
acid molecules encoding survivin promoter element with a granzyme B (Gr B) was utilised for 
specific targeting of survivin. This targeting strategy can be promoted in clinical therapeutic 
settings (Caldas & Altura 2006). Methods to increase the concentration of chemotherapeutic 
agents by incorporating a vector consisting of prodrug activating enzyme that can enhance drug 
action was formulated. In these studies, survivin expression was targeted  utilising prodrug 
activating enzyme - cytochrome P450 via caspase pathway(Waxman & Schwartz 2006).  Early 
diagnosis of ovarian cancer can be done with suitable essential biomarkers utilising luminex Lab 
MAP bead - type immunoassay (LabMAP technology).  Luminex Lab MAP bead - type 
immunoassay is a sandwich assay in which antigen is sandwiched between two binding agents, 
one being binding antibody and other a detectable microsphere bead group labelled with 
fluorochromes, enzymes or epitopes for binding antibody. Laser signals are detected depending 
on intensity of reported molecule to ultimately quantitate the concentration of antigen. 
ϱϯ

Antisurvivin antibodies are detected in serum levels for early detection of ovarian 
cancer(Lokshin 2007). 
The importance of angiopoietins (Ang -1,2,3) molecules in relation to survivin expression was 
deciphered in which  Ang - 1 in general accelerates adhesion and migration of endothelial cells 
via activation of PI3 kinase / AKT pathway upregulating survivin expression by inhibiting 
mitochondrial apoptosis(Yu 2009).  Importance of modulation of stability and dysregulation of 
native state of survivin protein in triggering pathophysiological responses  in various diseases 
like cancer, inflammation was noticed(Wang & Bulawa 2008). Survivin expression was targeted 
utilising pigment epithelium-derived factor  - zinc finger proteins (PEDF ZFP) activators 
delivered by an adenovirus vehicle that modulate expression of  zinc finger proteins 
(ZFP)(Zhang & Gregory 2008). Investigations were carried out to determine the role of check 
point kinase 2 (Chk2) in response to DNA damage during cell cycle phases on survivin 
expression.Chk2 is known to modulate DNA damage response pathways by controlling DNA 
damage and telomere erosion. Studies were carried out to assess the effect of Chk2 activation of 
survivin expression in tumours. Specific activation of Chk2 caused ablation of survivin 
expression and therefore, inverse correlation is noted among the both entities(Li, Rogoff & Chen 
2006). Survivin expression was assessed utilisiQJ D UHSRUWHU JHQH PRGXODWHG E\ ȕ - catenin 
transcription factor, a prominent molecule expressed in gastric cancers(Heyer & O'hagan 2007). 
B7-1 is a prominent molecule expressed on antigen presenting cells (APC) interacting with 
CD28 cells and promoting T cell mediated immunity against tumours. Our laboratory studies 
revealed the role of survivin in promoting immunosuppressive effect on tumour by rendering 
tumours more resistant to cytotoxic T cells (CTLs). In vivo studies conducted showed the 
treatment of tumours in combination with B7-1 molecule and antisense survivin or dominant 
ϱϰ

negative mutants showed marked downregulation of survivin followed by increased generation 
of CTLs leading to regression of tumours. Therefore, we have demonstrated for the first time that 
survivin expression in relation with B7-1 activity can be an effective prognostic and diagnostic 
marker for detection and treatment of aggressive tumours(Kanwar et al. 2001).  
B7-H1 is a negative regulator of T cell mediated immunity expressed in multiple tumours. 
Survivin expression was positively correlated with B7-H1 during tumour progression(Kwon et 
al. 2010). Assessment of the protective effect of XIAP molecule in tumour growth inhibition in 
relation to survivin and prolonging patient survival was done. Decreased level of survivin 
expression was noted in relation to increased expression of XIAP(Reed & Krajewski 2010). 
Investigations were undertaken to describe the delivery strategy of immunogen consisting of 
nucleic acid expressing antigen delivered in the host system via intravascular injection. Cancer 
vaccines comprising of survivin and telomerase antigens have been developed proving as an 
effective strategy to formulate universal cancer vaccine(Herweijer et al. 2007). The 
transcriptional regulation of survivin gene occurs in G2/M phase and survivin mediated 
apoptosis inhibition in mitotic cell cycle. Survivin is known to play a regulatory role in formation 
of chromosomal passenger complex by interaction with subunits INCENP and borealin / dasra B 
thereby proceeding to the formation of spindle apparatus during anaphase. Our studies have 
demonstrated  that survivin BIR motif mutant by interacting with aurora B kinase is able to 
accelerate mitotic cell division in G0/G1 phase growth arrested differentiated neuronal cells 
(Baratchi, Kanwar & Kanwar 2010d). 
 Furthermore, various agents that can modulate the interaction of survivin and tubulin during cell 
cycle were identified(Altieri 2002). The importance of combined cancer marker comprising of 
survivin and regenerating gene (REG) has been used for colon cancer. Human REG gene is 
ϱϱ

commonly associated with colorectal cancer and has a prominent role in modulation of cell 
growth and maturation. Furthermore, studies conducted deciphered that REG and survivin gene 
expression can be used as a combined cancer marker to predict clinical circumstances of 
cancer(LS9 7TF 2000). The inverse relation of prostate derived Ets transcription factor (PDEF) 
and survivin in relation to identifying candidates for treatment with a DNA methylation inhibitor 
was studied. Observations revealed increased survivin expression with decreased inhibition of 
PDEF. Therefore, confirming the candidate for treatment with a DNA methylation inhibitor(Li, 
Ghadersohi & Apontes 2009). The relation of expression of survivin, ErbB3 and E-cadherin in 
response to IGF-IR treatment was observed in cancer cells. Insulin growth factor receptor 
(IGFR) is associated with increased expression of survivin via activated Ras/MAPK and PBK 
signalling pathways, promoting tumour growth. Results showed the positive correlation of IGF-
1R along with survivin, E- cadherin and ErbB3 expression. However, inhibition of IGF-1R with 
inhibitors such as cyclolignan picropodophyllin (PPP) and tyrphostins  downregulated the 
expression of survivin, thus this strategy can be utilised as an effective cancer therapy(Witta et 
al. 2010). Another invention identified p53 based survivin downregulation by identifying a novel 
sequence element in the survivin promoter region. The binding of p53 to this identified specific 
sequence element caused survivin repression promoting cell death (Murphy 2003). Usage of 
multiplex immunoassay for detection of survivin in relation to various other tumour marker 
levels like Erb2,Her2 EFGR have been studied(Lokshin & Gorelik 2005). 
 
2.3.4 Anti cancer immunotherapeutics  
Studies were conducted to develop novel survivin derived tumour associated cytotoxic T cell 
(CTL) peptide epitopes for immunotherapy of cancer. This composition is used as a single 
ϱϲ

regime or in combination with other prominent tumour peptides for active st imulation of anti 
tumour response by immune T cell cells. the nature of peptide described in these studies 
specifically derived from human leukocyte antigen(HLA), HLA class 1 and class 2 molecules of 
cells and are helpful to use as a anti tumour vaccine composition to elicit anti tumour immune 
responses against survivin(Rammensee et al. 2010). Antagonists against Human OX40 receptor 
expressed in tumor necrosis factor receptor (TNFR) family of receptor in T cells were developed. 
OX40 receptor is also associated with survivin and hence, antibodies were directed against OX40 
that resulted in decreased survivin expression in a dose dependent manner(Salah-eddine, 
Zhengbin & Sanjaya 2010). Studies were conducted to develop CD4+ T epitopes of survivin 
capable of being presented by HLA 2 molecules. Survivin, being one of the most prominent 
antigen over expressed in tumour can be effectively targeted with CD4+ and CD8+ T 
lymphocytes resulting in eliciting anti tumour responses. This system can be an effective anti 
tumour vaccine strategy(Wang et al. 2009a). Elucidation of the functional mechanism of 
wingless and int homologue (Wnt) signalling pathway was explored in relation to survivin 
causing tumour growth. Wnt signalling pathway, a major pathway involved in cell development 
associates with survivin during proliferation. Hence, targeting of Wnt pathway with anti- Wnt 
antibodies resulted in marked downregulation of survivin expression followed by apoptosis 
activation due to caspase - 3 signalling mechanism(HE et al. 2004). A diagnostic method to 
detect autoantibodies against a disorder was designed. Results proved that lung cancer and colon 
cancer patients showed strong expression of survivin auto antibodies and hence, can be a 
diagnostic marker for the disease(Taylor & Gercel-taylor 2010). Experimental studies were 
conducted to assess PET - based peptide competition assay to detect level of survivin. Peptide 
sequence (MGAPTLPPAWQPF) was used and detection limit of 1nM was observed. Hence, this 
ϱϳ

strategy can be developed as an effective diagnostic tool(Lee et al. 2005). Tumour protein 
antigens were linked to surface of lipid based vesicles that can trigger cytotoxic T cell responses 
in tumours leading to survivin regression(Waelti 2006). The invention details MHC class 1 
restricted epitope peptides that are derived from survivin and eliciting a T cell immune response. 
Hence, these epitopes can be triggered to elicit immune responses against prominent tumour 
antigens(Straten & Andersen 2004). Survivin siRNA are expressed in urinary tract neoplasms 
and Hence, detection of survivin nucleic acid molecules can be developed as an efficient 
diagnostic tool(Nichols, Chan & Jouben-steele 2001). Tumour associated T helper cell peptide 
epitopes in association with tumour peptides that can trigger immune responses against tumours 
were developed and therefore can be utilised as anticancer vaccines. Survivin expression was 
studied by utilising this strategy with T helper cells binding to HLA 2 molecules derived from 
tumour cell lines(Singh et al. 2009). Biomarker screening methods for survivin with the CARD 
containing protein were designed. The level of survivin expression was compared with resistant 
and non resistant control cells(Zhou & Kimberly 2010). Immune response stimulation against 
survivin was carried out by administering an mRNA coding for survivin  antigen and also 
cytokine mRNA along with CpG DNA in conjugation with viral RNA(Hoerr & Pascolo 2008). 
 
2.3.5 RNA interference (RNAi) based cancer therapeutics  
Khvorova et al demonstrated a method for developing  siRNA algorithm to selectively monitor 
generation of functional and hyperfunctional siRNAs against survivin molecule (Khvorova et al. 
2009)]. Strategy was developed to design  treatment approach  involving siRNA based targeting 
of survivin with a combinatorial treatment in association with gemcitabine  hydrochloride, 
resulting in marked inhibition of survivin expression(Patel 2007). Experimental studies were 
ϱϴ

conducted to formulate a meroduplex ribonucleic acid molecule (mdRNA) and blunt ended 
double stranded ribonucleic acid against BIRC gene encoding survivin molecule. mdRNA 
comprises minimum of three strands to form a double stranded molecule that enables 
downregulation of survivin expression and whereas the other strand is complementary to target 
survivin mRNA . The results obtained suggested improved caspase activity resulting in survivin 
down regulation followed by cell death induction(Quay et al. 2010). Studies were conducted to 
target HBXIP factor, transcriptional regulation and acts as co factor for survivin regulation. 
siRNA based studies against HBXIP proved effective down regulation of survivin along with 
HBXIP molecule. Further studies to understand the role of these molecules are under 
investigation(Dobie, Dean & Bennett 2010). Studies reported in WO/2008/083174 on developing 
programmed cell death polypeptide (PD - 1) antagonists. Expression of PD-1 molecule 
functionally disables the apoptotic mechanisms following immune response suppression by T 
cells. Hence, PD-1 antagonists were developed in combination with survivin peptide 
(ELTLGEFLKL) that caused decreased PD-1 expression following by survivin suppression 
activating T cell immune response towards the antigen(Ahmed et al. 2010). Studies were 
conducted to inhibit STAT3 signalling pathway and its interaction with survivin promoter 
region. Hence, siRNA based targeting of STAT3 molecule inhibited the binding capacity of 
STAT3 to the survivin promoter region and hence promoting cell death(Yu et al. 2006). 
PPN/MG61 gene, a homologue of Drosophila porcupine gene that plays a major role in Wnt 
signalling pathway. This molecule is abundantly expressed in cancer cells but not in normal 
cells. Hence, siRNA based studies revealed the targeting of PPN/MG61 caused downregulation 
of Wnt signalling pathway following survivin and ß.catenin inhibition(Xu & Qin 2010). Bhat et 
al demonstrated different ways of modulating survivin expression based on oligonucleotide 
ϱϵ

targetting strategy. Oligonucleotides used in the invention includes a single or double stranded 
molecule comprising RNA like oligonucleotides and DNA like oligonucleotides(Bhat, Patel & 
Swayze 2009). WO/2004/009131 (US patent) describes inhibition of tumour angiogenesis by 
effective targeting of HIF-1alpha factor with antisense HIF ± ĮDQG survivin in combination 
with a antiangiogenic agent like endostatin, angiostatin or VEGF blocking peptide. This strategy 
caused downregulation of targeted proteins promoting inhibition of tumour 
angiogenesis(Krissansen, Sun & Kanwar 2005). Experimental studies were conducted on 
selective inhibition of survivin expression in tumour cells by introducing siRNAs and sh-RNAs 
that cause downregulation of survivin mRNA expression triggering programmed cell death in 
cancer cells(Altura, Caldas & Holloway 2006). Double and single stranded oligonucleotide 
targeting survivin was formulated comprising one modified sugar moiety and  cholesterol as a 
ligand that led to survivin inhibition in different types of cancer(Manoharan & Rajeev 2010).   In 
another invention oligomeric formulations comprising of oligonucleotides were developed which 
can be hybridised specifically with nucleic acids that encode survivin. These compositions led to 
survivin downregulation in wide range of cancers including lung, breast, brain, stomach, ovarian 
neoplasms (Hansen et al. 2010). siRNA molecule conjugated with a folic acid was developed for 
targeted delivery to cancer cells expressing folic acid. Results showed survivin  downregulation 
and hence subsequent gene silencing(Manoharan et al. 2009). Pretreatment strategy with a 
radiotherapeutic regime to the patient and later administration of appropriate amounts of 
nucleotide based compositon was followed to bring possible inhibition of the targeted over 
expressed gene. Interestingly, survivin showed positive correlation and hence, these studies 
would help in optimising dosage of oligonucleotide amount and pre treatment strategies for 
tumour inhibition(Brown 2007). Another innovative approach was to use asymmetrical duplex 
ϲϬ

RNA molecules capable of effectively silencing specific genes involving usage of first strand of 
RNA longer than second strand. This oligomeric system developed against survivin in these 
studies showed survivin gene silencing(Li et al. 2009). To develop LNA oligonucleotide 
molecule with a specific formula which showed effective antisense inhibition of survivin causing 
tumour inhibition in vivo. LNA oligonucleoide in combination with taxol showed significant 
apoptosis induction when compared to LNA nucleotides alone(Rosenbohm et al. 2009). 
Research studies were undertaken utilising rAAV- type 2 plasmid encoding mutant survivin 
(Cys84 Ala) that selectively induces apoptosis by downregulation of survivin gene 
expression(Tu et al. 2007).  Utilisation of recombinant vim viral vectors encoding eukaryotic 
initiation factor eIF4E was carried out in conjugation with  tissue specific survivin promoter that 
selectively express in tumour cells and help in delivery of therapeutic nucleic acids (Mathis, 
Debenedetti & Curiel 2006).The invention relates to usage of combinatorial approach to target 
cancer cell utilising multiple  promoters driven therapeutic targeting. Promoters of genes 
survivin, human telomerase reverse transcriptase (hTERT) and Mucl were utilised in association 
with truncated BH3 interacting domain death agonist (tBid), a pro-apoptotic gene that is 
selectively activated by transcriptional mechanisms of genes selectively expressed in tumour by 
the incorporated promoters. Hence, this strategy showed improved results and manifested 
efficient therapeutic strategy(Kazhdan 2008). Treatment of hyper proliferative disorder by 
targeting survivin using a vector comprising of nucleic acid encoding therapeutic agent by 
modulating in a cell cycle specific manner was carried out. The survivin nucleic acid molecule in 
the vector is controlled by a transcriptional repressor proteins like cell cycle dependent factor 1 
(CDF -1), glial cell specific glial fibrillary protein (GFAP) enhancer(Hui, Al-wei & Lam 2005). 
 
ϲϭ

2.3.6 Anti cancer peptides to combat cancer  
Investigations were conducted to demonstrate the role of survivin peptide mimics to 
downregulate survivin expression. The compositions involved survivin peptide mimics with 
enhanced property of MHC-1 binding characteristics to cause survivin inhibition. These 
combinations can be developed as survivin peptide vaccines(Andersen 2007). Studies showed 
the mechanism of eliciting anti tumour immune responses against survivin due to recognition of 
MHC -1 and MHC - 2 complexes. Hence, based on this strategy appropriate antigenic material 
can be used to stimulate MHC presentation of antigen and elicit an immune response(Leason & 
Spitler 2000). Research findings revealed the functional importance of FOXM1B, a forkhead 
transcription factor which play a key role in regulation of PI3K/ AKT signalling during cellular 
proliferation by binding to survivin promoter. Experimental studies conducted using anti-
FoxM1B antibodies caused reduced survivin expression along with FoxM1B factor (Costa, Costa 
& Wang 2010)]. Studies were conducted to develop alternative reading frame (ARF) 
polypeptides, antigen presenting Cells (APC) and dendritic cells (DC) based compositions 
against survivin to be useful in treatment of cancer and infectious diseases(Graddis et al. 2009). 
Usage of translocation peptides to deliver therapeutic protein to survivin as a targeted entity was 
attempted. Translocation peptides are peptide molecules of 30 to 50 amino acid molecules that 
help the native therapeutic protein to translocate across the cell membrane(Medicine Imperial 
College Road London SW7 2AZ 2003). Further, another  invention relates to peptides that 
interact with IAPs family of proteins like survivin, livin, XIAP, NIAP and cause the release of 
cancer cells from apoptosis block(Butz et al. 2004). Novel survivin binding proteins that have the 
ability to bind survivin and cyclin dependent kinases which regulate survivin expression were 
detected. Antibodies and antisense approaches against survivin binding proteins can be effective 
ϲϮ

therapeutic strategy for modulation of survivin expression(Reed & Krajewski 2010). Usage of 
metal binding therapeutic peptides (MBD) for targeting survivin was unfolded. As described in 
the patent, MBDs attach to the surface of red blood cells and mediate rapid intracellular transport 
with therapeutic cargo into the cytoplasm and nucleus of targeting cancer cells(Mascarenhas 
2008). Our laboratory had successfully formulated a recombinant cell permeable dominant 
negative survivin (C84A mutation) in fusion with a R9 polyarginine peptide cell penetration 
domain. Experimental findings in human prostate cancer cell lines confirmed that this 
recombinant peptide was successfully internalised within 30 min duration and initiated caspase 
dependent apoptosis (Kanwar et al. 2010c) (Cheung, Kanwar & Krissansen 2006). Research 
studies conducted at our laboratory confirmed the dual regulatory interaction of HSP90 and 
survivin, both in a positive and negative manner. Use of molecular inhibitors 17-AAG and 
Geldanamycin had a positive impact on survivin with increased expression by regulating 
transcription factors sp1, sp3. However, there was downregulated survivin expression when used 
proteasomal inhibitor MG-132 downregulated survivin expression. Hence, we elucidate that 
HSP90 and survivin interaction is mediated by geldanamycin and 17-AAG both by 
transcriptional and translational mechanisms(Cheung et al. 2010b). Research findings assessing 
the combinatorial effect of Tat ± fused HA2 peptide (HA2Tat) and shepherdin-Tat treatment on 
cancer cell treatment showed improved cytotoxicity. Tat ± fused HA2 peptide (HA2Tat), an 
endosome disrupting peptide showed improved Tat peptide release efficiency from endosome 
disruption. Hence, this treatment caused a synergistic effect on tumour inhibition prominently 
due to Tat ± fused HA2 peptide that enabled increased shepherdin-Tat antitumour activity(Sugita 
et al. 2007). Experimental studies were carried out with a novel antagonist 5-aminoimidazole-4-
carboxamide-1-â-D-ribofuranoside (AICAR) that mimics shepherdin function in destabilising 
ϲϯ

HSP90 chaperone and client proteins survivin, AKT and telomerase. Results obtained confirmed 
that AICAR binds to HSP90 N- domain, thereby causing functional inactivation of HSP90 
chaperone followed by destabilisation of various client proteins. However, this compound had a 
tumour specific inhibitory effect without affecting the growth of normal fibroblast cells(Meli et 
al. 2006). Research studies were conducted in acute myeloid leukaemia cell lines to develop and 
test the efficacy of shepherdin [79 - 83], a novel variant of shepherdin [79 - 87]. Unlike 
conventional shepherdin[79-87], shepherdin [79-83] caused  rapid mitochondrial apoptosis with 
in 30 min with the functional mechanism of competitive binding with the ATP pocket of HSP90 
leading to inhibition of formation of survivin ± HSP90 complex, thereby causing depletion of 
expression levels of HSP90 client proteins survivin, AKT(Gyurkocza et al. 2006).     
 
2.3.7 Chemotherapeutics approaches for cancer therapy 
The invention details about the chemotherapeutic strategy involved along with antisense 
oligonucleotide molecule targeting survivin. Survivin antisense oligonucleotide was used in 
combination with either gemcitabine hydrochloride or paclitaxel or doxorubicin. Results showed 
marked downregulation of survivin expression and susceptibility of cancer cells to 
chemotherapeutic agents leading to tumour regression(Patel 2009). The invention provides novel 
bradykinin antagonists that target survivin expression and lead to apoptosis. Mechanism includes 
activation of caspases and PARP cleavage in the cells resulting in decreased tumour growth.  
Furthermore, the invention also discusses about the usage of vector incorporated with survivin 
specific promoter linked with a reporter element to target survivin expression (Gera et al. 2010). 
Investigations were undertaken to detect the level of survivin in response to chemotherapeutic 
treatment based on the mechanism of signal transducers and activators of transcription protein 
ϲϰ

(STAT) signalling. Results obtained showed that phosphorylation of STAT molecule was 
correlated with the expression of survivin. Modulation of survivin dependent apoptosis can be 
carried without a STAT inhibitor(Jove et al. 2007). Use of TGF -beta activated kinase 1 (TAK1), 
mitogen-activated protein kinase 3 kinase 7 (MAPK3K7) inhibitor and assessing its effect on 
survivin expression by eliciting T cell immune resSRQVHVLQ%FHOOWXPRXUVDQG7FHOOOHXNHPLD¶V
in order to investigate the presence of deregulated TAK1 signalling molecules was perfomed. 
Hence, these studies proved that tumour cells possessing functionally aberrated TAK1 molecules 
are susceptible to TAK1 inhibitors  thereby eliciting tumour immune responses via TGF 
signalling causing downregulation of survivin(Byth et al. 2009). Further studies revealed that  
the combinational treatment approach  utilising CDK1 antagonist and chemotherapeutic agents 
like taxane or adriamycin that have inhibitory effect on survivin phosphorylation leading to 
apoptosis in an array of tumour types involving breast, ovarian, lung and non small lung cancers. 
Results obtained showed the synergistic effect of this approach in survivin downregulation and 
tumour inhibition(Altieri & O'connor 2005).  A US patent WO (/2008/042611) describes about 
the usage of combinatorial treatment approach utilising mitoxantrone and interleukin ± 6 (IL-6) 
antagonist, CNTO 328targeting survivin expression. Both the therapeutic molecules utilised, had 
an immunosuppressive effect on xenograft model of human harmone refractory prostate tumour 
cells in mice models subsequently causing down regulating survivin expression.Mitoxantrone 
confers an immune suppressive effect on B cell functional mechanism involving antigen 
presentation, antibody - dependent demyelination, and macrophage inhibition that play a 
prominent role in development of diseases like multiple sclerosis and autoimmune disorders. 
Thus, this therapeutic approach can also be extended towards other diseases such as multiple 
sclerosis and autoimmune disorders(Nemeth 2008). Research findings in the patent detailed 
ϲϱ

about usage of CDK inhibitors (roscovitine, R- roscovitine and CGP74514A) targeting XIAP by 
subsequent p53 activation and assessment of the effect on survivin function was done. 
Surprisingly, results showed inhibition of XIAP in a dose dependent manner of inhibitor, but 
survivin level was unaffected(Mohapatra & Pledger 2007).WO/2002/089795 proposes use of 
nordihydroguaiaretic derivatives which have suppressive effect on CDC -2 and survivin leading 
tumour apoptosis. Mechanism involves downregulation of survivin expression at both protein 
and mRNA level by nordihydroguaiaretic inhibitors, followed by subsequent activation of CDC-
2 and caspase apoptosis pathway(Huang, Heller & Chang 2004). Utilisation of parthenolide 
derivatives for tumour growth inhibition and its effect on survivin expression was investigated. 
Results obtained proved the effect of growth inhibtion of parthenolide inhibitor is mediated by 
NF-Kȕ and c-IAP2 pathways, but no possible effect of these compounds and signalling 
mechanisms was observed on survivin expression(Nakshatri & Sweeney 2005). United States 
patent 20060019907 details about the usage of guggulsterone and analogs which have an 
inhibitory effect on NK-Kȕ signalling and also repressed NF-Kȕ - dependent gene transcription 
for anti apoptotic genes like survivin, IAP1,XIAP etc(Aggarwal & Shishodia 2006).   In the 
patent  relating to treatment of cancer utilising Wnt signalling mechanisms to regulate apoptosis 
via ȕ-catenin. The chemical compounds mentioned in the invention had an inhibitory effect on 
survivin expression mediated by Wnt signalling, followed by caspase dependent apoptosis (Kahn 
et al. 2004). Development of novel compounds termed as reverse turn mimetics which mimic the 
confirmational stability of secondary structure of peptides and proteins targeting particular 
biological targets was undertaken. The synthesized compounds had an inhibitory effect on 
survivin expression targeting via TCF - beta-catenin signalling pathway, a prominent pathway 
associated with survivin during mitotic cell division(Moon et al. 2004). The invention describes 
ϲϲ

the synthesis of novel combinatorial library of compounds from a natural product - isodon 
excisus and assessing the effect on anti apoptotic molecules like survivin(Hergenrother et al. 
2009) Investigations were carried in deciphering the use of histone deacetylase inhibitor 
LAQ824 and Apo-2L.TRAIL ligand and results suggested  induction of apoptosis causing an 
inhibitory effect on survivin expression(Bhalla 2007).  Platinum based compound, IS3 295 was 
employed to treat dysregulated STAT3 - signalling prominently mediated by survivin expression. 
The inhibitor effectively modulated expression of STAT3 leading to downregulation of survivin, 
AKT, p53 molecules which play a prominent role in tumour progression. Hence, efficient 
inhibition promoted tumour growth inhibition(Turkson, Jove & Sebti 2007). Phase I trials were 
conducted with YM155 to determine the maximum tolerated dose (MTD) and assessing the 
pharmacokinetics in subjects with advanced haematological malignancies. Promising results 
were obtained with an appropriate YM155 dosage of 4.8 mg/m2/d with 168 hour continuous 
intravenous infusion for every 3 weeks(Tolcher et al. 2008). In an effort to elucidate functional 
mechanism of YM155 on human refractory prostate cancer cell (HRPC) a regression of survivin 
expression in p53 deficient HRPC cell (Nakahara et al. 2007a). The effect of combinatorial 
treatment of YM155 and platinum based drugs   - cisplatin and carboplatin in human non-small 
lung cancer cell lines (NSCLC).YM155 induced a delay in repair of double strand breaks that are 
generally caused by platinum based compounds. Immunofluorescence detection of g-H2AX 
factor prominently expressed during DNA damage was carried out to assess the synergistic effect 
of YM155 and platinum compounds. Hence, this combinatorial treatment had tumour inhibitory 
effect in vitro and in vivo (Iwasa et al. 2010). Similar kinds of studies were carried out using 
immunoflorescent detection of g-H2AX factor in assessing the radiosensitizing effect of YM155 
in NSCLC exposed to gamma radiation. Decreased tumour proliferation caused to a delay in 
ϲϳ

repair of double stranded breaks caused due to radiation. Hence, YM155 in combination with 
radiation therapy could be efficient therapeutic strategy (Iwasa et al. 2008). Phase I clinical 
studies conducted with YM155 in patients with advanced solid malignancies with observed 
grade 1 and 2 toxicities involving stomatitis, pyrexia and nausea. Phase 2 clinical studies with 
YM155 in patients with refractory diffuse large B cell lymphoma and Phase I trials in assessing 
the effect of YM155 in combination with docetaxel and prednisone in patients with hormone 
refractory prostate cancer is currently under evaluation(Ryan, O'Donovan & Duffy 2009). 
 
2.3.7 Conclusions and Future Directions: 
Vast knowledge generated from cancer pharmacology have had made tremendous progress in 
terms of drug development. One such example is YM155, a survivin inhibitor currently in phase 
2 clinical trials and an array of various survivin antagonist are in research and development 
pipeline. However, specific targeted approaches need to be developed. Utilisation of 
nanotechnology based drug delivery platforms offers a myraid of advantages such as improved 
solubility, controlled release and increased half life of the drug molecules. Furthermore, 
nanodelivery systems opened new vistas to direct a combinatorial therapeutic approach by 
tagging cancer specific markers that selectively target tumour cells while rendering normal cells 
unaffected(Kanwar, Mahidhara & Kanwar 2009). Despite advances in drug development, 
selective drug delivery to the tumours developed in sensitive organs of the body for example 
glioblastoma multiformae (brain tumour) is yet to foresee a positive therapeutic approach. This is 
due to the fact that many drugs administered fail to cross the blood brain barrier (BBB). Studies 
conducted with nanodelivery systems like nanoparticles, carbon nanotubes, lipid microtubes and 
nanowires showed promising results by effectively crossing blood brain barrier and causing  
ϲϴ

increased drug release at the tumour site(Baratchi et al. 2009b). Recent developments in 
understanding sub cellular localisation of survivin and above discussed nanobased drug delivery 
platforms would add a boost that enable tumour specific targeting of survivin rendering normal 
cells completely unaffected which is a major challenge in upcoming clinical approaches.  
Effective knowledge generation from the patents would enable commercialisation of survivin 
drug market producing cost and clinically effective drugs. 

2.3.8 Future outlook on cancer inhibitors   
 
There are some evidence showing the bifunctional functions of survivin in cell death (apoptosis) 
where survivin is overexpressed and in cell division or cell survival where it is un-expressed or 
expressed in control. Controversy around these dual roles still exists as to whether survivin can 
definitely accomplish these two distinct functions in normal and cancer cells. In our preliminary 
studies, we have shown that  in normal human differentiated neurons   where survivin is  known 
to be absent,  treatment with survivin antagonist protein led to  cell proliferation .Interestingly, in 
survivin overexpressing cells  such as cancer cells treatment with survivin antagonist protein  
induced cell death. Future systematic studies need to be done to further explore these 
bifunctional properties of survivin. 6XUYLYLQKDVEHHQDSURPLQHQWWKHUDSHXWLFWDUJHWGXHWRLW¶V
over expression in a wide range of cancers. The procancer activity of survivin is majorly 
manifested due to its primary role in regulating mitotic cell division, further leading to prolonged 
cell survival and promoting cancer angiogenesis, invasion and metastasis by modulating 
functional mechanisms of various tumour suppressor genes, oncogenes and growth promoting 
factors. Research work generated give us an outlook of current therapeutic strategies like RNA 
ϲϵ

interference, peptidometric, immunotherapeutic and chemotherapeutic based methodologies 
employed in down regulating survivin expression in cancer cells. However, the need to 
administer safer and effectively targeted drugs is always a clinical priority. Based on the 
knowledge generated and work carried out in our laboratory, we propose the utilisation of eco 
friendly natural product based compounds in combination with novel nanotechnology platforms 
like multifunctional nanodevices, nanocarriers coupled with promising RNA interference, 
microRNA and aptamer based technologies that can be effectively deployed to simultaneously 
detect, monitor, treat and also scavenge tumour cells in human body. With the relative infancy of 
nanobiotechnological research, there is a major need to generate productive research in field of 
therapeutic biology of anti apoptotic proteins,  that can provoke anticancer drug market to 
develop and commercialise economical and effective therapeutics in cancer research.  
 
 
 
 
 
 
 
 
Table 2.3 : Prominent patents on cancer therapeutics. 
 
 
 
ϳϬ

Patent No Description Reference 
United States Patent 7608707   Generation of functional and 
hyperfunctional siRNAs using 
siRNA algorithm. 
(Khvorova et al. 2009). 
United States Patent 
WO/2008/109382 
Formulation of meroduplex 
ribonucleic acid molecule 
(mdRNA) and blunt ended double 
stranded ribonucleic acid against 
BIRC gene encoding survivin 
molecule. 
(Quay et al. 2010). 
United States Patent 
WO/2008/011473   
siRNA based targeting of HBXIP 
factor, transcriptional regulation 
and novel co factor for survivin 
regulation. 
(Dobie, Dean & Bennett 2010). 
United States Patent  
WO/2008/083174 
Development of PD -1 antagonist 
in combination with survivin 
peptide (ELTLGEFLKL) to elicit 
immune response. 
(Ahmed et al. 2010). 
United States Patent  
WO/2004/009131 
Targeting of HIF-1Alpha factor in 
combination with antisense 
survivin to suppress tumour 
angiogenesis. 
(Krissansen, Sun & Kanwar 2005). 
United States Patent  
WO/2009/138236 
Development of survivin derived 
tumour associated cytotoxic T cell 
(CTL) peptide epitopes to elicit T 
cell immune response. 
(Rammensee et al. 2010). 
United States Patent  
WO/2008/106116 
Development of antagonists 
against Human OX40 receptor and 
targeting its association with 
survivin.   
(Salah-eddine, Zhengbin & 
Sanjaya 2010). 
ϳϭ

 
 
 
 
 
 
 
 
 
 
 
 
United States Patent  
WO/2004/032838 
Antibody mediated targeting the 
functional mechanism of Wnt 
signalling pathway in relation to 
survivin. 
(He et al. 2009). 
United States Patent Application 
20100056441 
Decipher the functional 
importance of FOXM1B, a 
Forkhead transcription factor, 
playing a key role in regulation of 
PI3K/ AKT signalling by binding 
to survivin promoter. 
(Costa, Costa & Wang 2010). 
United States Patent Application 
20080166344  
 
1-(2-methoxyethyl)-2-methyl-4,9-
dioxo-3-(pyrazin-2-ylmethyl) -4,9-
dihydro-1H-naphtho[2,3-
d]imidazol-3-ium bromide (YM 
155) in combination with  
docetaxel or rituximab markedly 
downregulated survivin 
expression. 
(Nakahara et al. 2008). 
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Table 2.4: Novel Chemotherapeutic agents for cancer management 
Patent no Drug Compound     Chemical structure  Mechanism of 
action 
Ref 
United States 
Patent 
WO/2008/12475
6 
Bradykinin            
antagonist 
 
Activation of 
caspase 
apoptosis and 
PARP cleavage 
(Gera 
et al. 
2010) 
United States 
Patent 
WO/2008/04261
1 
Mitoxantrone 
 
Immunosuppres
sive effect on 
tumour cells 
(Nem
eth 
2008) 
United States 
Patent 
WO/2002/08979
5 
Nordihydroguaiaret
ic derivatives 
 
Meso 1, 4 ± Bis(3,4-
dimethoxyphenyl)-(2R,3S)-
dimethylbutane 
 
  
Meso 1, 4 ± Bis(3,4-
Effect on CDC -
2 and survivin 
leading to 
tumour 
apoptosis. 
(Huan
g, 
Heller 
& 
Chan
g 
2004) 
ϳϯ

dimethoxyphenyl)-(2R,3S)-
dimethylbutane Hydrochloride 
Salt 
 
United States 
Patent 
WO/2001/04569
9 
Parthenolide 
derivatives 
 
Inhibition of 
NF-KB and c- 
IAP2 pathways 
(Naks
hatri 
& 
Swee
ney 
2005) 
United States 
Patent 
20060019907 
Guggulsterone 
analogs 
 
Inhibitory effect 
on NK-KB 
signalling 
(Agga
rwal 
& 
Shish
odia 
2006) 
United States 
Patent 
WO/2006/07181
2 
Platinum 
compound, IS3 295 
 
 
 
Dysregulated 
Stat3 - 
signalling 
prominently 
mediated by 
survivin 
expression 
(Turk
son, 
Jove 
& 
Sebti 
2007) 
United States 
Patent 
20090263390 
YM155  
 
 
Delay in repair 
of double strand 
breaks 
p53 deficient 
human 
(Naka
hara 
et al. 
2007b
) 
(Iwas
a et 
al. 
2010) 
(Naka
ϳϰ

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
hara 
et al. 
2008) 
(Kan
war et 
al. 
2010c
) 
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2.4. Multifunctional nanomedicine approaches for targeting of cancer cell and 
stem cell signalling mechanisms 
Had it not been attributed to the ignitable curiosity of the cancer researchers in propagating 
cancer nanomedicine, it would have certainly be an impossibility to dissect the multifaceted 
action of  novel anti cancer therapeutics in tumour biology(Holmes 2012). The predominant 
factorability of anti apoptotic molecules in modulating cancer, is envisaged in the realms of 
diagnostic and prognostic abilities, preferential modulation of intricate evolving cancer cell and 
stem cell signalling paradigms and pharmacological retaliation against prevailing therapeutic 
efficacies. Therefore, this column provides a snapshot of recent research and development 
pertaining to therapeutic biology of cancer (Holmes 2012; Kanwar, Kamalapuram & Kanwar 
2012a). 
2.4.1. Nano based cancer diagnostic strategies: Multiplexed nanoflare devices comprising of 
gold nanoparticle conjugates hybridised with the reporter, quencher and flourophore molecules 
had enabled to efficiently detect survivin messenger RNA (mRNA) at relative very low 
concentrations(Prigodich et al. 2012). Combinatorial multimodal nanotheranostic agents 
comprising of silencing RNA (siRNA) conjugates, membrane translocation peptides and 
flourophores coupled to the magnetic nanoparticles have concomitantly achieved survivin 
abrogation and therapeutic imaging by magnetic resonance imaging, fluoroscense imaging(Mura 
& Couvreur 2012). Detection of exosomes with survivin as a cargo protein has invigorated a 
relative novel speculation pertaining to the role of survivin in angiogenic propagation with 
excessive stabilisation and secretion of exosomes among the cancer cells(Kharaziha et al. 2012). 
Furthermore, in addition to the already existing debate about the dichotomic role of nuclear and 
ϳϲ

cytoplasmic survivin, nuclear survivin was detected proportionately along with Phosphohistone-
H3 (pHH3), prominent mitotic count biomarker(Brunner et al. 2012). Nevertheless, survivin is 
attributed in promoting drug resistant tumours. In accord with the previous observations nuclear 
and cytoplasmic counterparts showed a predominant role in stabilisation of drug resistance in 
cervical carcinoma in response to the radiation therapy(Chaopotong et al. 2012). 
2.4.2. Cancer cell signalling paradigms: Critical role of survivin in transcriptional inhibition of  
p21 gene, a crucial associate with p53 tumour suppression gene via p53 signalling mechanisms 
was noted(Tang et al. 2012a). Further, novel orphan nuclear receptor TR3 (NR41A) 
overexpression in lung carcinoma subjects was promoted by survivin via p53 and mammalian 
target of rapamycin (mTOR) dependent fashion(Lee et al. 2012). Furthermore, systemic 
modulation of the cell signalling mechanisms including sphingosine-1-phosphate receptor 1 ( a 
G-protein-coupled receptor for lysophospholipid sphingosine-1-phosphate (S1P)) - signal 
transducer and activator of transcription 3 (S1PR1-STAT3) signalling(Deng et al. 2012), 
modulation of DNA methylatory mechanisms(De Carvalho et al. 2012), Yes-associated protein 
(YAP) modulation in conjucture with  epidermal growth factor receptor (EGFR)  and 
hippopotamus like phentotype tumour growth - Yes-associated protein (hippo ± YAP) 
organogenesis developmental pathway(Huang et al. 2012), modulation of an array of 
PLFUR51$¶V PL5-542-3p, miR-494, miR-320a, miR-218, miR-708 and miR-203)(Xie et al. 
2012), intervention with  tumour necrosis factor apoptosis inducing ligand (TRAIL) associated 
anticancer therapies(Dimberg et al. 2012), modulation of mitochondrial apoptosis in association 
with  second mitochondrial-derived activator of caspase  (Smac) in receptor activating protein 1 
(RIP1)/caspase-8 and nuclear factor-kappa Beta (NF-Nȕ) signalling was noted(Wagner et al. 
2012). 
ϳϳ

2.4.3. Cancer stem cell signalling paradigms: Survivin was significantly associated with the 
novel stem cell signalling mechanisms including cluster of differentiation 34+ (CD34+ ) and 
differentiation 38- (CD38-) leukemic stem/progenitor cell mechanisms associated with 
unfavourable clinical prognosis(Carter et al. 2012), regulation of  human telomerase reverse 
transcriptase  and survivin specific cytotoxic T lymphocytes (CTLs) signalling(Anguille, Van 
Tendeloo & Berneman 2012),  survivin-DEx3, a survivin splice variant based modulation of cell 
cycle check point (Chk2) phosphorylation leading DNA damage promoting resistance to 
genotoxic therapies(Lopergolo et al. 2012), modulation of sonic hedgehog (SHh) developmental 
signalling pathway to promoted epithelial mesenchymal transition in promoting pancreatic 
cancer stem growth(Tang et al. 2012b),  modulation of  transforming growth factor (TGF)-ȕ
signalling in hepatic cancer cells thereby affecting  histone acetylation transferases (HATs) and 
histone deacetylases (HDACs) mechanisms that promote chromatin remodelling and fluxation of 
antiapoptotic products in hepatic stem cell growth(Majumdar et al. 2012). Pertaining to 
immunological aspects, survivin was known to critically modulate signal transducer and 
activator of transcription (STAT) signalling cascades having a regulatory effect on myeloid-
derived suppressor cell (MDSC) promoting stem cell progression in tumour 
environment(Gabrilovich, Ostrand-Rosenberg & Bronte 2012). 
2.4.4. Cancer nanomedicine therapeutic strategies: Novel nanoscale drug formulations have 
been formulated including bioreducible poly (b-amino esters) (PAEs), poly[bis(2-
hydroxylethyl)- disulfide-diacrylate-b-tetraethylenepentamine] (PAP) nanoformulation for the 
delivery of short hair pin RNA (shRNA) and siRNA for multidrug resistant protein (MDR) - P ± 
glycoprotein protein (PgP)) and survivin -  iMdr-1-shRNA and iSurvivin-shRNA in doxorubicin 
resistant human breast cancer cells (MCF7)(Yin et al. 2012), combinatorial formulation of b-
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cyclodextrin (b-CyD) and polyethylenimine (PEI) nanomicelle for codelivery of survivin shRNA 
and paclitaxel  in ovarian cancer cells (SKOV-3)(Hu et al. 2012), fabrication of lipid 
(DOTAP/DOPE) and apolipoprotein (APOA-I)  - cytochrome C for intracellular targeted drug 
delivery in in vivo lung cancer cell model (NCI-H460)(Kim, Foote & Huang 2012),  
multifunctional HER2 monoclonal antibody conjugated RNase A-associated CdTe quantum dot 
cluster (HER2-RQDs) nanoprobe for therapeutic imaging and targeted delivery in in vivo gastric 
cancer cell model (MCG803)(Ruan et al. 2012), Magnetic resonance (MR) sensitive liposomal 
nanoformulation entrapped siRNA (LEsiRNA) specific to survivin, promoted enhanced down 
regulation of survivin in vivo, leading to remarkable tumour reduction(Kesharwani, Gajbhiye & 
Jain 2012). 
2.4.5. Future prospects of cancer nanomedicine  
Needless to say, there is an incessant necessity to fabricate ecofriendly natural product derived 
multifunctional nanotheranostics that can offer lucrative advantages and ulterior therapeutic 
possibilities in comparison with conventional drugs(Mura & Couvreur 2012). Novel anticancer 
nanotherapeutics devised at our laboratory yielded remarkable in vivo anticancer efficacy in both 
breast and colon cancer models, parameterized by restoration of a myriad of critical apoptotic 
signalling cascades(Kanwar, Mahidhara & Kanwar 2012b). Furthermore, from a futuristic point 
of view, synergism of  the evolving research platforms such as cancer systems biology, 
bioinformatics, computational chemistry, molecular nanotechnology, quantum medicine enables 
the scientific community to concretely understand the evolving cancer growth mechanisms and 
also designing of drugs at atomic precise to aptly target the cancer signalling 
mechanisms(Kanwar, Kamalapuram & Kanwar 2012a). 
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2.5 Multimodal nanomedicine based anti cancer therapeutics and 
advancements    
                    There is an extensional necessity for the major amelioration of hybrid multimodal 
nanotheranostics, that can offer ulterior theranostic possibilities in the field of nano ± 
oncology(Cheon & Lee 2008; Kanwar et al. 2012c). Novel class of nanotheranostic medicines 
certainly warrant more throughput therapeutic abilities in comparison with conventional 
platforms(Svenson 2013). One such platform that dawned in the era of existing treatment 
efficacies is superparamagnetic iron oxide nanoparticles (SPIONS) nanotheranostics(Kanwar et 
al. 2012d). SPIONS are approved by food and drug administration, USA (FDA), safe, 
biocompatible and exhibit astounding capabilities in prominence, in realms of (1) diagnostic and 
prognostic platforms ± nanofluidic lap on chip devices, nanoarray systems, nanosensors(Kim et 
al. 2012b), (2) targeted  multimodal drug delivery and live imaging strategies ± pH responsive 
drug release(Diou, Tsapis & Fattal 2012), tumour oxygen and hypoxic sensors(De Leon-
Rodriguez et al. 2009), locked nucleic and chimeric aptamer conjugates(Kanwar, Roy & Kanwar 
2011b), fluorescence and bioluminescence approaches(Nair, Dileep & Rajanikant 2012), 
ribonucleic acid interference (RNAi) technology(Shim & Kwon 2012),  antibodies(Kievit et al. 
2012), nanobodies(Sawant, Jhaveri & Torchilin 2012), magnetic guided therapy(Kim et al. 
2013), sono photo dynamic therapy (SPDT) ± ultrasound and infrared laser(Li et al. 2013), 
photodynamic therapy (PDT)(Truby, Emelianov & Homan 2013), photothermal 
therapy (PTT)(Truby, Emelianov & Homan 2013), radio imaging and therapy(RIT)(Li et al. 
2013), photo acoustic imaging(PAI)(Cook, Frey & Emelianov 2013), magnetic resonance 
imaging and ultrasound therapy (MRI + US)(Owen, Pankhurst & Stride 2012), positron emission 
tomography(PET)(Amstad et al. 2009), single-photon emission computed tomography 
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(SPECT)(Amstad et al. 2009).In turn, variant therapeutic abilities of SPIONS congregate to offer 
interactive therapeutic feedback  monitoring over a time period, opening new vistas for 
personalised cancer nanomedicine(Kircher et al. 2003). 
                   Having a closer look at the conventional treatment regimes including chemotherapy, 
immunotherapy, it is a poignant fact that, these platforms certainly lack imaging ability, 
disqualifying them from being a theranostic(Svenson 2013). Furthermore, existing radio 
therapeutic platforms that fall in basket of current theranostic medicine are extremely toxic and 
even trigger recurrent cancers leading to drug resistance(Kanwar, Singh & Kanwar 2011). This is 
where; SPIONS are conquering the therapeutic ground exhibiting versatility in derivatizing 
combinational drug systems ± both with chemotherapeutic and natural product derived 
compounds (neem, curcumin, milk derived proteins)(Kanwar, Kamalapuram & Kanwar 2012b). 
SPIONS are well known for their exceptional superparamagnetic ability with high relaxivity, 
outstanding bio degradability, targeted delivery, moreover can be easily integrated with a myriad 
of drug delivery platforms, achieving multimodal action(Jiang et al. 2012). Hence, SPIONS are 
extensively utilised as clinical imaging agents for magnetic resonance imaging(Jeon et al. 2013). 
Novel class of SPIONS derived MRI contrast agents include  polyethylene glycol (PEG) - 
cleaved iron oxide nanoparticles (PEG - CIONPs)(Jeon et al. 2013), 
magnetoliposomes(Lorenzato et al. 2013), transferrin-conjugated SPIONS(Jiang et al. 2012). 
The existing class of MRI contrast agents such as gadolinium and manganese are highly toxic, 
exhibit nonspecific distribution in body, non biodegradable, cause extensive side effects and act 
as imaging only agent, lacking treatment ability(Hao et al. 2012). In addition to this, SPIONS 
also possess remarkable photo acoustic imaging ability in response to the ultrasound frequencies 
that can be integrated with its magnetic property making it a dual imaging contrast agent(Cook, 
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Frey & Emelianov 2013). Furthermore, both the ultrasound and magnetic property of SPIONS is 
widely exploited in targeted, controlled drug delivery and imaging applications(Niu et al. 2013). 
Few of recent SPIONS based dual contrast imaging agents include polyethylene glycol  - 
doxorubicin ± SPIONS (PEG ± DOX ± SPIONS)(Niu et al. 2013), endorem(Grootendorst et al. 
2013), magnetic microbubbles(Owen, Pankhurst & Stride 2012). The existent ultrasound contrast 
agents such as optison, definity, albunex, Sonovue, based microbubble systems have a potential 
toxic effect, shorter half life(Alzaraa et al. 2012) and also lack inherent therapeutic ability as 
compared to SPIONS derived nanotheranostics(Niu et al. 2013).     
              In conclusion, the holistic religion of SPIONS in the era of modern medical oncology 
offers infinite, exhilarating possibilities in targeted hurling of tumours, thereby quenching the 
thirst of cancer researchers and retaining the gist of healthy human kind in the cosmos(Kanwar, 
Kamalapuram & Kanwar 2011b; Kanwar et al. 2012a; Kanwar, Mahidhara & Kanwar 2012a).  
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2.6 Multifunctional nanotherapeutic approaches for cancer therapy and targeted molecular 
imaging 
                                                 The occurrence of cancer is well parameterized in a more systemic 
fashion due to abalative derailing of numerous cell signalling paradigms ultimately triggering 
explosive chaotization in cellular growth patterns(Kanwar, Kamalapuram & Kanwar 2012 
; Kreeger & Lauffenburger 2010). The ingenious complexity in a bunch of intricate cancer 
signalling mechanisms along with prominent tumour survival mechanisms including anti-
apoptotic proteins (survivin, livin, hypoxia, heat shock proteins etc), oncogenic signalling, 
tumour suppressor mechanisms have imposed a major cessation for the therapeutic success of 
current chemo and radiological treatment regimes thereby promoting drug resistant 
cancers(Baratchi, Kanwar & Kanwar 2010b; Kanwar, Kamalapuram & Kanwar 2011c; Kanwar 
et al. 2001; Kanwar, Singh & Kanwar 2011; Kanwar et al. 2010c). To address these concerns, 
nanotechnology based strategies have recently conquered therapeutic ground. Nanoscale entities 
tagged with functional tumour specific molecules such as receptor-mediated tumour ligands, 
aptamers, locked nucleic acid conjugates (LNA), RNA interference technology, microRNA, 
siRNA, peptidomemitics, nanobodies, antibodies, combinatorial therapeutic formulations, drug 
encapsulation and imaging probes are deemed to be relatively smaller than the cancer cell itself 
and hence, targeted drug delivery with enhanced selectivity and therapeutic synergism can be 
achieved (Kanwar, Roy & Kanwar 2011b) (Kanwar et al. 2012a; Kanwar, Mahidhara & Kanwar 
2011a; Kanwar, Roy & Kanwar 2011a). The dramatic outreach of multifunctional 
nanotherapeutic approaches have been exploited in the area of cancer diagnostics by utilisation 
of economically viable nanomicrofludLF µODE RQ FKLS¶ GHYLFHV SURPRWLQJ SHUVRQDOLVHG FDQFHU
nanomedicine. The area  of therapeutic imaging by utilisation of state of art imaging 
ϴϯ

technologies including fluorescent imaging strategies, magnetic resonance imaging (MRI), 
positron emission tomograpy (PET), single photon emission computed tomograpy (SPECT), 
photodynamic laser therapy (PDT) offer multitudinous nanotheranostic based therapeutic 
possibilities(Kanwar et al. 2012c, 2012d; Kievit & Zhang 2011). The major concerns arising due 
to prominent side effects associated with conventional therapeutics have forced the scientific 
community to explore natural product derived therapeutics including medicinal herbs, curcumin, 
bovine lactoferrin, neem etc for the anticancer efficacy and immunomodulation(Kanwar & 
Kanwar 2012). Surprisingly, these natural therapeutic entities revealed their promising capability 
in bursting out the nodal cancer signalling mechanisms causing remarkable inhibition in cancer 
progression(Kanwar et al. 2008b). 
Multifunctional nanodrug delivery systems were fabricated with natural product derived 
therapeutics. Polymer based formulations with drug encapsulated in alginate coated nanocarriers 
( ACNC) and alginate gel encapsulated chitosan ceramic nanocore nanocarriers caused enhanced 
tumour regression(Kanwar, Mahidhara & Kanwar 2012b). Another set of completely variable 
natural product based super paramagnetic iron oxide nanoparticle (SPIONS)  nanotherapeutic 
formulation were devised in a combinatorial strategy coupling with tumour targeting entities 
including epithelial cell adhesion molecule (EPCAM), aptamer variants in combination with 
locked nucleic acid conjugates including LNA - nucleolin aptamer, LNA ± EPCAM aptamer 
(Kanwar, Roy & Kanwar 2011b) (Kanwar, Roy & Kanwar 2011a). These multifunctional 
nanotherapeutics exhibited predominant anticancer activity both in vitro and in vivo (Kanwar, 
Roy & Kanwar 2011b)  (Kanwar et al. 2012a; Kanwar, Roy & Kanwar 2011a). Furthermore, 
advanced near infrared fluorescence in vivo imaging studies were conducted to delineate 
effective localisation patterns and antitumour activity of drug coupled SPIONS.  
ϴϰ

Studies to extrapolate the theranostic abilities of nanodrug delivery system utilising MRI, 
SPECT, PDT and SPECT imaging modalities are under progression (Kievit & Zhang 2011). 
In conclusion, multifunctional nanotherapeutic approaches can offer lucrative advantages in the 
realms of cancer diagnosis, targeted therapy and advanced therapeutic imaging 
capabilities(Kreeger & Lauffenburger 2010; O'Shea 2012). However, there is an inherent 
necessity to further channelize the developments in the era of nanomedicine along with unison of 
upcoming technologies including immunoinformatics and computational biology, systems 
biological engineering, metabolomics, quantum medicine approaches in order to reap maximum 
benefits from so called nanotherapeutics - ³WKHHQJLQHVRIKHDOLQJ´DVSKUDVHGDQGVSHFXODWHGE\
Eri[ 'UH[HO LQ KLV QRWDEOH ZRUN ³WKH HQJLQHV RI FUHDWLRQ´(Drexler 1986; Kreeger & 
Lauffenburger 2010).   
 
2.7. Recent advancements in multifunctional nanotheranostics for cancer therapy and 
targeted imaging 
³7KHUH¶VSOHQW\RIURRPDWWKHERWWRP´LVRQHRIWKHYLVLRQDU\FRQFHSWVSHUWDLQLQJWRPROHFXODU
nanotechnology  put forward by the nobel laureate Richard Feynman, envisaging the fabrication 
of exotic multifunctional nanoscale therapeutic platforms and medical devices  that lead to 
JHQHVLV RI  ³1DQRPHGLFLQH´(Freitas 2005). In turn, consistent effort from various scientific 
disciplines including material sciences, biotechnology, medicine and computational sciences 
have revolutionized the area of nanomedicine leading to exquisite edification of existing nano 
therapeutLFV LQWR D QHZ JHQHUDWLRQ SODWIRUP FDOOHG ³PXOWLIXQFWLRQDO QDQRWKHUDQRVWLFV´(Chen, 
Gambhir & Cheon 2011; Freitas 2005). Multifunctional nanotheranostic platforms preferentially 
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achieve contemporaneous cancer diagnosis, target specific drug delivery and therapeutic imaging 
by employing myriad of ultra-modern combinatorial technologies including RNA interference 
(RNAi), aptamers, locked nucleic acid conjugates (LNA), fluorescent imaging, magnetic 
resonance imaging (MRI), positron emission tomography (PET), single photon emission 
computed tomography (SPECT), photodynamic laser therapy (PDT), magnetic therapy (Kievit & 
Zhang 2011).  
It would certainly be an understatement to undermine the devastation triggered in human cancers 
out bounding conventional chemo and radio therapeutics(Kanwar, Kamalapuram & Kanwar 
2011c). Nevertheless, target specific drug delivery is profoundly comprehended by the ever 
acclimatizing and evolving complication in the functional modulation of nodal cancer cell 
signalling networks(Kanwar et al. 2010c). However, at this point nanotheranostics can sneak 
through in the current therapeutic basket to retaliate the battle with critical angiogenic signalling 
modules of cancer cells(Chen, Gambhir & Cheon 2011). Notable demarcation of cancerous from 
normal tissues including increased angiogenesis, leaky blood vasculature, expression of tumour 
specific biomarkers.etc can be potentially exploited to empower and ship the nanotheranostics 
through the human body to selectively deliver anticancer agents to infected sites relatively 
leaving normal tissues unharmed(Kanwar et al. 2012a; Kanwar, Mahidhara & Kanwar 2011a). 
With the advent of major toxicology associated with current treatment regimes, a new class of 
safe and natural product derived therapeutics including bovine lactoferrin, curcumin, neem etc 
are currently in lime light of research focus for their promising functional ability in abrogating 
key nodal cancer signalling paradigms, immunomodulation thereby escalating remarkable 
tumour growth inhibition(Baratchi, Kanwar & Kanwar 2010a; Kanwar et al. 2008b; Kanwar & 
Kanwar 2012). A predominant class of natural product based super paramagnetic iron oxide 
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nanoparticle (SPIONS)  nanotheranostic agents in conjucture with tumour specific targeting 
entities including epithelial cell adhesion molecule (EPCAM), aptamer variants in combination 
with locked nucleic acid conjugates including LNA - nucleolin aptamer, LNA ± EPCAM 
aptamer were fabricated (Kanwar, Roy & Kanwar 2011b)  
The above mentioned nanotheranostic agents were able to selectively induce tumour apoptosis 
exhibiting distinct anti-tumour activity as envisaged by advanced fluorescence imaging 
techniques. Furthermore, theranostic investigations by utilisation of plethora of ultra-modern 
imaging techniques including MRI, PET, SPECT, PDT are into consideration (Kanwar et al. 
2012b). 
In conclusion, multifunctional nanotheranostics in partnership with various upcoming 
technologies including nanorobotics, bioinformatics, cancer systems biology, molecular 
nanotechnology, femtomedicine will certainly hold substantial promise in opening new vistas for 
effective management of clinical cancers by their multimodal action(Freitas 2005; Kreeger & 
Lauffenburger 2010). 
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Chapter 3: Materials and Methods 
3.1. Materials 
Cancer cell lines ± colon cancer cell line (Caco2) and breast cancer (MDA-MB-231) were 
purchased from American type culture collection (ATCC), USA. The following chemicals were 
obtained from Sigma-Aldrich, Australia: chitosan (20-200 cp; low molecular weight), trypsin-
EDTA, pencillin- streptomycin, sodium tripolyphosphate(STTP), sodium alginate. The following 
chemicals were purchased from Invitrogen life technologies: CyQUANT cell proliferation assay 
kit, polymerase chain reaction reagents ± trizol reagent, cDNA synthesis system and lissamine 
rhodhamine B sulfonyl chloride. Multi well chamber slides and cell culture essentials were 
obtained from BD Biosciences. Vector mounting media and HRP peroxidase conjugate kit 
obtained from Vector Labs, USA. Immunohistochemical reagents such as haematoxylin, eosin, 
and crystal violet stain obtained from Lomb scientific, Vic, Australia. 
3.2. Fabrication of alginate coated chitosan nanogel encapsulated iron saturated lactoferrin 
(FebLf) nanocapsules (FebLf NCs) 
The fabrication of FebLf NCs was carried out according to previous methods with slight 
modifications (Kanwar et al. 2014; Kanwar et al. 2008a; Li et al. 2007; Samarasinghe et al. 
2014).  Briefly, 1:3 ratio of the 300mM iron (Fe3O4) and 600mM of nitrilotriacetate acid 
disodium salt (NTA) (MW = 235.10) were dissolved in sterile water. Further, pH was adjusted to 
7. Later, 0.1% solution of apobLf (iron free bovine lactoferrin) was substituted with 0.1 M solid 
sodium bicarbonate.  Later, pH was adjuted to 8. Then, the freshly prepared Fe - NTA solution 
was added dropwise to prepared apobLf solution while magnetically stirring the solution. In the 
presence of carbonate ions, structural confirmation of lactoferrin molecule possessing iron 
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binding pockets initiates the uptake of iron molecules. The Fe-NTA solution was added to the 
protein solution until a reddish black brown colour solution is formed. This colour formation 
signifies the 100%  iron saturation of lactoferrin. Further, the obtained mixture is subjected to 
overnight magnetic stirring at 40 C in order to stabilise the FebLf complexation. Later on, the 
FebLf solution was separated by centrifugation techniques at 5000 RPM for 10 minutes. The 
obtained FebLf formulation is thoroughly washed with sterile PBS. Further, the obtained FebLf 
was coated with chitosan nanogel layer (0.1% w/w) in presence of sodium tripolyphosphate 
(STTP) added dropwise, while magnetically stirring the solution. Later, the mixture was 
subjected overnight magnetic stirring, followed by collection of nanoformulation by 
centrifugation and thoroughly washed with sterile PBS. FebLf NCs were coated with alginate gel 
(0.1 % w/w) in presence of calcium chloride (CaCl2) solution added dropwise, while 
magnetically stirring the solution. The mixture was then subjected to 6 hour magnetic stirring 
and later, FebLf nanocapsule was separated by centrifugation techniques and washed with sterile 
PBS. Void NCs lack lactoferrin component in them. Alginate coated chitosan nanogel 
encapsulated FebLf nanocapsule nanoformulation obtained and lyophilisation of samples was 
carried out and utilised for further research studies. 
 
Physiochemical characterisation 
3.3 Scanning electron microscopy (SEM) analysis 
Scanning electron microscopy analysis was performed by utilisation of Zeiss Supra 55 SEM VP. 
FebLf NCs, void NCs samples were dispersed in sterile milliQ water and drop of sample was 
dispersed on the carbon coated SEM grid. Later, gold coating of the samples was carried out to 
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avoid reflection of the nanoparticle samples. The samples were analysed for determination of 
average particle size, size distribution and surface morphology.  
 
3.4 Dynamic light scattering spectroscopy (DLS) 
Dynamic light scattering spectroscopy was performed to determine the particle size and zeta 
potential measurement of FebLf NCs by using Malvern Zetasizer NanoZS (Malvern Instruments, 
UK) with the following protocol. 1 mg / ml of nanoparticles were dispersed in milliQ water, later 
a 1:100 dilution was performed to obtain the particle size. zeta potential measurements of the 
nanoparticles were carried out by quartz cuvette with electrodes. 
3.5 Fourier transformed infrared spectroscopic analysis (FTIR) 
Fourier transformed infrared spectroscopic analysis was carried out utilising Biorad FTIR 
instrument. The following protocol was followed. Lyophilised samples of FebLf NCs, void NCs, 
bovine lactoferrin (bLf) were mixed with potassium bromide (kBr) powder and later the 
composition was compressed to a kBr pellet with the sample. FTIR absorption spectrum was 
obtained for a wavelength range 1100-1 to 1400-1. 
 
3.6 X ± Ray diffraction analysis (XRD) 
X ± ray diffraction analysis of void NCs and FebLf NCs was performed by Panalytical powder X 
± ray Diffraction machine with the following parameters of voltage 2.5W and scanning theta 
angle range 20 degrees to 100 degrees. XRD spectrum of the void NCs, FebLf NCs were 
analysed for the specific X - UD\GLIIUDFWLRQEUDJJ¶VUHIOHFWLRQSHDNV.  
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3.7 Magnetization analysis 
Superparamagnetism property of FebLf NCs  was investigated by Squid magnetometer with - an 
applied magnetic field of -20000 Oe to + 20,000 Oe, emu/g saturation magnetisation between + 
100 to ± 100 and results are represented in the form of hysteresis loop analysis chart.  
3.8 pH dependent drug release analysis 
pH dependent drug release profile of FebLf NCs was analysed at variable pH range including pH 
- 2 (acidic), pH - 7 (neutral) and pH ± 9 (alkaline). The following protocol was followed as 
described earlier. Briefly, 10 mg of the nanoparticle sample was dispersed in PBS with pH -2, 7 
and 9 and incubated at 37 C. Later, 100 μl of sample was collected at designated time intervals 
of ± 1,2,4,6,8,10,12,24,48, 72 hours and subsequently replenished with equal amounts of fresh 
PBS. Spectrophotometric Bradford protein concentration quantifications were carried out at 660 
nm wavelength range to assess the drug release at each time intervals depending on the pH 
range.  
3.9 SDS PAGE analysis 
Sodium dodecyl polyacrylamide gel analysis was performed according to Lammeli method. The 
following materials were utilized for preparation of separating gel (12.5% v/v) and stacking gel 
(4% v/v): 1.5M Tris HCl pH 8.8 (ml) (separating gel preparation), 0.5M Tris HCl pH 6.8 (ml) 
(stacking gel preparation), 40% Acrylamide / bisacrylamide (ml), 20% SDS ȝO10% APS ȝO
and tetramethylethylenediamine (TEMED) ȝO 7KH FKHPLFDOV ZHUH REWDLQHG 6LJPD-Aldrich, 
NSW, Australia. The gel electrophoresis was carried out at 200 volts for 40 min (approximately). 
Later, obtained gel was subjected to coomassie brilliant blue staining by utilization of coomassie 
ϵϮ

blue dye solution and later gel was subjected to destaining.The gel was imaging by BioRad gel 
documentation imaging system (BioRad, NSW, Australia). 
 
In vitro cell and molecular biology studies 
3.10 Cell culture maintenance 
Breast cancer cell line (MDA-MB-231) and colon cancer cell line (Caco2) was obtained from 
$PHULFDQ W\SH FXOWXUH FROOHFWLRQ $7&& DQG ZDV FXOWXUHG DFFRUGLQJ WR PDQXIDFWXUHU¶V
protocol. Breast cancer cells were cultured as a monolayer in Levobitz media (GIBCO Inc) 
without carbondioxide (Co2), supplemented with 10% fetal bovine serum (FBS) and pencillin 
(20 units/ml) and streptomycin (20mg/ml) (Invitrogen) antibiotic solution. Colon cancer cells 
were cultured in Dulbecco's Modified Eagle Medium (DMEM) in 5% Co2 incubator with FBS 
and antibiotic solution as mentioned above. Trypsinisation (5 min) of cells were carried after 
reaching 80 ± 90 % confluency and cells were grown in 25 cm, 75 cm flasks at 37ºC incubator.   
3.11 FebLf NCs cellular internalisation studies in MDA-MB-231 cell line.  
Internalisation of FebLf NC, void NCs was carried out by confocal microscopic detection of 
rhodamine labelled FebLf NCs, void NCs. The nanocarrier system consists of an chitosan 
nanogel encapsulation with FebLf and whereas the void NCs has the chitosan nanogel 
encapsulation without FebLf. Chitosan nanogel encapsulation is incubated with 0.1% rhodamine 
solution over night at constant spinning. This enables conjugation of the carboxyl group present 
on the rhodamine with the free amino groups present on the chitosan. Since both void NCs as 
well FebLf NCs have presence of free amino groups on the surface, therefore both get 
ϵϯ

chemically conjugated with rhodamine (Kanwar et al. 2014) and immunocytochemistry based 
detection of lactoferrin in cells incubated with FebLf NCs was carried out. 
Confocal microscopic detection of cellular internalisation for rhodamine labelled FebLf NCs in 
MDA-MB-231 cell line: Cells were grown in 8 well chamber slide (GIBCO) seeded at a 
concentration of 1000 cells / well. When cells reached complete confluency, 150 μg / ml of 
protein concentration of FebLf NCs and equivalent amount of void NCs treatments were added 
at incubation time intervals ± 1hr, 2 hr, 4 hr. Void NCs were incubated for highest time interval 
of 4 hrs. Later, treatment concentrations were removed and cells were washed thoroughly with 
sterile PBS. Fixation of cells was carried out by 4% freshly prepared paraformaldehyde for 
duration of 20 minutes. Later, cells were rinsed in sterile PBS and mounted with DAPI mounting 
media (Sigma Aldrich). The prepared slides were imaged by utilising Zeiss confocal microscopy 
utilising DAPI and rhodamine laser channels at respective wavelengths 550 to 600 nm. Results 
were illustrated by confocal microscopic images and a representative histogram quantifying the 
internalisation efficiency by analysis of minimum of 6 confocal microscopy images in different 
fields were represented. 
Immunocytochemistry based detection of FebLf NCs:  Cells were seeded in an 8 well slide 
chamber slide at concentration of 1000 cells/well and grown until cells reached confluency. 
Later, cells were incubated with treatment concentrations of 150 μg/ml of FebLf NCs and 
equivalent amount of void NCs for about 24 hours. Treatments were removed and cells were 
thoroughly washed with sterile PBS. Fixation of cells was carried out by 4 % freshly prepared 
paraformaldehyde for 20 min. cells were washed with sterile PBS.  Cells were permeabilised 
with 0.1% triton X  for 2 minutes. Cells were washed with sterile PBS and 
immunocytochemistry was carried out as per the immune peroxidase kit (Vector Labs Inc). 
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Initially, blocking was carried out by 1% porcine gelatin for 1 hr. Later, cells were washed for 3 
times with sterile PBS and incubated with  anti - goat bovine lactoferrin (Bethyl antibodies) 
primary antibody with dilution 1:200 for 1 hr at 37º C. After incubation, cells were washed with 
sterile PBS. Secondary antibody ± anti goat peroxidase HRP conjugate kit was utilised with 
dilution range 1: 200 for 1 hr at 37º C. Later, cells were thoroughly washed and DAB substrate 
incubation (Sigma DAB tablets) was carried out for 10 min. Nucleus was stained with 1% 
propidium iodide (PI) solution in dark. Cells were washed. Slide was mounted by mounting 
media. Zeiss inverted microscope was utilised for obtaining images at 40 X magnification. 
 
3.12 CyQuant cell proliferation assay 
CyQuant analysis was performed to check cytotoxic effect of  FebLf NCs, void NCs as per the 
CyQuant assay kit protocol. Cells were seeded in 96 wellplate at concentration of 1000 cells / 
well. When cells reached confluency, the cells were subjected to FebLf NCs treatments at 
concentrations ± 400, 800, 1600 and 3200 μg / ml, void NCs equivalent to 3200 μg / ml FebLf 
concentration and incubated for 24 hrs. After 24 hours incubation, treatments were removed and 
cells were thoroughly washed with sterile PBS. Later the 96 well plate was stored at -80º C as 
per the protocol. After 24 hrs incubation, 96 wellplate was removed from freezer and CyQuant 
analysis was performed by incubation of CyQuant GR dye/ cell-lysis buffersolution for 5 - 10 
minutes in dark at 37º C. Later, fluorescence readings were obtained at 340 and 520 nm filters 
and cell proliferative effect was estimated.   
 
 
ϵϱ

3.13 Tumour clonogenic cytotoxic assay 
Tumour clonogenic formation assay was performed as per following protocol.  Briefly, cells 
were seeded in a 6 well plate at a concentration of 106 and allowed to grow till confluency. Later, 
FebLf NCs treatment concentrations ± 400, 800, 1600 and 3200 μg / ml were added to the cells 
and incubated for  24 hrs. After the incubation, supernatant was removed and cells were 
thoroughly washed with sterile PBS. Then, approximately 300 cells from each well were 
transferred to a 1% (w/v) agarose coated 6 well plates. Cells were allowed to grow for next 12 
days. Colony formation was observed from 2nd day of cell seeding and growth of colonies was 
monitored on a daily basis. After 12 days of incubation, colonies were fixed with 4 % 
paraformaldehyde. Later, colonies were stained with 1 % crystal violet dye solution. Colony 
counter was utilised to count no of colonies in the control, void NCs and FebLf NCs treatments 
and representative histogram was generated to determine colony formation efficiency.  
3.14 Tumour spheroid cytotoxic assay 
Three dimensional tumour spheroid assay is a well known model established to study the 
cytotoxic effect of drugs resembling in vivo tumour vasculature.  Tumour spheroid assay was 
performed with a slightly modified protocol. Initially, cells were seeded with a concentration of 
400 cells / well in a 1% (w/v) agarose coated 24 well plate following liquid over lay technique.  
The growth of spheroid was initiated for a period of approximately 12 days and a well grown 
compact tumour spheroids were obtained. Later, FebLf NCs treatments were added with 
concentrations - 400, 800, 1600 and 3200 μg/ml and  24 hour, 48 hour incubations were carried 
out.  Remarkable shrinkage in size of the tumour spheroids were observed in a dose dependent 
manner in 24 hours. A complete dissolution of spheroids was observed in a 48 hour time period. 
ϵϲ
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Inverted microscopic images at 40X magnification were captured, documenting the shrinkage of 
spheroids. Later, size quantification of the treated and untreated spheroids were carried out.  
Functional mechanism of FebLf NCs in MDA-MB-231 cell line. 
3.15 Mitochondrial membrane depolarisation assay 
Mitochondrial membrane depolarisation assay was performed according to the Sigma 
mitochondrial membrane depolarisation kit. JC 1 dye translocates in to the mitochondria, in the 
intact mitochondria it fluoresces as a red colour and when the mitochondrial membrane is 
ruptured, it translocates in the cytoplasm and appears as green colour representing mitochondrial 
membrane depolarisation.  The following protocol was followed. Cells were grown in 8 well 
chamber slides at density of 1000 cells per well. Later, FebLf NCs treatment concentrations ± 
400, 800, 1600, 3200 and void NCs treatment equivalent to 3200 μg/ml concentration was 
added. After 24 hour incubation, supernatants were removed and cells were washed thoroughly 
with sterile PBS. Later, Solutions of JC ± 1 and valinomycin control was prepared and incubated 
with cells for 1 hour at 37º C. After the incubations, fixation of cells was carried out by 4% 
freshly prepared paraformaldehyde.  Slide was mounted with DAPI (Sigma) and imaging was 
performed by Zeiss confocal microscopy. Results were represented as confocal microscopic 
images and representative histogram determining mitochondrial membrane depolarisation 
efficiency.  
3.16 Immunofluorescence based detection of survivin and cytochrome C expression 
Immunofluorescence detection of survivin was carried out as per the earlier protocol. Briefly, 
cells were grown in 8 well chamber slides at a density of 103 cells per well. When the cells 
reached  confluency, FebLf NCs treatment concentrations - 400, 800,1600, 3200 μg/ml and void 
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NCs treatment - equivalent in amount to 3200 μg /ml FebLf concentration was incubated to cells. 
After 24 hour incubation, supernatants were removed and cells were thoroughly washed. 
Fixation of cells was done by 4 % freshly prepared paraformaldehyde for 20 min. 
Permeabilisation of cells was carried out by 0.1 % triton X. After washing the cells with sterile 
PBS, blocking step was performed with 1.2% BSA for 1 hour at 37º C. Later, sterile PBS 
washing step was carried and respective primary antibody incubations - survivin with mouse anti 
survivin D8 (Invitrogen) at dilution 1:100 at 37º C for 1 hr and anti  cytochrome C antibody 
made in sheep with dilution 1:100 at 37º C for 1 hr was performed. Following this, secondary 
antibody incubations was done for survivin with anti mouse FITC (Invitrogen Inc) with 1:100 
dilution for 1 hr at 37º C and for cytochrome C with anti sheep FITC with dilution 1:100 at 37º C 
for 1 hr was performed. Later, cells were rinsed with sterile PBS and 1 % PI staining solution 
that is specific to nucleus was incubated for 30 min at 37º C in dark. After this step, cells were 
rinsed in sterile PBS and slides were mounted with mounting media. The prepared slides were 
imaged by utilising Zeiss confocal microscopy. 
 
3.17 Quantitative real time polymerase chain reaction (qRTPCR) analysis of FebLf NCs 
functional mechanism. 
Table: 3.1 Primer sequences and annealing temperatures for the genes. 
S.NO RECEPTOR FORWARD 
PRIMER 
REVERSE PRIMER Annealing  
Temperature 
(degrees C) 
Reference 
 
1 
Divalent metal ion 
transporter (DMT1) 
¶- 
TGTCACCGTCAG
TATCCCAA-¶ 
¶-GTGCAAT 
GCAGGATTCAATG-
¶ 
 
59.0650 
(Tallkvist, 
Bowlus & 
Lönnerdal 
2000) 
ϵϴ

 
2 
Ferroportin ¶-
TGACCAGGGCG
GGAGA-¶ 
¶-
GAGGTCAGGTAGTC
GGCCAA-¶ 
 
59.1833 
(Theurl et 
al. 2009) 
 
3 
 
Ferritin ± H (Heavy 
chain) 
¶-
GCCAAATACTTT
CTTCACC-¶ 
¶-
TTCATTATCACTGT
CTCCC-¶ 
 
58.9895 
(Kakhlon, 
Gruenbau
m & 
Cabantchi
k 2001) 
 
4 
Ferritin ± L (Light 
chain) 
¶-
AGGACATCAAG
AAGCCAG-¶ 
¶-
AGGAAGTCACAGA
GATGGG-¶ 
 
59.0703 
(Kakhlon, 
Gruenbau
m & 
Cabantchi
k 2001) 
 
5 
Lactoferrin (Lf) 
receptor 
¶-
ACCCAAGGAAA
GTGCAGCTGAGA 
- ¶ 
¶-
GTTCCCTCCCACAA
AACTCTCAACGA-¶ 
 
59 
(Suzuki, 
Shin & 
Lönnerdal 
2001) 
 
6 
 
Transferrin (TFR 1) 
receptor 1 
¶-
CTCACTTTAGAC
AATGCTGC- ¶ 
¶-
CTCATGACACGATC
ATTGAG- ¶ 
 
52 
(Kim et al. 
2004) 
 
7 
 
Transferrin (TFR 2) 
receptor 2 
¶-
GGAGTGGCTAG
AGGGCTACCTC- 
¶ 
¶-
GGTCTTTGGCATGA
AACTTGTCA- ¶ 
 
52 
(Herbison 
et al. 
2009) 
 
8 
Low density 
lipoprotein receptor-
related protein 
1 (LRP1) 
¶-
ATCGTGCCGCGA
GTATGCCG- ¶ 
¶- 
GTGTGGCGCGTGAT
GGTGGA -¶ 
 
52 
(Xu et al. 
2011) 
 
9 
Low density 
lipoprotein receptor-
related protein 2 
(LRP 2)  
¶- 
CCAAGTTGCTAT
TCGTGGG- ¶ 
¶- 
GCACCCAGTCTCCA
GTCAG- ¶ 
 
52 
(Grey et 
al. 2004) 
10 Glyceraldehyde 3-
phosphate 
dehydrogenase 
(GAPDH) 
¶-
CCATCACCATCT
TCCAGGAG- ¶ 
¶-
CCTGCTTCACCACC
TTCTTG- ¶ 
55.5 (Ueta et al. 
2005) 
11 Survivin ¶-CCA CCG CAT 
CTC TAC ATT 
CA-¶ 
¶-
TATGTTCCTCTATG
GGGTCG-¶ 
50 (Kim et al. 
2011) 
12 Livin ¶-
GTCAGTTCCTGC
TCCGGTCAA-¶ 
¶-
GGGCACTTTCAGAC
TGGACCTC-¶ 
55 (Oh, Lee 
& Kim 
2011) 
13 PI3K ¶-TCA AAG GAT ¶-GCC TCG ACT 55  
ϵϵ

TGG GCA CTT 
TT-¶ 
TGC CTA TTC AG-¶ 
 
In vitro and in vivo Receptor mediated internalisation mechanisms of FebLf NCs :  
Role of prominent internalisation receptors in translocation of FebLf NCs was studied in MDA-
MB-231 cell line and in vivo human xenograft colon cancer mice tissues. MDA-MB-231 cells 
were cultured in a six well plate at concentration of  106 and cultured till confluency. Later, cells 
were treated with 400 μg / ml concentration of FebLf NCs and respective Void NCs 
concentration. The incubation timings were for 12 hours, 24 hours and 48 hours. Further, RNA 
H[WUDFWLRQZDV FDUULHG RXW E\ 75L]RO PHWKRG ,QYLWURJHQ ,QF86$ DV SHU WKH PDQXIDFWXUHU¶V
instructions and purified RNA (5μg) was confirmed by 1% agarose electrophoresis. Obtained 
RNA was converted in cDNA by SuperScript® III First-Strand Synthesis System (Invitrogen Inc 
86$DVSHUWKHPDQXIDFWXUHU¶VSURWRFROT573&5DQDO\VLVRIWKHLQWHUQDOLVDWLRQUHFHSWRUJHQHV
(Table 1) carried out by quantitative real time polymerase chain (qRT-PCR) system (Biorad 
Inc,USA) utilising the respective primers (Table 1) and represented annealing temparatures 
(Table 1).The following protocol was followed: 15 ul of PCR reaction mixture containing 14 μ l 
of Sybergreen mixture (Biorad Inc USA), 1 μl of cDNA sample (in vitro study - FebLf NCs 
treatments and in vivo study : mice tissue samples)  and respective primer concentration 
(0.025μm) for genes (Table 1) up to 60 reaction cycles. Delta cT values of the genes were 
calculated with respective to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as 
housekeeping JHQH DQG UHSUHVHQWHG DV PHDQ  VWDQGDUG GHYLDWLRQ DV SHU WKH PDQXIDFWXUHU¶V
instructions of quantitative real time polymerase chain (qRT-PCR) system (Biorad Inc,USA). 
qRT-PCR products were analysed by 1% agarose gel electrophoresis and gel imaging was 
carried out by Biorad gel imaging documentation system.In vivo work: RNA isolation from the 
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colon cancer mice tissue samples was carried out in similar manner as mentioned for in vitro 
study. cDNA preparation and qRT ± PCR analysis of the internalisation receptors were also 
carried out as mentioned above for the vehicle control and FebLf NCs treated mice tissue 
samples. 
 
Apoptotic signalling mechanisms of FebLf NCs in MDA-MB-231:  
qRTPCR analysis was performed by BioRad real time polymerase chain reaction system and 
following apoptotic genes ± survivin, PI3K and livin. Briefly, cells were cultured in 6 well plate 
at density of  106 till confluency. Later, 3200 μg/ml - treatment concentration of FebLf NCs and 
equivalent void NCs treatment  were incubated for 24 hours. Later, supernatant was removed and 
cells were washed thoroughly with sterile PBS. RNA extraction was carried out according to the 
TRizol method (Invitrogen Inc) as per the kit protocol. Later cDNA synthesis was carried out as 
per the kit protocol (Invitrogen Inc) and reaction mixture was prepared with the following 
components ± purified RNA(5μg) Taq buffer, dNTPs, random hexamers, super script, RNA ase 
H and nuclease free water. Following cDNA preparation, quantitative real time PCR analysis 
was carried out by utilisation of Syber green reaction mixture(14μl), RNase free water, forward 
and reverse primers (0.025 μm) for apoptotic genes (table 1) and cDNA. The reaction time was 
run for 60 cycles and later, the samples were further analysed by performing 1% (w/v) agarose 
gel electrophoresis. Quantitative real time PCR data values were analysed with respective to 
house keep gene (actin/GAPDH) and delta cT values were analysed.  
 
 
ϭϬϭ
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3.18 Caspase activity analysis 
Caspase - 3 activity analysis was performed as per the kit protocol. Cells were plated out in 6 
well plate at a concentration 106  and grown till confluency. Later, the cells were incubated for 24 
hours with treatment concentration of FebLf NCs ± 400, 800, 1600, 3200 μg/ml and void NCs 
equivalent in amount of  FebLf  NCs - 3200 μg / ml concentration. After the incubation, 
supernatant was collected and caspase - 3 activity was performed. The volume (in μl) needed to 
get 100 μg/ ml of protein concentration in the supernatant of control, void NCs and FebLf NCs 
treatment concentrations were calculated and respective amounts were taken in a 96 well plate. 
To the supernatants, 100 μl of RIPA + DTT mixture at concentration was added and later, 7 μl of 
caspase 3 substrate was added to the supernatants. Plate was incubated in dark for 3 hours and 
spectrophotometric analysis of samples was carried out at 550 nm.  
3.19 Ex vivo intestinal assay loop analysis 
Briefly, freshly derived mice intestines were obtained and thoroughly subjected to washing with 
sterile PBS. Later, intestinal loop was made by ligating one end of the intestine with surgical 
thread. Now, 400 μg / ml concentration of rhodamine labelled FebLf NCs  was injected in the 
intestinal loops. Later, the other end of the loop was ligated with surgical thread and intestinal 
loop was maintained in 6 well plate supplemented with Roswell park memorial institute (RPMI) 
colourless media. The loops were incubated in RPMI media for 24 hours. 800 μl of samples was 
collected and replenished with equal amount of RPMI media. Later, the collected samples were 
assessed for fluorescent intensities by fluorescence spectrometer. Obtained fluorescence reading 
were quantified and represented in form of histogram analysis to examine the FebLf NCs 
transcytosis mechanism and absorption. 
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3.20 In vivo nude mice (Balb C nu/nu) studies to evaluate antitumor efficacy of FebLf NCs 
in human xenograft breast and colon cancer models. 
In vivo nude mice studies were conducted to assess the antitumour efficacy in human xenograft 
breast and colon cancer model by oral administration of FebLf NCs and vehicle control group. 
The study is performed as per the animal ethics regulations and project registration no : A91-
2010. C57 Balb C nu/nu ± nude mice model was employed to develop human xenograft breast 
(MDA-MB-231) and colon (Caco2) cancer model. AIN93G diet (Speciality feeds, Perth, 
Australia) mixed with 2.4 % w/w of FebLf was utilised for oral cancer therapy. FebLf NCs were 
mixed with the AIN93G diet and oral administration of diet was carried out in the form of 
pellets. 
Diet was prepared as previously described. AIN93G composition includes: Fat, fibre elements, 
vitamins, carbohydrates and protein. The diet is free from the casein (milk component), inorder 
to nullify the therapeutic adjuvant effect of casein. Components of AIN93G : barley, soyameal, 
mixed vegetable oils, salt, canola oil, wheat, calcium carbonate, magnesium oxide, dicalcium 
phosphate, trace minerals and vitamins. 
Study was designed as described below: 
Human xenograft breast and colon cancer model studies: 8 weeks old athymic mice were 
administered with tumour cell lines - MDA-MB-231 cells (106 cells /each mice) and Caco2 (107 
cells / each mice). (1) Prevention model studies (n=5): Mice were pretreated with oral 
administration of FebLf NCs nanoformulated diet, prior to two weeks of tumour inoculation. (2). 
Treatment model studies: vehicle control NCs diet treatment group (n=5) and FebLf NCs diet 
treatment group (n=5) were administered with tumour cell line. Later, after reaching tumour 
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volume range of 50 ± 60 mm3, oral administration of nanoformulated diet was carried out. 
Routine monitoring of mice weight, body condition and behaviour was monitored. Tumour 
volume monitoring was carried out by vernier calipers and calculated by the formula- tumour 
volume (mm3) = ½*L*W; L = Length - longest tumour dimension and W = width ± shortest 
tumour dimension. The study was conducted for 90 day period and later, Vital organs of mice 
were collected by sacrificing. Mice tissues were processed and stored in appropriate medium to 
be utilised for protein, RNA work and histopathology work.   
3.21 Near infrared (NIR) fluorescence based cancer imaging strategies to evaluate 
antitumor efficacy of FebLf NCs in human xenograft breast and colon cancer models. 
Near infrared (NIR) fluorescence imaging was carried out by utilisation of IVIS - 2 Lumina 
imaging system, according to Deakin University animal ethics approval. Live mice imaging was 
conducted by anaesthetising mice for a shorter time period. Fluorescent FebLf NCs were 
detected by the fluorescent signal of the tag in the wavelength range (675 ± 740 nm) and 
fluorescent photographs were obtained. The obtained mice images were analysed to determine 
the localisation and bio distribution patterns of FebLf NCs in the mice body. The fluorescent 
signal obtained at the tumour site was quantified to assess the tumour regression trend in terms of 
radiant efficiency and area of fluorescent signal at the tumour site. Furthermore, ex vivo mice 
organ imaging analysis was conducted to assess the biodistribution patterns of FebLf NCs in 
mice. 
3.22 Histopathology studies. 
Histopathology analysis was carried out by Haematoxylin and eosin staining of mice tissues to 
determine the effect of nanotoxicy and structural integrity of vital organs. Tissues were spot 
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sterilised by sterile PBS and snap frozen in optimal cutting media (OCT) and stored at -80º C. 
Tissue sectioning was carried out by utilising BioRad cryostat instrument and tissue sections of 
10m, 20 m thickness were cut and transferred to polylysine glass slides. Later, the slides were 
fixed with 100% ice cold acetone or 50% ice cold acetone : 50% methanol and stored for further 
studies. Hametoxylin and eosin staining was carried out with following protocol. Slides were 
processed in different stain solutions in the following order (1). Distilled water (2-3min); (2) 
haematoxylin stain (2 to 5min); (3) running tap water (5min); (4) acid alcohol(1min); (5) eosin 
stain (2-4 min); (6) 70% alcohol(3min);(7) 90% alcohol (3min);(8) 100% alcohol(3min); (9) 
xylene(2-3min);(10) slide mounting and fixation. Slides were imaged by utilising Olympus 
inverted microscope.   
 
3.23 Statistical analysis 
The results were represented as mean±SEM(standard error of the mean).Statistical significance 
was evaluated by paired VWXGHQW¶VW-test for the samples with respect to the control.* P <0.05 is 
considered as significant and ** P<0.005 is considered as highly significant.  

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Chapter 4: Fabrication of iron saturated lactoferrin nanocapsules and 
evaluation of anti - tumour activity in in vitro and in vivo cancer models  
4.1 Introduction 
Cancer is disease caused due to system progression of uncontrolled cell proliferation with the 
help of a myriad of cell signalling paradigms with their evolving complexity (Kanwar, 
Kamalapuram & Kanwar 2011a; Kanwar, Mahidhara & Kanwar 2011c; Kanwar et al. 2010c). 
The Key nodal signalling molecules in turn enhance cancer progression and thus is challenging 
aspect for cancer therapeutics to combat cancerous growth(Kanwar, Kamalapuram & Kanwar 
2010; Kanwar, Kamalapuram & Kanwar 2012a). Current therapeutics have incessantly resulted 
in failure due to mentioned limitations including  less bio availability,  less circulation half life, 
harmful side effects arising due to radiation effects and  chemotherapeutic agents that are not 
able to control cancer and hence leading to drug resistance which is a major problem(Kanwar et 
al. 2010c). To address these concerns of conventional chemo and radiotherapeutics, natural 
product derived therapeutics have had been in the lime light for their obsoletely no side effects 
and also  specific cancer targeting ability relatively without harming normal tissues(Kanwar, 
Mahidhara & Kanwar 2009). Earlier,  our research findings proved that iron saturated form of 
lactoferrin is a multifunctional protein with outstanding  immunomodulatory properties including 
assisting the voracious production of interleukins, activation of macrophages, dendritic cells, 
CD8 and natural killer (NK) cells and its ability in specifically targeting  cancer cells leaving 
normal cells completely safe(Kanwar et al. 2008a; Kanwar et al. 2012b). Hence, this molecule is  
economically viable option for development as a therapeutic and would be a  great boon for 
specifically for the developing world(Kanwar et al. 2010c). However, some concerns arise with 
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respect to free form of lactoferrin as a therapeutic such as -  decreased half life of lactoferrin in 
body circulation and also degradation of the molecule(Kanwar et al. 2012a). In order to 
overcome these above mentioned limitations, multifunctional nanotherapeutics have been 
designed with improved therapeutic properties and abilities such as  specific targeting to 
cancerous tissues, enabling multifunctionalisation to the therapeutics that can achieve a 
multitargeted therapy involving diagnostic, imaging and therapeutic aspect at contemporaneous 
rate(Kanwar 2012). Multifunctional nanotheranostics are designed with improved therapeutic 
properties such as targeted drug delivery, multimodal action enabled by tagging with tumour 
targeting entities such as aptamers, locked nucleic acid conjugates, that would certainly  enhance 
their therapeutic functionality and  can foresee their  application in platform of cancer 
therapeutics (Kanwar, Roy & Kanwar 2011b) (Kanwar, Kamalapuram & Kanwar 2011a; 
Kanwar, Roy & Kanwar 2011b; Kanwar et al. 2012c, 2012d). Our research studies with 100 % 
iron saturated bovine lactoferrin (FebLf) encapsulated in alginate coated ceramic nanocarriers 
(ACSC ± bLf) had shown remarkable anticancer activity  with 100 % biocompatible, during both 
in vitro and in vivo investigations in colon and breast cancer models (Kanwar, Mahidhara & 
Kanwar 2011c; Kanwar, Mahidhara & Kanwar 2012b). The functional studies of ACSC  FebLf 
nanocarriers revealed myriad of mechanisms involving down regulation of survivin, 
mitochondrial disruption and activation of caspase signalling mechanisms showing its multi 
modal action(Kanwar, Kamalapuram & Kanwar 2011a). Similar studies with alginate coated 
FebLf ceramic nanocores (ANCC FebLf) had been studied and revealed its multifunctionality 
with a  similar functional mechanism as discussed earlier(Kanwar et al. 2012a; Kanwar, 
Mahidhara & Kanwar 2012b; Kanwar et al. 2012b). The current focus of the cancer research is to 
develop safe nanotheranostic agents that could be used for cancer therapy and imaging. Recent 
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studies conducted with natural product based curcumin and neem nanocarrier nanodrug systems 
yielded promising observations in terms of improved cancer therapy and also imaging ability by 
employing fluorescence, bioluminescence and magnetic resonance imaging.  Hence, keeping in 
mind the need for multifunctional natural product derived nanotheranostic agents, we 
hypothesize that novel alginate coated chitosan nanogel encapsulated  FebLf nanocapsules  
(FebLf NCs) can exhibit antitumour activity both in in vitro and in vivo cancer models and 
further, FebLf NCs can be strategically employed as a nanotheranostic agent for cancer 
therapeutic imaging purposes(Kanwar et al. 2008a). Nanocapsule fabrication mechanism in brief 
involved utilisation of nanoprecipitation and ionic gelation techniques to formulate alginate 
coated chitosan encapsulated iron saturated lactoferrin nanocapsules (FebLf NCs) (Figure 
4.1)(Kanwar et al. 2008a).  
The study surrounds around fabrication of alginate coated chitosan nanogel encapsulated iron 
saturated lactoferrin nanocapsules (FebLf NCs) (refer Figure 4.1), physiochemical 
characterisation with techniques ± scanning electron microscopy (SEM), dynamic light scattering 
spectroscopy (DLS), fourier transform infrared spectroscopy (FTIR), magnetization analysis. 
The findings confirmed a relative small size of 80 nm with a remarkable superparamagnetic 
ability at saturation magnetization 50 emu/g. In vitro cell and molecular biology studies were 
carried out in a MDA - MB - 231 cell line, a prominent breast cancer cell line. Cytotoxic analysis 
was conducted in a two dimensional breast cancer model, clonogenic formation assay and three 
dimensional tumour  spheroid model studies were performed, Functional mechanism of FebLf 
NCs  in terms of cell uptake was mediated by low density lipoprotein receptor-related proteins 
(LRP ± 1 & 2), Transferrin receptor proteins (TFR ± 1 & 2), divalent metal ion transporter 
protein (DMT 1), ferroportin and ferritin heavy and light chain receptors. Furthermore, 
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anticancer signalling mechanisms of FebLf NCs including survivin, mitochondrial activity, 
various anti-apoptotic genes was carried out. Ex vivo intestinal loop assay analysis confirmed 
preferential uptake of FebLf NCs and localisation of FebLf NCs in the intestine samples was 
observed. However, no damage to intestine samples was seen with the transcytosis of FebLf 
NCs. In vivo human xenograft breast and colon cancer studies were conducted and are discussed 
in detailed in the later section. Based on our findings, we hypothesize for a completely safe, 
ecofriendly natural product derived FebLf nanocapsule nanodrug formulation with its less size, 
remarkable superparamagnetism ability, functional mechanism and ex vivo analysis.  
 
Schematic Illustration of FebLf NCs nanoformulation. 
 
Figure 4.1: Schematic Illustration of FebLf NCs nanoformulation.Figure represents the 
multimodal FebLf NCs schematic. FebLf is encapsulated in chitosan nanogel in presence of 
sodium tripolyphosphate (STTP) , followed by alginate coating. Fluorescent tag is attached to the 
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FebLf NCs, which can enable the multimodal imaging ability by near infrared imaging 
techniques. 
Results 
4.2 Characterisation analysis of FebLf NCs 
4.2.1 Scanning electron microscopy (SEM) analysis 
SEM analysis confirmed a homogeneous size distribution of FebLf nanocapsules with an average 
size of 50 nm - 80 nm. Absolute spherical surface morphology of the nanocapsules were 
observed as represented in figure (4.2).  The spherical morphology with uniform size distribution 
could certainly enable enhanced cellular uptake of the nanoparticles(Kanwar, Mahidhara & 
Kanwar 2009; Kievit et al. 2012). 
 
Figure 4.2: Scanning electron microscopy (SEM) analysis for void NCs and FebLf NCs 
nanoformulation. SEM observations revealed a spherical morphology of FebLf NCs with equal 
size distribution in range of 50 - 80 nm, similar to void NCs in Figure 4.2 (a) void NCs (b) FebLf 
NCs.(n=3).    
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4.2.2 Dynamic light scattering (DLS) spectroscopy 
DLS observations revealed a homogenous average size confirmation of  around  95 nm of the 
nanocapsules, in accord with SEM results (Figure 4.3). An optimal zeta potential of 37 mV was 
noted, conclusively comphrending the fact that these FebLf nanocapsules can achieve a 
favourable dispersive capability pertaining to drug delivery applications(Dilnawaz, Singh & 
Sahoo 2012). 
 
Figure 4.3 : Dynamic light scattering (DLS) spectroscopic observations for void NCs and 
FebLf NCs nanoformulation.  DLS observations revealed an average size 80 - 95 nm of FebLf 
NCs and void NCs size range at 58 nm.(n=3). 
4.2.3 Fourier transformed infrared spectroscopic analysis 
FTIR analysis revealed successful fabrication of FebLf nanocapsules by detection of 
characteristic bonding patterns under wavelength range 1100-1 to 4000-1. The functional groups 
including NH3 peaks were observed in the range of 1000-1 ± 1600-1, OH peaks - 3000-1 to 4000-1 
and fe ± O bonding patterns - at 1100-1 wavelength was noted (Figure 4.4). These observations 
pertaining to illustrations of functional groups detection confirms successful fabrication of FebLf 
nanocapsules as described previously (Kievit et al. 2012). 
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Figure 4.4: Fourier transform infrared spectroscopic analysis for void NCs and FebLf NCs 
nanoformulation. FTIR analysis of Void NCs (represented with red line)  and FebLf NCs 
(represented with green line) showed successful fabrication of FebLf NCs with protein specific - 
NH3 group peak and OH group peak patterns.(n=3).     
 
4.2.4 X ± Ray diffraction analysis 
X ± ray diffraction spectrum analysis of  void NCs and FebLf NCs confirmed similarity in 
crystal structure of FebLf nanocapsules. Specific BUDJJ¶VUHIOHFWLRQSHDNLQWHQVLWLHVZHUHQRWHG
respective to the  void NCs spectrum at 122, 132 angles (Yallapu et al. 2011). These 
observations confirm that fabrication of the FebLf nanocapsules had retained its similarity in the 
crystal structure (Figure 4.5). 
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Figure 4.5: X ± Ray diffraction spectrum analysis for void NCs and FebLf NCs 
nanoformulation.  X ± ray diffraction analysis of FebLf NCs showed similarity in structure with 
respect to void NCs. Characteristic bragg reflections peaks was noted in X-ray diffraction 
spectrum of FebLf NCs, along with the void NCs.(n=3). 
4.2.5 Magnetization analysis 
Remarkable superparamagnetic ability of FebLf nanocapsules was detected as represented by 
hysteresis loop in the Figure 4.6. FebLf nanocapsules exhibited  superparamagnetic ability  
between 20 to 80 emu / g magnetization in a range of - 30000 to + 30000  H(Oe). The observed 
superparamagnetic ability of FebLf nanocapsules can be preferentially exploited for magnetic 
drug targeting and as a potential magnetic resonance imaging (MRI) contrast imaging agent with 
1.5 T1  and T2 magnetic relaxivities as described earlier(Kievit & Zhang 2011). 
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Figure 4.6: Magnetization analysis for void NCs and FebLf NCs nanoformulation. 
Remarkable superparamagnetic property of  FebLf NCs was observed with respect to the void 
NCs. A saturation magnetisation of 60 emu/g was observed, that represents the 
superparamagnetic ability of the FebLf NCs nanoformulation as denoted in figure.(n=3). 
4.2.6 pH dependent drug release analysis 
pH dependent profile of  FebLf nanocapsules revealed an incremental patterns of  drug release  
in a consistent manner at  pH 7 and pH 9 when compared to pH 2 (Figure 4.7). This pattern of 
enhanced drug release at intestinal absorption patterns can be favourably exploited for oral drug 
delivery applications(Norris, Puri & Sinko 1998). Moreover, this consistent release pattern of 
FebLf nanocapsules can enhance the increased circulation half life of lactoferrin, when 
administered for an in vivo drug delivery applications, as noted earlier(Kanwar et al. 2014). 
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Figure 4.7: pH dependent drug release analysis for FebLf NCs nanoformulation. pH 
dependent profile of  FebLf nanocapsules revealed an incremental patterns of  drug release  in a 
consistent manner at  pH 7 and pH 9 at intestinal pH ranges over a 72 hour time period, that can 
enable optimal oral route of drug delivery.(n=3). No variation in the SEM values was observed 
during this study therefore, the SEM bars are buried in the respective bars. Results represented 
are mean±SEM.  
4.2.7 SDS PAGE analysis for detection of FebLf NCs 
SDS PAGE analysis of FebLf NCs was carried out to determine the intact nature of lactoferrin 
molecule in the form of nanoformulation. SDS analysis revealed that intact protein structure and 
configuration of the FebLf molecule was retained in the nanoformulations. Figure 4.8 represents 
lactoferrin specific bands obtained in FebLf NCs samples with respect the ApobLf band. This 
shows that FebLf NCs is a stable complex retaining the native integrity of lactoferrin, even in the 
nanoformulated form. SDS-PAGE was performed only to demonstrate the molecular weight of 
the protein released (which is equal to 75 kDa corresponding to the bLf forms). The Fe-bLf is 
quite stable to heat as well as enzymatic based degradation. Moreover, previously published 
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studies from our laboratory demonstrated the stability of Fe-bLf in this NCs in varying pH and 
with increase in time (Kanwar et al. 2014).  
 
Figure 4.8 SDS PAGE detection of FebLf NCs. SDS PAGE analysis of FebLf NCs was carried 
out to examine the integrity of the protein in nanoformulation. The SDS PAGE analysis confirms 
intact protein configuration of FebLf in the FebLf NCs nanoformulation, in comparison ApobLf. 
(n=3). 
 
4.3 In vitro cell and molecular biology studies in MDA-MB-231 cell line. 
4.3.1 FebLf NCs cellular internalisation studies in MDA-MB-231 cell line. 
Confocal microscopic analysis revealed enhanced uptake of rhodamine labelled FebLf 
nanocapsules within 2 hour of incubation time and a consistent time dependent increase of 
uptake was noted (Figure 4.9). Maximum internalisation of FebLf nanocapsules was perceived in 
the 4 hour time interval. Results are represented as confocal microscopic images with nucleus 
represented in blue colour stained with DAPI and red colour representing rhodamine labelled 
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FebLf nanocapsules and a representative histogram demonstrates that more than 95 % 
internalisation had been achieved within 4 hrs of incubation timing when compared to void NCs 
nanoformulation.  
Immunocytochemistry based detection of lactoferrin was clearly observed as shown in the Figure 
4.10. The brown colour is representative of the specific reaction of lactoferrin antibodies with 
FebLf NCs internalised in breast cancer cells. Hence, all together the observations noted in 
FebLf nanocapsule cellular internalisation including confocal microscopic detection of 
rhodamine labelled FebLf nanocapsules and immunocytochemistry based detection of FebLf 
nanocapsules are in accord with each other and conclusively echo remarkable internalisation 
efficiency of FebLf nanocapsules within 4 hour duration.   
The possible mechanism of internalisation might be through endocytosis and receptor mediated 
endocytosis mediated with  low density lipoprotein receptors (LRP 1&2), transferrin receptors 
(TFR, TFR1,2), divalent metal ion transporter proteins, ferritin receptors, as evidenced by the 
increase in gene expression patterns of above mentioned molecules as noted in quantitative real 
time polymerase chain reaction (qRTPCR)  studies of the  above mentioned genes to be 
discussed later and as shown in previous observations(Geetha et al. 2011a; Hohnholt, Geppert & 
Dringen 2011; Mohanty et al. 2011).  Additionally, FebLf nanocapsule cell internalisation 
mechanism can be preferentially mediated via iron specific receptors including divalent metal 
ion transporter proteins (DMT 1), ferritin, ferroportin receptors, that enable specific translocation 
of fe ions across the cell membrane and through macrophage receptor(Cengelli, Voinesco & 
Juillerat-Jeanneret 2010; Dilnawaz et al. 2012; García-Montoya et al. 2012; Kanwar et al. 
2008a). 
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Figure 4.9: Confocal microscopic observations for cellular internalization analysis in MDA-
MB-231 cell line treated with void NCs and FebLf NCs nanoformulation. Confocal 
microscopic observations revealed a time dependent internalisation pattern of FebLf NCs. FebLf 
NCs showed an internalisation efficiency at 1 hr incubation - 32(%) ± 2 ; 2hrs incubation ± 
64(%) ± 4; 4 hrs incubation ± 85(%) ± 2. Void NCs with 4 hour incubation exhibited 
internalisation efficiency ± 51(%) ± 4. Hence, an effective internalisation pattern of FebLf NCs 
was observed in MDA-MB-231 cell line. *p<0.05; **p<0.005. (n=3). (Student t test). Results 
represented are mean±SEM. 
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4.10: Immunocytochemistry based detection of FebLf NCs in MDA-MB-231 cell line 
treated with void NCs and FebLf NCs nanoformulation. Immunocytochemistry based 
detection of FebLf NCs with lactoferrin specific antibody, revealed remarkable internalisation 
pattern. FebLf NCs exhibited internalisation efficiency of 96%. **p<0.005. (n=3). (Student t 
test). 
4.3.2 CyQuant cell proliferation assay  
CyQuant analysis revealed a dose dependent cell proliferative inhibition ability of FebLf 
nanocapsules within 24 hrs incubation as illustrated in Figure (4.11). The following observations 
were noted in terms of cell proliferation ability in the samples. Control (untreated) - 100 %; 20% 
FBS - 106%; void NCs (equivalent amount in concentration - 3200μg/ml FebLf NCs) ± 75.42% ; 
FebLf NCs treatment concentrations: 400 μg/ml -76.23% ; 800 μg/ml ± 70.45 % ; 1600 μg/ml ± 
49.30% ; 3200 μg/ml ± 4.94%. %. IC50 value observed for FebLf NCs was 1.195*104 NCs and 
void NCs was 6.51*104 NCs. Hence, remarkable dose dependent cytotoxic response of FebLf 
NCs was noted. 
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Figure 4.11: Cell proliferation analysis in MDA-MB-231 cell line treated with void NCs and 
FebLf NCs nanoformulation by CyQuant cell proliferation assay. CyQuant cell proliferation 
analysis showed the cell proliferation inhibition ability of FebLf NCs. Cell proliferation analysis: 
Control (untreated) ± 100 %; 20%FBS ± 106% ; void NCs (equivalent amount in concentration - 
3200μg/ml FebLf NCs) ± 75.42% ; FebLf NCs treatment concentrations: 400 g/ml ± 76.23% ; 
800 g/ml ± 70.45 % ; 1600 g/ml ± 49.30% ; 3200 g/ml ± 4.94%. IC50 value observed for FebLf 
NCs was 1.195*104 NCs and void NCs was 6.51*104 NCs. (B) FebLf NCs dose response curve 
had been represented. *p<0.05; **p<0.005. (Student t test). (n=3). 
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 4.3.3 Tumour clonogenic cytotoxic assay 
Clonogenic formation assay results (Figure 4.12) revealed remarkable inhibition in colony 
formation efficiency in duration of 1 to 12 day time period.  A dose dependent response of 
colony growth inhibition patterns was noted in samples treated with FebLf NCs.The following 
observations were noted in terms of colony growth in the samples - Control (untreated) -  100 
(%) ± 0.5 ; void NCs (equivalent amount in concentration - 3200μg/ml FebLf NCs) - 88(%) ± 2  
; FebLf NCs treatment concentrations: 400 g/ml - 24(%) ± 3 ; 800 g/ml ± 17(%) ± 4 ; 1600 g/ml - 
6(%) ± 2; 3200 g/ml ± 2(%) ± 1. These results were in accord with our previous findings 
pertaining to remarkable colony formation inhibition capability of lactoferrin(Kanwar, 
Mahidhara & Kanwar 2011c). The capability of downscaling the clonogenic potential of FebLf 
NCs can be primarily attributed to a well known mechanism of lactoferrin (Lf) on stem cell 
signalling by modulation of STAT signalling node and activating cytokine signalling(Chang et 
al. 2012; Francis et al. 2011). Further, FebLf selectively inhibits growth factors associated 
significantly with the recurrence of cancer growth such vascular endothelial growth receptor 
(VEGF), epidermal growth factor receptor (EGFR) and fibroblast growth factor as described 
earlier (Francis et al. 2011). 
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Figure 4.12: Cytotoxicity analysis by tumour clonogenic formation assay in MDA-MB-231 
cell line treated with void NCs and FebLf NCs nanoformulation. Figure (4a) represents the 
percent tumour colony formation efficiency after nanoformulation treatments. The following 
observations were noted - Control (untreated) -  100 (%) ± 0.5 ; void NCs (equivalent amount in 
concentration - 3200μg/ml FebLf NCs) - 88(%) ± 2  ; FebLf NCs treatment concentrations: 400 
g/ml - 24(%) ± 3 ; 800 g/ml ± 17(%) ± 4 ; 1600 g/ml - 6(%) ± 2; 3200 g/ml ± 2(%) ± 1.  Figure 
(4.12b) represents the crystal violet stained colonies formation in the 6 well plate for (a) control 
(b) void NCs (c) FebLf NCs (3200μg/ml). *p<0.05; **p<0.005. (n=3). (Student t test and two 
way ANOVA) Results represented are mean±SEM.   
4.3.4 Tumour spheroid cytotoxicity assay 
Tumour spheroid assays were performed to assess the anticancer activity of FebLf NCs in a well 
established three dimensional MDA ± MB ± 231 breast cancer spheroids. Notable shrinkage in 
tumour spheroid diameter was observed as shown in Figure 4.13 in comparison with control 
spheriod within 24 hour incubation duration. Observations noted were sustainably in accord with 
our previously findings for the ability of lactoferrin for downgrading the proliferogenic potential 
of the cancer cells in a three dimensional cancer models (Katiyar & Aplin 2011; Lin et al. 2006). 
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Figure 4.13: Cytotoxicity analysis for void NCs and FebLf NCs nanoformulation in MDA-
MB-231 cell line by tumour spheroid assay formation assay. Tumour spheroid growth 
inhibition was noted with FebLf NCs treatments. Figure (4.13A) represents the inverted 
microscopic images of (a) control (untreated) tumour spheroid (b) FebLf NCs treated tumour 
spheroid. Reduction of the diameter of the tumour spheroid is noted, after FebLf NCs treatments 
with 24 hour incubation. Figure (4.13B) represents (a) control ± 100(%) ± 1.67 (b) FebLf NCs 
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treatment (3200μg/ml) - 54 (%) ± 4.3 reduction in tumour spheriod diameters.Initial spheroid 
size: 2 cm±0.3. Figure (4.13C) represents the decrease in spheroid size at different time points 
(24hrs and 48hrs) in terms of pixels (Image J software NIH,USA). *p<0.05; **p<0.005. (Student 
t test and two way ANOVA). (n=3). Results represented are mean±SEM. 
In vitro cell and molecular biology mechanism studies 
4.3.5 Mitochondrial membrane depolarisation assay 
FebLf NCs caused depolarisation of mitochondrial membrane as represented in confocal images 
with green colour signifying ruptured mitochondria and red colour representing intact 
mitochondria in comparison to the control and void NCs (Figure 4.14). A dose dependent 
depolarisation activity of FebLf NCs was observed and polarisation efficiency at 1600 μg/ml 
FebLf NCs - 15(%) ± 1 and 3200 μg / ml FebLf NCs - 6.6(%) ± 1 was observed, in comparison 
with the control (96 (%) ± 1)  and void NCs (76(%) ± 2). The observations can be attributed 
towards innate anticancer activity of FebLf mediated by generation of reactive oxygen species 
(ROS) triggering mitochondrial apoptosis(Ande & Mishra 2011; Martin, St-Pierre & Dufour 
2011; Mbeh et al. 2012). FebLf nanocapsule activity in abrogating mitochondrial signalling is 
clearly reflected in its potential to initiate apoptosis by elevation of caspase signalling 
mechanism and cytochrome C expression as noted with caspase - 3 activation and 
downregulation of survivin as confirmed by the experimental observations. Results are 
convincingly in relevance with the previous findings for the ability of FebLf loaded ACSC and 
FebLf loaded ACNC nanoformulation to selectively ablate the function of mitochondria(Kai et 
al. 2011; Kanwar, Mahidhara & Kanwar 2011c). Furthermore, critical impact of mitochondrial 
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degradation in functional modulation of anti apoptotic and pro apoptotic genes are discussed in 
later section. 
 
 
Figure 4.14: Mitochondrial membrane depolarization assay to determine mitochondrial 
activity ȥ in MDA-MB-231 cell line treated with void NCs and FebLf NCs 
nanoformulation. Mitochondrial membrane depolarisation was observed with FebLf NCs 
treatments in MDA-MB-231 cell line. Mitochondrial membrane polarisation for samples: 
Control (untreated) ± 96 (%) ± 1;  void NCs (equivalent amount in concentration - 3200μg/ml 
FebLf NCs) ± 76(%) ± 2  ; FebLf NCs treatment concentrations:400 μg/ml ± 65(%) ± 2; 800 
μg/ml ± 40(%) ± 1.5 ; 1600 μg/ml - 15(%) ± 1 ; 3200 μg/ml - 6.6(%) ± 1.FebLf NCs showed 
mitochondrial membrane depolarisation efficiency. *p<0.05; **p<0.005. (Student t test). (n=3). 
Results represented are mean±SEM. 
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4.3.6 Immunofluorescence based detection of survivin expression 
FebLf NCs caused significant downregulation of survivin expression as noted at FebLf NCs 
concentration - 1600 μg/ml and 3200 μg/ml, in comparison to control and void NCs as 
represented in confocal image and representative histogram analysis (Figure 4.15). Lactoferrin 
(Lf) was known to cause downregulation of survivin as noted earlier (Jiang et al. 2011). FebLf 
NCs downregulatory effect on survivin is reflected in its ability of triggering tumour cell 
apoptosis, causing growth inhibition as observed in observation of clonogenic potential ((figure 
4.12) and cytotoxic assay (figure 4.13)). Furthermore, the anticancer mechanism of FebLf NCs 
via downregulation of survivin expression caused escalation of myriad of apoptotic signalling 
cascades to be discussed in the later sections. 
 
 
ϭϮϳ

Figure 4.15: Immunofluorescence based determination of survivin protein expression in 
MDA-MB-231 cell line treated with void NCs and FebLf NCs nanoformulation. 
Downregulation of survivin expression was observed with FebLf NCs treatments in MDA-MB-
231 cell line. Survivin expression in the samples: Control (untreated) ± 95 (%) ± 2  ;  void NCs 
(equivalent amount in concentration - 3200μg/ml FebLf NCs) ± 75 (%) ± 3  ; FebLf NCs 
treatment concentrations: 1600 μg/ml ± 32 (%) ± 1 ; 3200 μg/ml ± 5(%) ± 1 .FebLf NCs showed 
enhanced survivin expression inhibition effect. *p<0.05; **p<0.005. (Student t test) (n=3). 
Results represented are mean±SEM. 
4.3.7 Immunofluorescence based detection of cytochrome C 
Cytochrome C is noted as a hallmark of mitochondrial apoptiosis. Upregulation of cytochrome C 
was observed with 3200 μg/ml FebLf NCs treatments (Figure 4.16).  The upregulation of  
cyctochrome C is a major land mark certifying the mitochondrial apoptosis,  as a result of 
mitochondrial membrane depolarisation as noted earlier in the Figure 4.14 (Wang et al. 
2011).Hence, release of cytochrome C, followed by mitochondrial apoptosis boosted  the anti 
cancer  functional mechanism of FebLf  NCs, modulated by shunting survivin expression, 
escalation of caspase 3 apoptosis signalling leading to derailing of  apoptotic signalling 
cascades(Yallapu et al. 2011). The crucial role played by cytochrome C in FebLf anti apoptotic 
signalling mechanism is further detailed in the discussion section. 
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Figure 4.16: Immunofluorescence based determination of cytochrome C expression in 
MDA-MB-231 cell line treated with void NCs and FebLf NCs nanoformulation. 
Upregulation of cytochrome C expression was observed with FebLf NCs treatments in MDA-
MB-231 cell line. Cytochrome C expression in the samples: Control (untreated) - 0; void NCs 
(equivalent amount in concentration - 3200μg/ml FebLf NCs)  - 18 ± 2.8 ; FebLf NCs treatment 
concentration 3200 μg/ml -  80 ± 3.6. FebLf NCs treated MDA-MB-231 cell line showed 
upregulation of cytochrome C. **p<0.005. (Student t test). (n=3). Results represented are 
mean±SEM. 
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4.3.8 Quantitative real time polymerase chain reaction (qRTPCR) analysis of FebLf NCs 
functional mechanism in MDA-MB-231 cell line. 
qRTPCR analysis revealed interesting  findings backing up the earlier observations of FebLf 
NCs anticancer signalling, cytotoxic ability and clonogenic inhibition potential of FebLf NCs.  
Cellular internalisation mechanism of FebLf NCs:  Enhanced expression of LRP1, LRP 2, TFR, 
TFR 1, TFR 2, DMT-1, ferroportin, ferritin - heavy chain and ferritin -light chain receptor genes 
was noted in response to FebLf NCs treatments incubation timings ± 12 hrs, 24 hrs and 48 hrs. 
(Figure 4.17, Table 4.1). Membrane receptors are known to play a crucial role in uptake of 
various drug molecules inside the cell. (Lin et al. 2009). These observations ponder a relative 
speculation that uptake of FebLf nanocapsules are mediated via following receptors ± LRP1, 
LRP2, TFR & TFR -1, TFR - 2 as noted for their inherent ability to transport the FebLf NCs in 
the breast cancer cells and also with respect to findings pertaining to ceramic FebLf nanocarriers 
as observed previously(Tucker 2011).  Transferrin (TFR)  receptors are  well characterized 
mainly for the metabolism of iron content and there is a compelling evidence from our 
observations that FebLf nanocapsules were uptaken in an enhanced manner, as cancer cells 
express more iron metabolism receptors(Bhaskar et al. 2010; Olakanmi et al. 2002). 
Nevertheless, there is also a notable internalisation than can be mediated via divalent metal ion 
receptors (DMT 1), ferroportin, ferritin receptors that can enable shuffling of iron ions across the 
cellular membrane. Drug internalization mechanism of FebLf NCs is mediated via cell 
membrane receptors and lactoferrin is also known to utilize the lactoferrin specific receptors. 
Iron saturated lactoferrin is quickly up taken by the metal ion specific receptors (DMT1, 
transferrin, ferritin receptors etc). FebLf follows a consistent absorption patterns and functional 
action of FebLf is tightly regulated via myriad of cell signaling molecules and FebLf is well 
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established immunomodulator, affecting a range of cytokines, macrophage and phagocyte 
signaling that lead to triggering of antitumour immune responses. Whereas, void NCs have a 
negligible functional role with respect to FebLf NCs interms of immune activity and antitumour 
responses. Hence, internalization mechanism of FebLf NCs has difference in comparision to void 
NCs (Kanwar et al. 2014) (Samarasinghe, Kanwar & Kanwar 2014) (Samarasinghe et al. 2014) 
Hence, these observations collectively provide us with a snapshot of the vivid internalisation 
mechanisms observed with FebLf nanocapsules mediated via  endocytosis, transcytosis, receptor 
mediated endocytosis with LRP 1 & 2, TFR, TFR 1&2, Lf, DMT 1, ferritin heavy and light chain 
and ferroportin receptors(Hoedt et al. 2010; Nelson 1999; Olakanmi et al. 2002). The fold 
increase of the receptor genes is denoted in Table 4.1. 
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Figure 4.17: Quantitative real time polymerase chain reaction (qRTPCR) analysis to 
determine cellular internalization mechanism mediated via cell internalization receptors in 
MDA-MB-231 cell line treated with void NCs and FebLf NCs nanoformulation. Figure 
legends detailing the treatment conditions and incubation timings (in hours): 1 - Control ; 2  - 
Void NCs - 12 hours ; 3  - FebLf NCs (400 μg/ml) ± 12 hours ;  4  - Void NCs - 24 hours ; 5  - 
FebLf NCs (400 μg/ml) - 24 hours ;  6  - Void NCs - 48 hours ; 7 -  FebLf NCs (400 μg/ml)  - 48 
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hours. FebLf NCs enhanced cellular internalisation in MDA-MB-231 was observed at 24 hour 
and 48 hour incubation time period. The fold increase in the receptor expression is summarised 
in the following table. *p<0.05; **p<0.005. (Student t test). (n=2). Results represented are 
mean±SEM. 
Table 4.1: Fold change increase in expression of cell internalisation receptors of MDA-MB-
231 cell line after 24 hour and 48 hour incubation time period. 
Receptor Fold change in 
receptor 
expression at 24 
hour incubation 
Fold change in 
receptor 
expression at 48 
hour incubation 
LRP1 45 25 
LRP2 4.3 3 
TFR 4.2 4 
TFR1 0.25 2 
TFR2 6 5.8 
DMT-1 1.25 2.2 
Ferroportin 0.2 1.2 
Ferritin ± heavy 
chain 
1 3 
Ferritin ± light 
chain 
1.2 1.6 
 
Apoptotic signalling mechanism  of FebLf NCs:  The following observations noted in case of 
anti-apoptotic genes - remarkable downregulation of survivin (6 fold decrease), livin (8 fold 
decrease), PI3K(7.5 fold decrease) and  further observation include escalating the upregulation of 
caspase  3   was noted (Geetha et al. 2011a) (Geetha et al. 2011b; Lee et al. 2009). The qRTPCR 
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analysis (Figure 4.18 ) results were conclusively in accord with the earlier observations of 
immunofluorescence experiments, caspase 3 analysis and also cytotoxic mechanisms 
propounding the significant antitumour activity of FebLf nanocapsules. These findings help us to 
conclusively draw  a concise signalling modulation map of FebLf nanocapsules in a MDA - MB 
- 231 breast cancer model to be elaborated in discussion section later and represented in Figure 
4.19 - detailing about the anti cancer signalling mechanism of FebLf nanocapsules.  
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Figure 4.18: Quantitative real time polymerase chain reaction (qRTPCR) analysis to 
determine cell apoptosis mechanisms in MDA-MB-231 cell line treated with void NCs and 
FebLf NCs nanoformulation. Apoptotic signalling mechanism of FebLf NCs was examined 
and relative gene expression was quantitated with respect to the actin expression. 
Downregulation of mRNA levels of survivin, PI3K, livin expression was observed. The fold 
decrease in the gene expression is summarised in the following table. *p<0.05; **p<0.005. 
(Student t test). (n=2). Results represented are mean±SEM. 
Table 4.2: Fold change decrease in expression of anti-apoptotic genes in MDA-MB-231 cell 
line treated with FebLf NCs.  
Receptor Fold change 
decrease of anti-
apoptotic gene 
Survivin 6 
PI3K 7.5 
Livin 8 
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Anticancer functional mechanism of FebLf NCs 
 
Figure: 4.19: Functional mechanism of FebLf NCs in MDA-MB-231 cell line. The diagram 
represents FebLf NCs functional mechanism. Cellular internalisation mechanism is mediated by 
internalisation receptors (TFR, LRP, DMT.etc) through receptor mediated endocytosis 
mechanism. Anti-cancer mechanism of FebLf NCs includes downregulation of anti-apoptotic 
molecules ± livin, PI3K,survivin, triggering mitochondrial apoptosis leading to upregulation of 
cytochrome C and Caspase 3 expression leading to tumour apoptosis.  
4.3.9 Caspase - 3 activity analysis 
Caspase  - 3 activity analysis revealed an increase in caspase - 3 levels in the supernatants of the 
FebLf NCs treated samples with the following observations -  highest being 0.25 μM of caspase - 
3 substrate activity observed in 3200 μg / ml FebLf NCs in comparison to control (0.16 μM) and 
void NCs (0.16μM) as represented in the Figure 4.20. Notable increase in caspase - 3 levels in 
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the FebLf NCs treatments conclusively prove that anticancer signalling of FebLf NCs is solely 
modulated via apoptotic signalling mechanisms.  Dose dependent increase in caspase - 3 
observations are consistent with our previous findings of FebLf and apolactoferrin ± iron free 
form (apobLf) and native lactoferrin, initiating apoptotic signalling mechanisms leading to 
increase in caspase - 3 expression ultimately triggering tumour apoptosis(Jiang et al. 2011). 
Increase in caspase 3 expression was noted in FebLf nanocapsule treated breast cancer (MDA-
MB-231) cells. Further, functional studies showed mitochondrial mediated apoptosis of FebLf 
NCs, warranting a subcellular organelle based compartmental drug delivery approach for novel 
multimodal FebLf NCs nanoformulation (Kanwar et al. 2014).     
 
Figure 4.20: Determination of caspase - 3 expression in MDA-MB-231 cell line treated with 
void NCs and FebLf NCs nanoformulation by caspase 3 activity. Caspase - 3 activity analysis 
revealed upregulation of caspase - 3 signalling mechanism with FebLf NCs treatments in MDA-
MB-231 cell ine. Caspase - 3 activity was quantitated in terms of μM/ml and following 
observations were noted - Control: 0.16± 0.0006; Void NCs: 0.16±0.013; FebLf NCs treatments 
- 1600μg/ml: 0.191±0.009; 3200μg/ml:0.25±003. *p<0.05; **p<0.005. (n=3). (Student t test) 
Results represented are mean±SEM. 
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4.4 Ex vivo intestinal loop analysis 
Ex vivo intestinal loop assay analysis confirmed remarkable uptake capability of the FebLf NCs 
in the ex vivo intestinal loop section including ileum, jejunum and duodenum of mice intestines. 
Quantified fluorescence readings obtained for successive time intervals 2,4, 6, 12 and 24 hrs as 
illustrated in the Figure 4.21 demonstrates the maximum absorption capability of FebLf NCs as 
noted in case of ileum sections,  followed by jejunum and duodenal regions of the intestine. This 
observation was in accord with the our previous studies that demonstrated the preferential uptake 
of FebLf alone,  FebLf nanodrugs,  mediated  prominently via peyer patch mechanisms, 
paracellular pathways and transcellular pathways as represented in figure 4.23 (2¶1HLOO HW DO
2011; Plapied et al. 2011; Xin et al. 2012). Furthermore, in this study attempt was made to 
uncover the selective detection of rhodamine labelled FebLf nanocapsule localisation in the 
intestinal tissue sections. The confocal microscopic images illustrated in the Figures 4.22 
represent the localisation of FebLf nanocapsules in the villi of the intestinal section during the 
transcytosis period. The maximum fluorescence intensities were observed in villi section 
followed by mucosal and serosal section of the intestinal samples as represented in the Figure 
4.22b. The basic mechanism of the transcytosis of Lf is well characterized earlier in our previous 
studies and current ex vivo analysis demonstrated the remarkable ability of FebLf nanocapsule 
uptake in intestine tissue sections. Altogether, these findings conclusively allow us to speculate 
the inherent capability of intestinal absorption patterns of  FebLf that could open new vistas for 
selective fabrication of FebLf nanocapsules for oral therapeutic delivery. Further, the preferential 
intestinal transcytosis mechanism involved in FebLf nanocapsule shipping through intestine is 
elaborated in discussion section. 
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Figure 4.21: Fluorescence spectrophotometric observations to determine the intestinal 
absorption patterns in mice intestines incubated with rhodamine labelled FebLf NCs 
nanoformulation. An increased absorption pattern was noticed in ileum sections, followed by 
jejunum and duodenum sections. Fluorescent intensities are quantified in terms of relative 
fluorescent units as represented in the graph diagram. *p<0.05; **p<0.005. (Student t test) (n=3). 
Results represented are mean±SEM. 
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Figure 4.22: Confocal microscopic based detection of rhodamine labelled FebLf NCs 
nanoformulation in mice intestinal sections. Localisation of rhodamine labelled FebLf NCs 
was observed in the intestinal section of the villi, represented with arrow marks in Figure 
(a).Figure (b) represents the intestinal absorption trends in different parts of intestinal sections - 
villi (78%±2), mucosa (50%±1), serosa(27%±2). *p<0.05; **p<0.005. (Student t test). (n=3). 
Results represented are mean±SEM. 
 
Figure 4.23: Intestinal transport mechanism of FebLf NCs in mice intestinal sections. The 
diagram illustrates the intestinal transcytosis mechanism of FebLf NCs. FebLf NCs transcytose 
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the intestine via transcellular uptake, paracellular uptake mechanism and also immune cell 
mediated uptake including macrophages and phagocytes present in the intestinal tissue. 
 
4.5 In vivo anti - tumour activity and near infrared fluorescence imaging of iron saturated 
      lactoferrin nanocapsules (FebLf NCs) in a human xenograft breast and colon cancer 
     mice model. 
The ever increasing complexity in the cancer cell signalling paradigms has hindered the current 
therapeutic regimes from effectively targeting cancer in the clinic(Lammers et al. 2012). Novel 
class of cancer therapeutics include nanotechnology based drug delivery systems can offer 
significant advantages in comparison to conventional therapeutics that can achieve diagnostic, 
therapy and imaging of cancer termed as multifunctional nanodrug systems(Kanwar et al. 
2012b). Nanomedicine enables multiplexation of the therapeutic efficacies with targeted moieties 
and ligands that can selectively ship the drug to cancer site. Furthermore, natural product derived 
therapeutic molecules such as lactoferrin, curcumin had garnered profound interest for effective 
cancer treatment, due to their advantages interms of non toxic nature, nil side effects and also 
they help in boosting the immune system of the body(Kanwar et al. 2010a; Meetoo 2013). In 
vivo studies in various animal models including colon and breast cancer, showed the 
effectiveness of nanoformulations devised with natural product therapeutics(Kanwar, Mahidhara 
& Kanwar 2012b). Our laboratory findings with nanoformulated iron saturated lactoferrin 
procured most prominent observations in terms of exhibiting anticancer activity in colon and 
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breast cancer models. Iron saturated lactoferrin is well known to exhibit its anticancer activity by 
modulation of crucial apoptotic signalling mechanisms and furthermore, it is known increase the 
cytokine, interleukin levels that help in boosting the immune system of the body(Kanwar, 
Mahidhara & Kanwar 2012b; Kanwar et al. 2008a). The lime light of current research had made 
a dramatic shift towards the development of multimodal nanomedicine based drugs inorder to 
enable the simultaneous cancer imaging and therapy(Ahmed, Fessi & Elaissari 2012). Recent 
findings were reported with respect to the lactoferrin nanotherapeutic for brain tumour imaging 
by utilisation of magnetic resonance imaging strategy(Hu et al. 2009). Near infrared cancer 
therapy and imaging studies conducted to understand the anti tumour activity of nanoformulated 
curcumin in mice models revealed selective localisation of the drugs at the tumour site and 
exhibited anticancer activity without any side effects(Yallapu et al. 2013). Current research 
studies were focussed to understand the near infrared cancer imaging and therapeutic ability of 
FebLf NCs nanoformulation in the in vivo colon (Caco2) and breast (MDA-MB-231) cancer 
models. Alginate enclosed chitosan nanogel encapsulated iron saturated lactoferrin nanocapsules 
(FebLf NCs) were fabricated and oral administration of nanocapsules were carried out in the 
tumour bearing mice models. Our observations noted that iron saturated lactoferrin preferentially 
localised at the tumour site as seen in the near infrared fluorescence imaging photographs (Figure 
± 4.30& 4.38) and exhibited anti-tumour activity. Further, ex vivo imaging analysis of vital 
organs revealed enhanced absorption patterns of  FebLf NCs at the tumour site, kidney, spleen, 
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stomach and intestine. Histopathology analysis revealed intact tissue structure of vital body 
organs and nil cytotoxic nature was observed. These observations were in accord with our 
previous findings(Kanwar, Mahidhara & Kanwar 2012b). Hence, we postulate nanoformulated 
iron saturated lactoferrin exhibited in vivo anti tumour activity in colon and breast cancer tumour 
models, showing preferential localisation at tumour site as confirmed by near infrared 
fluorescence imaging strategies. Furthermore, ongoing studies are underway to understand the 
magnetic resonance imaging ability. In conclusion, nanoformulated lactoferrin can be a safe with 
multifunctional nanomedicine its multimodal imaging and therapeutic abilities(Kievit & Zhang 
2011).              
 
4.5.1  Evaluation of in vivo nanotoxic nature of FebLf NCs in human xenograft breast and 
colon cancer models 
Studies were conducted to evaluate the nanotoxic nature of nanocapsules. The observations 
include mice weight monitoring, body condition and appearance, monitoring water and diet 
intake, natural behavioural patterns, clinical signatures concerning respiration and gait 
movements. Oral administration of the nanoformulated diet was carried out in the form of 
pellets. The diet parameters are described below in the Table 4.3. 
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Table 4.3: Description of nanoformulated diet parameters  
Diet Parameters  
Diet Name AIN93G diet 
Dosage of nanoformulation - 2.4 % w/w of FebLf NCs 
/ kg of AIN93G diet. 
- Approximate of 1011  
FebLf NCs / kg of 
AIN93G diet. 
Mode of administration Oral administration of diet in the 
form of diet pellets. 
 
Weights of the mice were routinely monitored and a consistent increase of weight was observed 
in prevention (FebLf NCs diet prevention group) and treatment (vehicle control NCs diet group; 
FebLf NCs diet treatment group) mice models. Human xenograft breast cancer: prevention 
model (n=5) showed a weight range of 20.38 ± 0.34 gm and treatment models including vehicle 
control NCs diet group(n=5) showed 22.76 ± 1.15 gm, FebLf NCs diet treatment group (n=5) 
showed 20.48 ± 2.03 gm. Human xenograft colon cancer: prevention model (n=5) showed a 
weight range of 19.32 ± 1.43 gm and treatment models including vehicle control NCs diet 
group(n=5) showed 22.56 ± 1.86 gm , FebLf NCs diet treatment group (n=5) showed 21.8 ± 1.63 
gm. These observations showed a consistent increase in the weight of mice throughout the study 
period.  
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Figure 4.24: Body weight analysis of human xenograft breast cancer model. Mice body 
weight was routinely monitored as shown in the chart. Vehicle control NCs diet group(n=5) 
showed an weight range - 22.76 ± 1.15 gm; FebLf NCs diet treatment group (n=5) showed a 
weight range - 20.48 ± 2.03 gm ; FebLf NCs diet prevention model group (n=5) showed an 
weight range - 20.38 ± 0.34 gm .  Consistent increasing trend of weight was observed. Results 
represented are mean±SEM. 
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Figure 4.25: Body weight analysis of human xenograft colon cancer model. Mice body 
weight was routinely monitored as shown in the chart. Vehicle control NCs diet group(n=5) 
showed an weight range - 22.56 ± 1.86 gm; FebLf NCs diet treatment group(n=5) showed a 
weight range - 21.8 ± 1.63 gm  ; FebLf NCs diet prevention model group(n=5) showed an weight 
range - 19.32 ± 1.43 gm. Consistent increasing trend of weight was observed. Results 
represented are mean±SEM. 
 
 
Figure 4.26:  Ex vivo weight analysis of mice body organs in human xenograft breast cancer 
model. Excised mice organs was subjected to weight analysis and all the organs as shown in the 
figure showed optimal weight patterns in vehicle control NCs diet group(n=5) and FebLf NCs 
diet treatment group (n=5). Results represented are mean±SEM. 
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Figure 4.27:  Ex vivo weight analysis of mice body organs in human xenograft colon cancer 
model. Excised mice organs was subjected to weight analysis and all the organs as shown in the 
figure showed optimal weight patterns in vehicle control NCs diet group(n=5) and FebLf NCs 
diet treatment group(n=5). Results represented are mean±SEM. 
 
4.5.2 Evaluation of in vivo anti-tumour efficacy of FebLf NCs in human xenograft breast 
and colon cancer models 
Studies were conducted to examine the in vivo anti-tumour efficacy of vehicle control NCs, 
FebLf NCs.  Routine monitoring of tumour volume was carried out as per the Deakin University 
animal ethics guide lines.  
Tumour volume monitoring in human xenograft breast cancer: prevention model - FebLf NCs 
diet prevention group(n=5) showed a tumour volume of 0.14 ± 0.11 mm3. These observations 
testify a drastic tumour growth reduction patterns in the mice. Treatment model ± vehicle control 
NCs diet group(n=5) treated mice showed a tumour volume of 50.83 ±  8.33 mm3 and FebLf 
NCs diet treatment group(n=5) treated mice showed a tumour volume of 0.053 ± 0.044 mm3. In 
comparison to the vehicle control NCs diet group, FebLf NCs diet treatment group treated mice 
showed a significant, consistent reduction in tumour volume. These observations conclusively 
establish the remarkable ability of FebLf NCs in downgrading the tumour.  
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Figure 4.28: Assessment of in vivo anti-tumour efficacy of nanoformulations in human 
xenograft breast cancer model. Tumour volume monitoring was carried out as represented in 
the chart. (1) Prevention model group (n=5) : FebLf NCs diet was given two weeks prior to the 
administering MDA-MB- 231 breast tumour cell line. FebLf NCs diet prevention group showed 
a tumour volume range - 0.14 ± 0.11 mm3. FebLf NCs pretreatment prevented tumour growth. 
(2) Treatment model group: Nanoformulated diet was given to mice at a 50 - 60 mm3 tumour 
volume range, around 52nd day. Vehicle control NCs diet group (n=5) showed a tumour volume 
range - 50.83 ±  8.33 mm3. Further, increasing trend in tumour volume was observed. FebLf NCs 
diet treatment group (n=5) showed a tumour volume range - 0.053 ± 0.044 mm3. Regression 
trend in tumour volume was observed in FebLf NCs treated mice in comparision to vehicle 
control NCs diet group. **p<0.005. (Student t test).  Results represented are mean±SEM. 
Tumour volume monitoring in colon cancer: prevention model - FebLf NCs diet prevention 
group (n=5) showed a tumour volume range of 1.8 ± 1.3 mm3. Remarkable tumour growth 
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inhibition trend was noted in prevention model. Treatment model - vehicle control NCs diet 
group (n=5) mice showed a tumour volume of 58.15 ± 14.12 mm3 and FebLf NCs diet treatment 
group (n=5) treated mice had a tumour volume range of  0.060 ± 0.044 mm3. Time dependent 
and decremental pattern in the tumour volume was noted in FebLf NCs diet administered mice, 
when compared to the vehicle control NCs diet group. The Fe-bLf NCs diet treatment was 
started on the 35th day, after reaching appropriate tumour size. Therefore, as can be seen from the 
Figure 4.29, once the mice were fed on the Fe-bLf NCs diet, it led to a remarkably significant 
downregulation in the tumour volume. The mice were fed on this diet continuously from 35th day 
until 90th day where complete regression in tumour volume was observed. Therefore, it can be 
confirmed using this study that these NCs had the potential to completely regress the tumour 
volume if fed continuously. Moreover, in the preventive studies the mice fed on the NCs diet for 
65 days did not show any tumour growth, therefore it can also be concluded that these FebLf 
NCs has potential to be used as an anti-cancer therapeutic as well as a cancer preventive 
treatment for colon cancer. Collectively, FebLf NCs exhibited consistent anti-tumour efficacy 
and nontoxic nature in colon cancer model.   
ϭϰϵ

 
Figure 4.29: Assessment of in vivo anti tumour efficacy of nanoformulations in human 
xenograft colon cancer model. Tumour volume monitoring was carried out as represented in 
the chart. FebLf NCs diet prevention group (n=5): Administration of  FebLf NCs diet was carried 
out two weeks prior to the administering Caco2 colon tumour cell line. FebLf NCs diet 
prevention group showed a tumour volume range - 1.8 ± 1.3 mm3. FebLf NCs pretreatment 
prevented tumour growth. Treatment model group: Administered of nanoformulated diet was 
carried out to mice at tumour volume range of 50 ± 60 mm3 tumour volume range, around 35th 
day. Vehicle control NCs diet group (n=5) showed a tumour volume range - 58.15 ± 14.12 mm3. 
Increasing trend in tumour volume was observed. FebLf NCs diet treatment group (n=5) showed 
a tumour volume range - 0.060 ± 0.044 mm3. Regression trend in tumour volume was observed 
in FebLf NCs treated mice in comparison to vehicle control group. **p<0.005. (Student t test). 
Results represented are mean±SEM. 
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4.5.3 Near infrared fluorescence based live mice imaging strategy in human xenograft 
breast cancer model  
Experimental studies were carried out to conduct near infrared fluorescence based live mice 
imaging by utilizing IVIS Lumina imaging system. The imaging studies were carried out as per 
the Deakin University animal ethics guidelines. The imaging parameters are described in the 
Table 4.4.  
Table 4.4: Live mice imaging parameters in human xenograft breast cancer model.  
Instrument IVIS ± 2 Lumina - Near 
infrared fluorescent live 
mice imaging system; 
Calipers life sciences. 
Imaging entity Fluorescent  FebLf NCs 
nanoformulation    
Near infrared fluorescent 
wavelength range 
 670 nm to 740 nm 
imaging range of 
fluorescent dye. 
 
Selective localization of the fluorescent FebLf NCs were observed at the tumour site in human 
xenograft breast cancer model (Figure 4.30 a&b). A time dependent, consistent decremental 
pattern of tumour volume was noted (Figure 4.30 c), as observed by the near infrared in vivo 
imaging of fluorescent FebLf NCs. The obtained images were quantified in terms of radiant 
efficiency, area (cm2), area (interms of ccd camera pixels) for graphical representation of tumour 
reduction pattern in the mice. The Figure - 4.31 represents radiant efficiency, Figure - 4.32 
represents area ( in terms of ccd camera pixels), Figure 4.33 represents - area (cm2), representing 
consistent reduction pattern of the tumour volume. Collectively, these observations show the 
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remarkable capability of fluorescent FebLf NCs for their preferential localization at the tumour 
site. Furthermore, periodic imaging observations revealed that FebLf NCs were consistently 
retained at tumour site and promoting their anti tumour activity. 
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Figure 4.30: Near infrared fluorescence based live mice imaging in human xenograft breast 
cancer model. Figure (A) and (B) - represent the selective localisation of FebLf NCs at the 
breast cancer tumour site located at the mammary pad. Figure (C) represents regression in the 
tumour volume after the treatment of mice with FebLf NCs over a time period. FebLf NCs 
localisation trend was quantified in terms of radiant efficiency to denote the anti-tumour efficacy 
of FebLf NCs in the human xenograft breast cancer model. (n=5). 
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Figure 4.31: Quantification of tumour site radiant efficiency for near infrared fluorescent 
images to determine tumour regression trend in human xenograft breast cancer model.  
Radiant efficiency at the breast cancer tumour site was quantified over a 25 day live mice tumour 
monitoring and a regression pattern of the tumour volume was noticed in terms of decreasing 
intensity of the fluorescent signal at the tumour site.(n=5).   
 
 
 
Figure 4.32: Quantification of tumour site area (in ccd pixels) for near infrared fluorescent 
images to determine tumour regression trend in human xenograft breast cancer model. 
Breast cancer tumour site area was quantified interms of ccd pixels over a 25 day live mice 
tumour monitoring and a regression pattern of the tumour volume was noticed in terms of 
decrease in intensity of area (interms of ccd pixels) of the FebLf NCs fluorescent signal at the 
breast cancer tumour site.(n=5).  
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Figure 4.33: Quantification of tumour site area (in cm2) for near infrared fluorescent 
images to determine tumour regression trend in human xenograft breast cancer model. 
Breast cancer tumour site area was quantified in terms of cm2, over a 25 day live mice tumour 
monitoring and a regression pattern of the tumour volume was noticed in terms of decrease in 
intensity of area (in terms of cm2) of the FebLf NCs fluorescent signal at the breast cancer 
tumour site.(n=5).   
 
4.5.4 Near infrared ex vivo imaging analysis for mice body organs in human xenograft 
breast cancer model. 
Ex vivo near infrared fluorescence imaging investigations of mice body organs were carried out 
to profile the biodistribution patterns of FebLf NCs. The imaging parameters were followed as 
described in the Table 4.5. 
Table 4.5: Ex vivo imaging parameters for excised mice organs of human xenograft breast 
cancer model. 
Instrument IVIS ± 2 Lumina - Near 
infrared fluorescent live 
mice imaging system; 
Calipers life sciences. 
Imaging entity Fluorescent  FebLf NCs 
nanoformulation    
Near infrared fluorescent 
wavelength range 
670 nm to 740 nm 
imaging range of 
fluorescent dye. 
 
Figure 4.34 (a,b,c) represents the biodistribution of  FebLf NCs at the tumour site, intestine, 
spleen  and kidney. Interestingly, tumoral and intestinal uptake of FebLf NCs is promoted by the 
LRP, TFR receptors as described previously. The promising observation in terms of intestinal 
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localization testify that oral administration of the FebLf NCs is more effective for their 
absorption, biodistribution mediated via receptors present in the intestine. Furthermore, splenic 
uptake of FebLf NCs was noted and can be attributed for the innate ability of lactoferrin to get 
selectively absorbed by the receptors present on the spleen or on lymphocytes. Kidney 
absorption of FebLf NCs helps in elimination of nanosystem from the reticuloendothelial system. 
The biodistribution patterns of  FebLf NCs in various mice organs are denoted in Table 4.6. 
Figure 4.35 represents the black and white photograph of the fluorescent image in the Figure 
4.34a. Interestingly, very less or sparse localization of FebLf NCs was noted in the mice organs 
as represented in the Figure 4.36. Figure 4.37 represents the black and white photograph of the 
fluorescent image of the Figure 4.36a. The biodistribution patterns of  FebLf NCs in various 
mice organs are denoted in Table 4.6.  These results uncover the multimodal imaging ability of 
FebLf NCs in terms of preferential localisation at the tumour site, contemporaneous in vivo 
cancer therapy and imaging. Further, the multifunctional ability of FebLf NCs can be improvised 
by employing aptamer, antibody and nanobody based tumour targeting strategies. 
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Figure 4.34: Near infrared ex vivo imaging analysis for mice body organs in human 
xenograft breast cancer model ± 1.  Ex vivo fluorescence imaging of mice organs was carried 
out as represented in figure (a). Localisation of FebLf NCs was noticed at the following organs ± 
tumour, stomach, spleen, kidney, and intestine. The fluorescent intensity of FebLf NCs was 
represented in terms of radiant efficiency as represented in figure (b). The image is a 
representative of the imaging analysis performed in FebLf NCs treatment model group (n=5). (c) 
Quantification of flouroscent intensities to determine biodistribution patterns of FebLf NCs in 
mice body organs: Ex vivo biodistribution analysis of FebLf NCs was quantified with radiant 
efficiency.The following organs: tumour, stomach, spleen, kidney, intestine showed localisation 
of FebLf NCs.Results represented are mean±SEM.  
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Figure 4.35: Black and white imaging analysis (for figure 4.34a) for mice body organs in 
human xenograft breast cancer model ± 1. Ex vivo black and white imaging of mice organs 
was carried out as represented in figure (a). The black and white colour scale is represented in 
the form of counts in figure (b). The image is a representative of the imaging analysis performed 
in FebLf NCs treatment model group (n=5). 
 
 
 
 
Figure 4.36: Near infrared ex vivo imaging analysis for mice body organs in human 
xenograft breast cancer model ± 2. Ex vivo fluorescence imaging of mice organs was carried 
out as represented in figure (a). Localisation of FebLf NCs was noticed at the following organs ± 
Liver and brain. The fluorescent intensity of FebLf NCs was represented in terms of radiant 
efficiency as represented in figure (b). All the other organs denoted the figure (a) showed sparse 
localisation of FebLf NCs. The image is a representative of the imaging analysis performed in 
FebLf NCs treatment model group (n=5). 
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Figure 4.37: Black and white imaging analysis (for figure 4.36a) for mice body organs in 
human xenograft breast cancer model ± 2. Ex vivo black and white imaging of mice organs 
was carried out as represented in figure (a). The black and white colour scale is represented in 
the form of counts in figure (b). The image is a representative of the imaging analysis performed 
in FebLf NCs treatment model group (n=5). 
 
Table 4.6: Bio distribution pattern of fluorescent FebLf NCs in breast cancer mice tissues. 
  
S.No Mice 
Organ 
Bio 
distribution 
pattern of 
fluorescent 
FebLf NCs in 
breast cancer 
mice tissues. 
S.No Mice Organ Bio 
distribution 
pattern of 
fluorescent 
FebLf NCs in 
breast cancer 
mice tissues. 
1 Brain 
 
2+ 8 Liver 
 
1+ 
2 Eyes 
 
- 9 Tumour 
 
3+ 
3 Heart 
 
1+ 10 Pancreas 
 
- 
4 Spleen 
 
2+ 11 Ovary 1+ 
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5 Kidneys 
 
2+ 12 Rectum 1+ 
6 Lungs 
 
1+ 13 Spinal cord 1+ 
7 Intestine 
 
3+ 14 Stomach 3+ 
 
7DEOH/HJHQG³-´ Nil; 1+ = low;  2+ = medium;  3+ = high. 
 
 
 
 
4.5.5 Near infrared fluorescence based live mice imaging strategy in human xenograft colon 
cancer model  
Near infrared fluorescence based live mice imaging was carried out to decipher the multimodal 
therapeutic ability of fluorescent FebLf NCs. The imaging studies were conducted as per the 
Deakin University animal ethics guidelines and by utilisation of IVIS lumina imaging 
system.The imaging parameters are described in the Table 4.7.  
Table 4.7: Live mice imaging parameters in human xenograft colon cancer model.  
Instrument IVIS ± 2 Lumina - Near 
infrared fluorescent live 
mice imaging system; 
Calipers life sciences. 
Imaging entity Fluorescent  FebLf NCs 
nanoformulation    
Near infrared fluorescent 
wavelength range 
670 nm to 740 nm 
imaging range of 
fluorescent dye. 
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Fluorescent FebLf NCs localisation were noted at the tumour site (Figure 4.38a & b). Near 
infrared fluorescence imaging showed that FebLf NCs exhibited a time dependent, downgrading 
pattern in tumour volume (Figure 4.38 c). Radiant efficiency of the fluorescent signal at the 
tumour site, area (in cm2) of the fluorescent signal at tumour site and area (in terms of ccd pixels) 
of the fluorescent signal at tumour site were quantitated to denote the decrease in tumour volume 
over the time period. Radiant efficiency is represented in Figure 4.39, similarly, area (in cm2) in 
Figure 4.40 and area (in terms of ccd pixels) in Figure 4.41 uncovers the tumour reduction trend.  
In summary, multimodal imaging capacity of FebLf NCs revealed tumour specific localisation, 
promising therapeutic activity as monitored by the near infrared imaging modality. Furthermore, 
tumour specific drug targeting with improved therapeutic efficiency can be achieved by 
employing combinatorial therapeutic imaging platforms including magnetic resonance imaging, 
positron emission tomography.  
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Figure 4.38: Near infrared fluorescence based live mice imaging in human xenograft colon 
cancer model. Figure (A) and (B) - represent the selective localisation of FebLf NCs at the 
colon cancer tumour site.Figure (C) represents regression in the tumour volume after the 
treatment of mice with FebLf NCs over a time period. FebLf NCs localisation trend was 
quantified in terms of radiant efficiency to denote the anti-tumour efficacy of FebLf NCs in the 
human xenograft colon cancer model.(n=5) 
 
Figure 4.39: Quantification of tumour site radiant efficiency for near infrared fluorescent 
images to determine tumour regression trend in human xenograft colon cancer model. 
Radiant efficiency at the colon cancer tumour site was quantified over a 25 day live mice tumour 
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monitoring and a regression pattern of the tumour volume was noticed in terms of decreasing 
intensity of the fluorescent signal at the tumour site.(n=5).   
 
 
Figure 4.40: Quantification of tumour site area (in ccd pixels) for near infrared fluorescent 
images to determine tumour regression trend in human xenograft colon cancer model. 
Colon cancer tumour site area was quantified in terms of ccd pixels over a 25 day live mice 
tumour monitoring and a regression pattern of the tumour volume was noticed in terms of 
decrease in intensity of area (interms of ccd pixels) of the FebLf NCs fluorescent signal at the 
colon cancer tumour site.(n=5).  
 
 
 
Figure 4.41: Quantification of tumour site area (in cm2) for near infrared fluorescent 
images to determine tumour regression trend in human xenograft colon cancer model. 
Colon cancer tumour site area was quantified in terms of cm2, over a 25 day live mice tumour 
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monitoring and a regression pattern of the tumour volume was noticed in terms of decrease in 
intensity of area (in terms of cm2) of the FebLf NCs fluorescent signal at the colon cancer 
tumour site.(n=5).   
 
 
4.5.6 Near infrared ex vivo imaging analysis for mice body organs in human xenograft 
colon cancer model. 
Biodistribution trend of FebLf NCs were evaluated by performing ex vivo near infrared 
fluorescence imaging analysis of mice body organs. The following imaging parameters were 
described in the below Table 4.8. 
Table 4.8: Ex vivo imaging parameters for excised mice organs of human xenograft colon 
cancer model. 
Instrument IVIS ± 2 Lumina - Near 
infrared fluorescent live 
mice imaging system; 
Calipers life sciences. 
Imaging entity Fluorescent  FebLf NCs 
nanoformulation    
Near infrared fluorescent 
wavelength range 
670 nm to 740 nm 
imaging range of 
fluorescent dye. 
 
FebLf NCs biodistribution were noted at the following organs: tumor site, intestine, spleen and 
kidney as represented in the Figure 4.42. Tumour site specific localisation and increased 
intestinal uptake of FebLf NCs is significantly mediated via following receptors including LRP, 
TFR, Lf receptors that are located on their surface. Furthermore, iron metabolism and iron 
ϭϲϰ

specific receptors such as DMT-1, ferroportin, ferritin receptors play a crucial role in absorption 
of  FebLf NCs. FebLf  NCs  retention was detected in the spleen and can be due to the presence 
of iron specific receptors, spleenic macrophage receptors that increasingly promote the uptake of  
FebLf NCs. Kidney absorption of  FebLf NCs show that FebLf NCs are easily eliminated 
through the system without causing toxicity in the mice body. Figure 4.43 represents the black 
and white photograph of the fluorescent image of the Figure 4.42a. Interestingly, sparse 
biodistribution of  FebLf NCs was noted in the organs represented in the figure 4.44. Figure 4.45 
represents the black and white image of the figure 4.44a. The biodistribution patterns of  FebLf 
NCs in various mice organs are denoted in Table 4.9. 
 
 
Figure 4.42: Near infrared ex vivo imaging analysis for mice body organs in human 
xenograft colon cancer model ± 1. Ex vivo fluorescence imaging of mice organs was carried out 
as represented in figure (a). Localisation of FebLf NCs was noticed at the following organs ± 
ϭϲϱ

tumour, stomach, spleen, kidney, and intestine. The fluorescent intensity of FebLf NCs was 
represented in terms of radiant efficiency as represented in figure (b). The image is a 
representative of the imaging analysis performed in FebLf NCs treatment model group (n=5). 
 
 
 
Figure 4.43: Black and white imaging analysis (for Figure 4.42a) for mice body organs in 
human xenograft colon cancer model ± 1. Ex vivo black and white imaging of mice organs was 
carried out as represented in Figure (a). The black and white colour scale is represented in the 
form of counts in Figure (b). The image is a representative of the imaging analysis performed in 
FebLf NCs treatment model group (n=5). 
 
ϭϲϲ

 
Figure 4.44: Near infrared ex vivo imaging analysis for mice body organs in human 
xenograft colon cancer model ± 2. Ex vivo fluorescence imaging of mice organs was carried out 
as represented in Figure (a). Localisation of FebLf NCs was noticed at the skin. The fluorescent 
intensity of FebLf NCs was represented in terms of radiant efficiency as represented in Figure 
(b). All the other organs denoted the Figure (a) showed no localisation of FebLf NCs. The image 
is a representative of the imaging analysis performed in FebLf NCs treatment model group 
(n=5). 
ϭϲϳ

 
Figure 4.45: Black and white imaging analysis (for Figure 4.44a) for mice body organs in 
human xenograft colon cancer model ± 2. Ex vivo black and white imaging of mice organs was 
carried out as represented in Figure (a). The black and white colour scale is represented in the 
form of counts in Figure (b). The image is a representative of the imaging analysis performed in 
FebLf NCs treatment model group (n=5). 
 
Table 4.9: Bio distribution pattern of fluorescent FebLf NCs in colon cancer mice tissues. 
S.No Mice 
Organ 
Biodistribution 
pattern of 
fluorescent FebLf 
NCs in colon 
cancer mice 
tissues. 
S.No Mice 
Organ 
Biodistribution 
pattern of 
fluorescent FebLf 
NCs in colon cancer 
mice tissues. 
1 Brain 
 
2+ 8 Liver 
 
1+ 
2 Eyes 
 
1+ 9 Tumour 
 
2+ 
3 Heart - 10 Pancreas 1+ 
ϭϲϴ

  
4 Spleen 
 
3+ 11 Ovary 1+ 
5 Kidneys 
 
3+ 12 Rectum - 
6 Lungs 
 
- 13 Stomach 3+ 
7 Intestine 
 
2+ 
 
7DEOH/HJHQG³-´ Nil; 1+ = low;  2+ = medium;  3+ = high. 
 
4.5.7 Haematoxylin and eosin staining for determination of tissue integrity in human 
xenograft colon cancer mice tissues 
Histopathology analysis of FebLf NCs administered mice tissues were carried out by 
haematoxylin and eosin staining, to determine the tissue integrity and nanotoxic effect. Intact 
configuration of mice tissue sections were observed in colon cancer tissue sections. Figure 4.46 
represents H and E staining images of colon cancer of mice tissue sections ± tumour, 
brain,intestine, liver, heart, lungs, kidney, ovary. Relatively, undamaged tissue structure was 
noticed, retaining original intact tissue configuration. Hence, no cytotoxic nature of 
nanoformulation was observed in the Figure 4.46. 
 
ϭϲϵ

 
 
Figure 4.46: Haematoxylin and eosin staining for colon cancer mice tissue sections.H and E 
staining of mice tissue sections are represented. Intact structural configuration of the tissues was 
noted at the following organs ± (a) tumour tissue section (20μm,100X), (b) brain tissue section 
(20μm, 20X), (c) intestine tissue section (10μm, 10X), (d) liver tissue section (10μm, 10X), (e) 
ϭϳϬ

heart tissue section (20μm, 10X), (f) lung tissue section (10μm, 10X), (g) kidney tissue section 
(20μm, 10X). (h) ovary tissue section (20μm, 10X).(n=3). 
 
4.5.8 Eosin staining for determination of red blood cell morphology of human xenograft 
breast and colon cancer model. 
Eosin staining of the mice blood smears was carried out to determine the integrity of the blood 
cell morphology. Red blood cells present in abandunce in the smear are known to take the eosin 
stain and appear pinkish red colour. Intact red blood cell morphology was observed in (a) RBC 
of colon cancer mice blood smear and (b) RBC of breast cancer mice blood smear. This shows 
that FebLf NCs enhance the red blood cell production, by activating the innate immune system 
and helpful in combating cancer.(Figure 4.47). 
  10X 
Figure 4.47: Eosin staining to examine red blood cell morphology of human xenograft colon 
and breast cancer model. Eosin staining of RBC cells was carried out and an intact, healthy 
RBC configuration was noted. Figure (a) represents RBC of colon cancer mice blood smear and 
figure (b) represents RBC of breast cancer mice blood smear.(n=3).Inverted microscope images 
were obtained at 10X magnification. 
 
ϭϳϭ

4.5.9 Quantitative real time polymerase chain reaction (qRTPCR) analysis to determine 
receptor based internalisation mechanisms of FebLf NCs in human xenograft colon cancer 
mice tissues. 
qRTPCR analysis of receptor based internalisation mechanism was studied in the human 
xenograft colon cancer mice tissues. Prominent receptors that are noted to be involved in 
internalisation mechanism of FebLf NCs are ± LRP1, LRP2, ferroportin, ferritin receptors. 
Tumour cells are well characterised to possess the following receptors: LRP receptors that help 
in successive absorption of lactoferrin molecule and FebLf(Hu et al. 2009). Ferroportin and 
ferritin receptors that play a crucial role in iron absorption and metabolism(Dunn, Rahmanto & 
Richardson 2007). Various studies had successfully established that body organs including ± 
brain, eye, heart, intestine, spleen, kidney, liver are well established to possess the crucial 
membrane receptors - LRP1, LRP2, Ferroportin, Ferritin ± light chain receptor(Dunn, Rahmanto 
& Richardson 2007; Kakhlon, Gruenbaum & Cabantchik 2001). The experimental findings 
revealed that FebLf NCs internalisation in the mice body organs are well mediated via the above 
membrane receptors. The following observations were noted in terms of receptor expression in 
mice tissues of FebLf NCs treated group and are represented as relative gene expression in terms 
of 2 delta cT values with respect to vehicle control treated group mice tissues. 
Table 4.10: Relative gene expression of receptors genes in the colon cancer mice tissues. 
Mice 
tissue 
LRP 2 LRP 1 Ferroportin Ferritin - L Ferritin - H 
Tumour 0.036 ± 0.0071 0.055 ± 0.0057 0.959 ± 0.008 0.014± 0.00018 15.65± 1.376 
ϭϳϮ

Brain 10.254 ± 7.306 15.21± 0.216 12.48± 1.494 7.044 ± 0.483 46.726 ± 3.493 
Eye 2.486 ± 1.943 0.056± 0.024 0.732± 0.00917 1.934± 0.132 0.332± 
0.22921 
Heart 2.600± 2.101 0.093± 0.034 0.633± 0.184 24.23± 6.01 8.058± 5.333 
Intestine 0.816± 0.25 1.330± 0.0316 0.736±0.009 1.587± 0.013 12.470 ±5.786 
Spleen 0.305±0.128 0.177± 0.040 0.060± 0.0032 0.701±0.0071 5.983± 0.2531 
Kidney 0.869± 0.175 1.538± 1.114 0.588± 0.123 5.36 ± 0.151 42.36± 6.093 
Liver 0.0827 ±  
.0116 
0.309± 0.0199 0.0481 ± 0.0032 0.0269 ± 0.0017 0.931± 0.095 
  
 
ϭϳϯ

 
 
ϭϳϰ
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Figure 4.48: Quantitative real time polymerase chain reaction (qRTPCR) analysis for 
determination of receptor based internalisation mechanisms of FebLf NCs in human 
xenograft colon cancer mice tissues. qRTPCR analysis of mice tissues revealed that FebLf NCs 
internalisation were crucial by cell membrane receptors ± LRP2, LRP1,Ferroportin,Ferritin ± 
heavy chain and Ferritin ± light chain. Table 4.10  represents the relative gene expression in 
terms of 2 delta cT values with respect to vehicle control treated group mice tissues. *p<0.05; 
**p<0.005. (Student t test) (n=2). Results represented are mean±SEM. 
 
 
ϭϳϱ
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Figure 4.49: Agarose gel electrophoresis for qRTPCR products to examine receptor based 
internalisation mechanisms of vehicle control NCs and FebLf NCs in human xenograft 
colon cancer mice tissues. Agarose gel analysis of qRTPCR products to examine receptor based 
internalisation mechanisms of vehicle control NCs and FebLf NCs showed the gel bands of 
internalisation receptors in the mice tissues. 
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4.6 Discussion 
SEM and DLS observations (Figure 4.2 & 4.3) revealed a unique homogeneous size range of 50 
- 80 nm with exact spherical morphology. Pertaining to these findings, the small size of FebLf 
NCs enhances its ability for greater cellular internalisation as seen in the internalisation patterns 
represented in the Figure 4.9 & 4.10. Furthermore, smaller size of FebLf NCs enabled to exhibit 
its enhanced superparamagnetic ability(Figure 4.6) in relevance to the observations established 
earlier echoing the increase in superparamagnetic property is substantially dependent on its size 
confirmation(Cengelli, Voinesco & Juillerat-Jeanneret 2010; Kanwar, Mahidhara & Kanwar 
2009). 
Optimal zeta potential values of around +37 mv was observed,  promoting FebLf NCs as a 
suitable nanoformulation for drug delivery applications with its equal dispersive nature in 
colloidal solutions and having very less aggregation. The observed zeta potential further enables 
us to formulate combinatorial therapeutics such as silencing RNA (siRNA), aptamers 
conjugation to FebLf NCs for more targeted drug delivery application. 
FTIR findings (Figure 4.4) clearly establish successful formulation of the FebLf NCs with 
protein specific NH3 bonding observations in between ± 1100-1 to 1600-1 wavelength range and 
OH bonding patterns between:1600-1 to 2000-1 wavelength range. These observations 
articulatively echo the active functional confirmation of the protein and the protein confirmations 
remains unaltered in its nanoformulatory form(Gupta & Curtis 2004; Iafisco et al. 2011). 
Furthermore, iron saturation enabled to increase the stability of the protein, conferring 
protection. Fe ± O bonding observations noted in the FTIR  spectrum confirm the conjugation of 
iron with the lactoferrin in the form of a nanoformulation(García-Montoya et al. 2012).  
ϭϳϳ

XRD analysis spectrum represents the crystal structure stability and integrity of the FebLf NCs 
with respect to void NCs. The Bragg¶s reflection peaks as observed in case of  FebLf NCs 
spectrum, convincingly correlate with the peak patterns of the void NCs (Figure 4.5). These 
findings conclusively signify that the crystal structure pattern and crystal integrity is consistently 
maintained even in  FebLf nanoformulation. The peak patterns observed in FebLf nanocapsules 
echo the amorphous crystal nature of the FebLf nanoformulation, that can be aptly suitable for 
drug delivery applications and also enhances FebLf NCs for up gradation as magnetic 
therapeutic with its remarkable superparamagnetic ability. 
Remarkable superparamagnetism of FebLf NC at saturation magnetism in range of 20 to 80 
emu/g with -30000 to + 30000 H(Oe) range as noted in the Figure 4.6  and a relative 50-80nm 
small size range of FebLf nanocapsules as noted in SEM and DLS observations (Figure 4.2 & 
4.3), makes it more superparamagnetic(Cengelli, Voinesco & Juillerat-Jeanneret 2010; Lin et al. 
2009). These findings promote FebLf nanocapsules as the most suitable agent for the 
development as a cancer nanotheranostic,  making it widely suitable for MRI contrast imaging, 
magnetic guided therapy for targeted drug delivery applications conquering the platform of  
multimodal cancer therapeutics(Chang et al. 2012). 
pH dependent drug release profile of FebLf NCs as shown in the  Figure 4.7  signifies a 
consistent release patterns over a 72 hour time period and is very much pH dependent. FebLf 
NCs release is initiated in a time dependent manner and burst release was observed, followed by 
sustained release over a 72 hr time period and drug release for individual time points was 
represented. This helps FebLf in activating the immune signalling mechanisms like macrophages 
, pro inflammatory cytokines enabling multitasking of  FebLf in rejunuvating immune system 
when utilised in a combinatorial treatment strategy such as magnetic guided therapy and 
ϭϳϴ

photodynamic laser thermal ablation(Kanwar et al. 2008a). Pertaining to the pH dependent 
release, an enhanced release patterns of FebLf was observed at intestinal pH ranges of 7 and 9 in 
comparison to acidic pH 2.  Hence, these findings can enable us to effectively upgrade FebLf 
nanocapsule nanoformulatation for  oral anticancer therapeutic and more specifically for colon 
cancer therapeutics due to innate property of lactoferrin and FebLf to get absorbed more 
thoroughly through the intestinal tissues as observed in our earlier findings(Kanwar et al. 2008a). 
However, additional biocompatible polymeric coatings can be devised for FebLf nanocapsules 
aiming for more fine tuning of the pH dependent release patterns. Altogether, these observations 
summate a consistent pH dependent release observations that can improve functional half life of 
FebLf and moreover specifically at intestinal pH ranges that can help to upgrade FebLf 
nanocapsules as a safe oral anti cancer therapeutic.  
The confocal microscopic (Figure 4.9) analysis of FebLf NCs unanimously reported the 
enhanced time dependent internalisation patterns as observed. Furthermore, 
immunocytochemistry (Figure 4.10) detection of lactoferrin not only confirms the internalisation 
efficiency, but also lactoferrin was noted in a functionally active confirmation, promoting 
apoptotic signalling mechanisms. The mechanism of internalisation of FebLf NCs was majorly 
dependent on receptor mediated endocytosis pertaining to the previous observation of lactoferrin 
(Lin et al. 2009; Mohanty et al. 2011). qRTPCR  analysis (Figure 4.17) confirmed an enhanced 
increase in LRP ± 1 & 2  receptors in FebLf NCs treated MDA ±MB ± 231 cell lines(Figure 4.17 
and Table 4.1). These findings are consistent with the earlier observations that lactoferrin 
internalisation was prominently mediated by LRP receptors. Inturn, FebLf NCs cellular uptake 
can also be mediated by its own lactoferrin receptors as that prevail in abundance in tumour 
tissues (Lin et al. 2009). However, earlier findings reported lactoferrin is also internalised via 
ϭϳϵ

transferrin receptor (TFR1, TFR2), iron transporter molecules (ferritin, ferroportin) over 
expressed in cancer cells. In accord with these findings, transferrin receptors(TFR, TFR 1, TFR 
2), ferroportin, ferritin showed an increase in its expression certifying its role internalisation 
(Figure 4.17 and Table 4.1)(Li et al. 2012). In its expression, lactoferrin also showed  a vivid 
internalisation mechanisms, Nevertheless, FebLf NCs being a combinatorial molecule, there is 
also incessant possibility of FebLf NCs uptake to be mediated via a divalent metal transporter 
proteins(DMT 1)(Olakanmi et al. 2002). Research studies confirmed that metal binding proteins 
are preferentially transhipped across the cell membrane. Hence, there is definitely a possibility 
that DMT1, FST molecules also play their part in migration of FebLf into the cells and thereby 
enhanced expression in DMT-1 was noticed as represented in Figure 4.17 and Table 4.1 
(Hohnholt, Geppert & Dringen 2011). Sideways, a relatively novel class of macrophage 
receptors also known to play a role in transport of lactoferrin molecule. The key mechanism 
behind the macrophage can certainly a boon for the  FebLf NCs to enable its direct delivery at 
tumour site and further activating immune signalling cascades, justifying its role as 
multifunctional molecule(Kanwar et al. 2008a). Altogether, the above mentioned findings 
coherently echo the most diverse and vivid internalisation patterns of FebLf NCs involving a 
myriad of cell signalling receptors, showing an enhanced time dependent internalisation 
maintaining  FebLf NCs in its functionally active confirmation in MDA ±MB -231 cancer cells 
in order to modulate prominent apoptotic signalling mechanisms. 
Cytotoxic effect of FebLf NCs in MDA-MB-231 two dimensional breast cancer cell model 
revealed remarkable dose dependent proliferation inhibition ability as represented in CyQuant 
cell proliferation analysis in the Figure 4.11. These observations are consistent with our previous 
findings as seen in case of ACSC FebLf and ACNC FebLf nanoformulations(Kanwar, 
ϭϴϬ

Mahidhara & Kanwar 2012b), prompting FebLf NCs as an effective anticancer agent(Kanwar, 
Mahidhara & Kanwar 2012b). Further, it was important to uncover the long term of effect of 
FebLf NCs in a three dimensional tumour environment. Hence, the cytotoxic efficacy of FebLf 
NCs in clonogenic formation assay and tumour spheroid assay was assessed as discussed in next 
section. 
Remarkable colony formation inhibitory effect of FebLf NC was observed as shown in Figure 
(4.12a) and Figure 4.12b  illustrates not only reduction in formation of no of colonies to 98 % 
inhibition rate with respect to controls,  but also the dramatic reduction in average diameter of 
size of colonies were observed. These observations are particularly in favourable accord with our 
earlier observations noted in case of both in in vitro, in vivo cancer studies and tumour reduction 
efficiency of ACNC and ACSC encapsulated lactoferrin and with FebLf protein its self (Kanwar, 
Mahidhara & Kanwar 2012b; Kanwar et al. 2012b). The noted colony inhibition capability of 
FebLf NCs can be attributed for its increased bioavailability in the cellular environment, 
modulating critical signalling mechanisms pertaining to angiogenesis(Chang et al. 2012). 
Pertaining to the above observation, downregulation in expression of survivin was noted in 
qRTPCR analysis as represented in Figure 4.18. EGFR and survivin are known to play a critical 
role in stem cell angiogenic signalling mechanisms in a three dimensional tumour 
microenvironment(Jiang & Lönnerdal 2012).  Hence, FebLf mediated abrogation of the critical 
angiogenic signalling modules including survivin, EGFR, hypoxia, HSP90.etc  can certainly 
trigger a cytotoxic effect particularly in relevance to stem cell markers that enable long term 
colony formation capability(Jiang & Lönnerdal 2012; Jiang et al. 2011). Hence, adhering to the 
observed results, we were able to conclusively chart a notion that FebLf NCs  cytotoxic effect in 
ϭϴϭ

abrogating colony formation of tumour cells can be certainly related to the effect of lactoferrin 
on stem cell signalling mechanisms(Iigo et al. 1999).  
Inaccord with the above investigations, the observations noted in tumour spheroid assay clearly 
signify the cytotoxic effect of FebLf NCs in a three dimensional tumour environment. 
Substantial reduction in the size of the tumour spheroids was observed as illustrated in the Figure 
4.13. The functional mechanism of FebLf NCs in triggering the depreciation in spheroid 
diameters is certainly attributable for innate modulatory effect of lactoferrin on stem cell and 
metastatic signalling modules leading to the overall reduction in levels of survivin, livin, PI3K as 
observed in experimental findings in Figures 4.18 and also other relevant tumour biomarkers 
hypoxia, HSP90, PI3/AKT, MAPK etc as reported by other investigators (Geetha et al. 2011a) 
(Geetha et al. 2011b). 
FebLf  NCs cellular internalisation was mediated by a myriad of receptor mediated endocytosis 
mechanisms involving  LRP1 & 2 , TFR1 & 2, Lf receptors and divalent metal transporter 
receptors such as DMT1, DMT2, FST, NMRF macrophage as detailed in internalisation section 
earlier(Kunzmann et al. 2011; Tucker 2011). Apart from all these mechanisms, there is a certain 
possibility of FebLf uptake to be mediated via pinocytosis mechanisms, due to its relative small 
size (50 - 80 nm) of FebLf NCs and also clathrin pit mediated endocytosis mechanisms as 
reported(Kunzmann et al. 2011). 
Following endocytotic internalisation mechanisms, FebLf is released from the endocytic vesicles 
due to pH variations in the cytoplasmic component in the cells. FebLf triggered rupture of the 
mitochondrial membrane orchestrating significant depolarisatory effect as illustrated in the 
Figure (4.14)  in green colour representing destroyed mitochondria in a articulative dose 
ϭϴϮ

dependent fashion(Kai et al. 2011; Martin, St-Pierre & Dufour 2011). Further, prominent release 
of cytochrome C in the cytoplasmic pool was observed as illustrated in Figure 4.16  
strengthening the phenomenon of mitochondrial apoptosis(Ande & Mishra 2011). Following 
initiation of mitochondrial apoptosis, a myriad of apoptotic signalling cascades were activated - 
including  regression in survivin, livin, PI3K expression as noted in qRTPCR analysis (Figure 
4.18), comphrending the mitochondrial rupture. This also led to downregulation of survivin, as 
represented in Figures (4.15 and 4.18) (Figuerola et al. 2010; Yallapu et al. 2011) . Survivin is 
one of the nodal anti apoptotic signalling molecule triggering cloudistic derailing of  major 
apoptotic signalling mechanisms.  Hence, FebLf inhibitory effect on survivin expression can be 
majorly exploited towards potentiating its multifaceted role with targeted drug delivery strategies 
(magnetic guided therapy, photodynamic laser ablation therapy etc), that can enable concomitant 
activation of preferent immune signalling cascades, resurgence of apoptotic pathways ultimately 
promoting anti angiogenic effect in tumours(Kumar et al. 2010). With the manifestation of 
relative downregulation of prominent anti-apoptotic molecules as mentioned above, downstream 
caspase signalling cascades including caspase - 3 showed upregulation, establishing a cytotoxic 
effect on MDA ±MB -231 breast cancer cells(Baumrucker et al. 2006). Apart from the above 
mentioned molecules, FebLf  NCs can significantly effect other nodal cell signalling circuitries 
such as PI3/AKT , hypoxia, HSP90 etc as reported earlier with mechanism particularly  in 
relevance to lactoferrin anticancer signalling mechanisms(García-Montoya et al. 2012). With 
respect to our earlier findings with regards to  Lf, FebLf, ACSC FebLf, ACNC FebLf  
nanoformulations and the current discussed experimental observations,  we can possibly 
speculate the modulatory effect of FebLf in inhibiting stem cell signalling paradigms as observed 
in case of clonogenic  assay (Figure 4.12 ) reflecting the remarkable colony inhibition ability and 
ϭϴϯ

reduction in size of tumour spheroids (Figure 4.13)(Francis et al. 2011; Kanwar, Mahidhara & 
Kanwar 2012b). 
Taken together, the above discussed appreciative anticancer signalling mechanism of FebLf NCs 
is mediated via apoptotic pathways. Further, in vivo investigations to delineate the functional 
mechanism of FebLf NCs in modulation of crucial apoptotic signalling cascades, stem cell 
signalling and metastatic ability are under consideration. 
Ex vivo intestinal loop analysis revealed a remarkable uptake pattern of FebLf NCs in different 
parts of intestinal segments including duodenum, jejunum and ileum (Figure 4.21, 4.22, 
4.23)(Kanwar et al. 2008a). Relative small size of  FebLf NCs had enabled efficient uptake with 
in 1hour duration and maximum absorption was noted in ileum sections followed by jejunum and 
duodenum (Figure 4.21). These observations pertaining to intestinal uptake of FebLf NCs are 
aptly in accord with our previous ex vivo findings (Kanwar, Mahidhara & Kanwar 2012b; Xin et 
al. 2012). Basic uptake mechanism is mediated through the well known peyer patch uptake of Lf 
in the intestinal layers. Peyers patches are known to exhibit more LRP receptors that can mediate 
enhance absorption capability(Norris, Puri & Sinko 1998). Moreover, the mucoadhesive nature 
of  FebLf  NCs can enable more stronger  interaction of positive charge of iron with the negative 
charge of the mucus. Hence, the positive and negative charge interactions among  FebLf NCs 
and mucus layer respectively can promote more stronger bonding between them, enabling 
increased uptake in the intestinal tissue layer(das Neves et al. 2011). The basic mechanism 
pertaining to transport of FebLf  NCs through the intestine is illustrated in the Figure 4.23, 
detailing about transcytosis mechanisms including  LRP, DMT receptors in the intestinal 
layers(Chen et al. 2011). Apart from this, paracellular transport is also known to play a major 
role in side wise distribution of the FebLf NCs in the intestinal layer as illustrated in the Figure 
ϭϴϰ
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4.23 (Plapied et al. 2011). Furthermore, surface coatings by muco adhesive biocompatible 
polymers can mediated more faster uptake enabling stronger surface charge interactions between 
nanoformulations and intestinal layers(Soares, Carvalho & Veiga 2007). The confocal 
microscopic observations reveal the localisation of  FebLf NCs in the intestinal tissue sections 
seen in villi sections as represented as red fluorescence in Figure 4.22 (Jin et al. 2012). 
Altogether, the ex vivo analysis showed that FebLf NCs are enchantingly uptaken by intestinal 
tissues without being damaged. Hence, these observations can foresee the upgradation of  FebLf 
NCs as a safe anticancer oral therapeutic. Further, in vivo studies to delineate intrinsic 
mechanisms of intestinal uptake and absorption kinetics are under progress.  
 
In vivo anti - tumour activity and near infrared fluorescence imaging of iron saturated 
lactoferrin nanocapsules (FebLf NCs) in a human xenograft breast and colon cancer mice 
model. 
The study was conducted to evaluate the multifunctional ability of FebLf NCs in targeting cancer 
and its use as therapeutic imaging agent at the tumour site. It is a well-established fact that, 
lactoferrin is a prominent anticancer molecule for its multimodal ability in targeting the cancer 
cell signalling, there by shunting down tumourigensis(Yang et al. 2002). The immunomodulatory 
activity of lactoferrin helps to activate the immune cells including interleukins, cytokines, 
macrophage signaling, that inturn help in causing tumor apoptosis(Varadhachary et al. 2004; Yao 
et al. 2013). Our laboratory studies revealed that iron saturated form of lactoferrin has a 
remarkable anticancer ability, activates immune system. In vitro and in vivo studies have shown 
the antitumor activity and augmentational therapeutic role of FebLf in combination with the 
chemotherapeutic regime(Gibbons, Kanwar & Kanwar 2011). Results confirmed that FebLf play 
ϭϴϱ
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a significant role in activation of immune cells including NK cells, IL -18, TNF-Į DFWLYDWLRQ
macrophages enabling boosting of immune system in evading tumor xenografts, there by 
promoting therapeutic augumentation  along with taxol treatment regime (Kanwar, Mahidhara & 
Kanwar 2012b; Kanwar et al. 2008a). In order to achieve an increase in biodistribution, 
therapeutic half life prolong activity of FebLf, nanoformulated lactoferrin was 
fabricated(Kanwar et al. 2012b). The ceramic ±polymeric nanoconjugates: FebLf - calcium 
phosphate chitosan nanocarriers were evaluated for in vitro and in vivo anticancer activity in 
colon and breast cancer models. Interestingly, FebLf nanocarriers executed the remarkable 
ability in modulation of cancer signalling mechanism by abrogating survivin, VEGF expression 
and thereby activating downstream caspase signalling cascades potentiating tumoral 
apoptosis(Kanwar et al. 2012a). The current work deals with the fabrication of  Nanocapsules -
FebLf NCs and to uncover the multimodal action in targeting cancer and to evaluate its 
nanotheranostic ability by near infrared florescence imaging strategies to monitor the tumour. 
FebLf nanocapsule formulation was prepared as described in the methods section, by slight 
modifications as per earlier protocol. N and C terminal sections in the structural confirmation of 
lactoferrin has the ability to bind reversibly with two iron molecules based on chemical bonding 
interactions including polypeptide chain ligands (tyrosine, histidine and aspartic acid) and also in 
presence of carbonate and bicarbonate ions.Hence, iron saturated lactoferrin was prepared and 
further proceeded for polymeric based nanoencapsulation. Chitosan coating of FebLf was carried 
out by utilization of sodium tripolyphosphate (STTP) as a cross linking agent, reacting with 
positively charged amine group in chitosan by electrostatic interactions.Further, alginate gel 
nanoencapsulation of chitosan coated FebLf was initiated in the presence of Cacl2  by ionic 
gelation technique.Hence, fabrication of multimodal FebLf nanocapsule nanocarriers was carried 
ϭϴϲ
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out (Kanwar et al. 2014) (Samarasinghe et al. 2014) (Samarasinghe, Kanwar & Kanwar 2014). In 
vivo colon and breast cancer studies were carried out to access the tumorigenic ability of 
nanocapsules. Breast cancer (MDA-MB-231) and colon cancer (Caco2) is the most prevalent 
type of epithelial cancers leading to further tumour metastasis. Our previous laboratory findings 
with respect to FebLf NCs revealed antitumour activity and hence, novel multimodal FebLf NCs 
were examined as a proof of concept studies for anticancer activity along with near infrared 
fluorescence imaging strategies. Further, FebLf NCs promising warrant for conducting 
nanotheranostic  investigations in wide range of cancers including brain cancer, lung cancer etc 
(Kanwar et al. 2014). Oral administration of nanoformulated diet to the tumour bearing mice 
proved to be more efficient.Consistent increase in weight was observed in the vehicle control 
NCs and FebLf NCs diet. Furthermore, the mice appeared to be more healthier, active in FebLf 
NCs administered diet group. Improved body score conditions were noted with increase in 
weight, active behaviour and normal diet and water intake trend.  Collectively, these findings 
summate the absolute nontoxic nature of FebLf NCs diet with anti-tumour activities. These 
findings certainly warrant the promising approach of oral administration of nanoformulated 
lactoferrin and were in accord with our earlier findings (Kanwar, Mahidhara & Kanwar 2012b; 
Kanwar et al. 2008a; Kanwar et al. 2012b). In vivo antitumour efficacy of FebLf NCs was 
observed in human xenograft colon cancer model in comparison of the vehicle control NCs. A 
time dependent decrease in trend of tumour volume was noted in case of orally administered 
FebLf NCs treated mice. Whereas, vehicle control NCs administered mice showed in initial 
stabilization of tumour growth for a time period. Further, an increase in tumour volume was 
evident. Similarly, the oral administration of vehicle control NCs in the human xenograft breast 
cancer model initially slowed down the tumour growth significantly till third week, in turn an 
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
incremental trend in the tumour volume was observed till 90th day. The observation noted with 
respect to the vehicle control may be due to temporary generation of reactive oxygen species,  
free radicals, however vehicle control NCs in vivo retention is considerably less due to 
elimination of control NCs by reticuloendothelial system and macrophage, phagocytic immune 
cell detection in the body (Samarasinghe, Kanwar & Kanwar 2014) (Kanwar et al. 2014). 
Interestingly, a remarkable downsizing of tumour volume was clearly noted in case of mice 
administered with FebLf NCs diet. Collectively, these findings unravel the promising in vivo 
antitumour efficacy of FebLf NCs in both breast and colon cancer models. The above mentioned 
observations were in accordance with our earlier findings with respect to the anticancer activity 
of lactoferrin, iron saturated lactoferrin and nanoformulated lactoferrin(Kanwar, Mahidhara & 
Kanwar 2012b). The oral administration of vehicle control NCs, FebLf NCs showed no signs of 
biotoxicity. Mice were in healthy condition without any signs of weight loss, hairloss, dizziness. 
These studies further warrant for the development of oral natural product derived anticancer 
nanoformulations with no toxicity, biocompatible, that can exhibit multifunctional therapeutic 
possibilities(Huang et al. 2010). Lactoferrin is known to undergo receptor mediated endocytosis 
promoted by the cell membrane receptors including lactoferrin (Lf), transferrin (TFR, TFR 1, 
TFR 2), LRP 1, LRP 2 receptors(Steegmann-Olmedillas 2011). Various mice body tissues 
including tumour, brain, heart, liver, lung, kidney, spleen, pancreas, intestine are known to 
express lactoferrin (Lf), transferrin (TFR, TFR 1, TFR 2), LRP 1, LRP 2 receptors(Grey et al. 
2004; Suzuki, Shin & Lönnerdal 2001). Tumour cells are well characterized for their abundant 
expression of previously mentioned internalisation receptors -lactoferrin (Lf), transferrin (TFR, 
TFR 1, TFR 2), LRP 1, LRP 2 receptors(Herbison et al. 2009). Iron metabolism receptors play a 
crucial role in regulating and metabolisation of iron in the body(Ahmad et al. 2012; Wang et al. 
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
2011). DMT-1 receptor is a crucial iron transporter protein, mediating iron uptake like other 
divalent ions such as zinc, magnesium, calcium. Iron specific receptors including ferritin - heavy 
and light chain, ferroportin receptors are significantly expressed on the tumour cells(Evans, 
Kong & Hider 2012). DMT-1, ferritin, ferroportin mediate the iron uptake by catalyzing the 
ferric form of iron into ferrous form, thereby promoting and regulating iron metabolism in the 
body(Steegmann-Olmedillas 2011). In vivo cancer studies carried out to delineate the 
internalisation mechanism of FebLf NCs revealed that lactoferrin internalisation was 
prominently mediated via - lactoferrin (Lf), transferrin (TFR, TFR 1, TFR 2), LRP 1, LRP 2 
receptors. In accord with earlier observations, quantitative real time polymerase chain reaction 
analysis reveals that receptor mediated internalisation of FebLf NCs was crucially mediated by 
myriad of internalisation receptors in human xenograft colon cancer model(Iigo et al. 1999; 
Kurmi et al. 2011). The present experimental findings uncover that, the following receptor 
expression:lactoferrin (Lf), transferrin (TFR, TFR 1, TFR 2), LRP 1, LRP 2 receptors, DMT-1, 
ferritin ± heavy chain, ferritin ± light chain, ferroportin was noticed and their expression patterns 
are represented in Table 4.10. These findings confirm that, FebLf NCs internalisation mechanism 
is promoted via cell membrane receptors. During the NCs preparation, Free Fe-bLf was removed 
post centrifugation and washing steps. Therefore, no free Fe-bLf was present in the NCs 
suspension. Oral drug delivery of FebLf NCs exhibited consistent release of FebLf and further, 
polymeric coatings including chitosan, alginate surrounding FebLf dissolute themselves and 
protect the drug from the harsh acidic and alkaline environment conditions in digestive system. 
Hence, sustained presence of FebLf in the systemic circulation enables the activation and 
increase in expression of cell membrane receptors leading to internalization of the drug. Further, 
continuous oral feeding of FebLf nanocapsules in the in vivo colon and breast cancer models 
ϭϴϵ

showed increase in expression of lactoferrin,LRP receptors, transferrin, ferritin receptors 
(Kanwar et al. 2014). Apart from this, due to the smaller size of FebLf NCs, internalisation can 
also be triggered by other internalisation mechanisms including pinocytosis, enhanced 
permeation and retention effect of tumour blood vessels(Camp et al. 2013; Legrand et al. 2004). 
The multifunctional nanotherapeutics that enable simultaneous cancer therapy and imaging are in 
lime light of anticancer research(Ahmed, Fessi & Elaissari 2012). Near infrared fluorescence 
imaging of fluorescent FebLf NCs revealed tumour specific localisation in both human xenograft 
breast and colon cancer mice model. The observations confirm that prolonged retention of FebLf 
NCs at the tumour site was evident(Kievit & Zhang 2011). Furthermore, the Figure representing 
the fluorescent images were quantified in terms of radiant efficiency and area (cm2, ccd pixels). 
These observations unravel multimodal nature of FebLf NCs for their ability in preferential 
localisation at the tumour site, with prolonged antitumour activity, enabling simultaneous cancer 
therapy and disease monitoring(Ashokan et al. 2013; Chiang et al. 2013). Fluorescent signals 
from FebLf NCs localized at the tumour site was quantified in terms of radiant efficiency that 
represents FebLf NCs distribution patterns.  Ex vivo near infrared fluorescence imaging of vital 
organs in both colon and breast cancer models showed prominent localization of FebLf NCs at 
the tumour site, intestine, kidney, spleen and stomach. Oral administration of nanoformulated 
FebLf is very effective, escaping the acidic environment of the digestive system (Ensign, Cone & 
Hanes 2012; Hayes et al. 2006b). Polymeric coatings such as chitosan  and alginate protect the 
iron saturated lactoferrin and improve its activity(Ensign, Cone & Hanes 2012). Enhanced 
tumoral, intestinal uptake of FebLf NCs is promoted by receptors, correlating with qRTPCR 
analysis of in vitro and in vivo observations. Spleen uptake of FebLf NCs is essential for 
activation of immune system. FebLf NCs are taken up by macrophage receptors localized at 
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spleen surface. This leads to activation of macrophages, recruitment of cytokines, interleukins 
and trigger the activation of immune system and localized at the tumour site promoting immune 
activation for engulfing the tumour cells and abdoning the tumour growth(Kanwar et al. 2008a). 
Kidney absorption is further important for the biocompatible nature, removal of the residual NCs 
from the body system. This supports the biocompatible, nontoxic nature of nanocapsules(Kanwar 
et al. 2012a). Interestingly, very less or sparse localization of FebLf NCs was observed at the 
following organs: liver, eye, heart, brain, rectum, ovary, lungs, limbs, bone, muscles, skin. These 
promising observations speculate the potential of FebLf NCs towards the targeted cancer 
therapy(Prabhakar et al. 2013). Further, FebLf NCs targeted tumour site can be improved by 
improvising with target specific ligands such as aptamers, nanobodies, antibody and siRNA 
technology(Diou, Tsapis & Fattal 2012).  
Histopathology analysis was conducted with haematoxylin and eosin staining and findings 
revealed the intact structural configuration of mice tissues, no abnormality and no inflammation 
noted in the tissues. This shows that FebLf NCs are nontoxic, exhibit compatible nature(Kanwar 
et al. 2008a). FebLf NCs showed no effect on the other tissues by specific localization at the 
tumour site. Hence, these observations pave way for the development of multimodal 
nanocapsules that can be employed for contemporaneous therapy and imaging by NIRF, MRI, 
PET, SPECT(Davis et al. 2013; Wang et al. 2012). In conclusion, FebLf NCs nanoformulation 
showed remarkable in vivo antitumor efficacy, nontoxic, multimodal imaging by NIRF in breast 
and colon cancer models. 
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4.7 Conclusion and future challenges 
In conclusion, fabrication of novel eco friendly natural product derived FebLf NCs therapeutic. 
FebLf NCs exhibited relatively size range of 50 - 80 nm with remarkable superparamagnetism 
and enhanced preferential uptake  mechanism mediated via LRP, TFR1&2, DMT-1, ferritin, 
ferroportin  receptor mechanisms demonstrated by qRTPCR analysis(Figure 4.18). Research 
findings from our laboratory uncovered the stability profile of FebLf and nanoformulated FebLf. 
The shelflife and storage of freeze dried samples of FebLf showed stability for 30 weeks and 
nanoformulated FebLf nanocarriers and nanocapsules were stable for 90 weeks. Furthermore, 
both FebLf and FebLf nanocarriers and nanocapsules exhibited stability in pH ranges ± 2,4,6,8, 
convincingly warranting for preclinical and clinical studies for development of oral delivery of 
anticancer nanotherapeutics (Kanwar et al. 2014). The cytotoxic studies including clonogenic 
formation assay and three dimensional tumour spheroid model revealed a dose dependent 
cytotoxic effect having a remarkable inhibition in clonogenic potential as noted in Figure(4.12 
a,b), and also size reduction of tumour spheroid was observed in three dimensional tumour 
spheroid model as represented in Figure(4.13a,b). The functional mechanism of action of  FebLf 
NCs was articulately uncovered by a myriad of techniques -immunohistochemical studies 
demonstrated active confirmation of protein in treated cells,  FebLf NCs selectively modulated 
the prominent apoptotic mechanisms by promoting mitochondrial membrane depolarisation 
which led to release and increase in cytochrome C levels in cytoplasm as detected in Figure 4.16.  
Further, caused mitochondrial destruction, survivin, livin, PI3K downregulation and followed by 
activation of downstream caspase - 3 signalling mechanisms (Figure 4.18, 4.20). Interestingly, 
FebLf NCs also downregulated PI3K signalling node, which is one of the key factor responsible 
for metastatic mechanism. Hence. Further in vivo studies are ongoing for uncovering  - 1. The 
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stem cell signalling and metastatic inhibition capability of FebLf NCs in relation of down 
regulation of survivin and EGFR.  2. Multimodal action of FebLf NCs that can be exploited for 
selectively diagnostic capability, therapeutic platforms and also contemporaneous imaging. 
Current studies with variants of FebLf and Lf nanotherapeutics are underway that included 
combinatorial formulation of aptamers including nucleolin and EPCAM in conjugation with 
FebLf NCs, showed enhanced in vivo anti tumour activity(Kanwar et al. 2012a; Kanwar, 
Mahidhara & Kanwar 2012b; Kanwar et al. 2010a; Kanwar, Roy & Kanwar 2011b). 
Furthermore, FebLf NCs nanotherapeutic can be developed as a magnificent multimodal 
nanotheranostic agent in association with a myriad of ultramodern imaging platforms including 
magnetic resosnance imaging (MRI), positron emission tomography(PET), single photon 
emission tomography (SPECT), magnetic guided therapy, photodynamic laser thermal ablation 
therapy(Kanwar, Kamalapuram & Kanwar 2011a; Kanwar, Mahidhara & Kanwar 2011c; 
Kanwar et al. 2012b; Kanwar et al. 2012c, 2012d). Hence, ecofriendly drug delivery systems like 
FebLf NCs discussed in this section, is in much need to be in venture with the upcoming 
technological intervention that enable modelling of multi targeted drugs for safe cancer therapy 
and imaging, thus enabling a predominant safe cure for cancer. 
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Chapter 5: Conclusion and future directions 
In conclusion, FebLf NCs was fabricated and their multimodal nanotheranostic ability was 
uncovered.  
Table 5.1: Critical observations in the research work studies 
Investigation Findings and Observation 
In vitro cellular internalisation mechanisms of 
FebLf NCs in breast cancer ± MDA-MB-231 cell 
line.  
Receptor mediated internalisation was observed. 
Receptors include ± LRP1, LRP2, TFR, TFR1, 
TFR2, DMT-1, ferroportin, ferritin ± heavy chain 
and ferritin ± light chain. 
Anti-cancer mechanism of FebLf NCs in breast 
cancer ± MDA-MB-231 cell line. 
Downregulation of survivin, PI3K, livin; 
mitochondrial apoptosis;increase in cytochrome 
C and caspase - 3 signaling mediated tumour 
apoptosis.  
Anti-tumour cytotoxic effects Tumour clonogenic inhibition potential, tumour 
spheroid growth inhibition. 
In vivo anti-tumour efficacy in human xenograft 
breast(MDA-MB-231) and colon(Caco2) cancer 
models 
Oral administration of FebLf NCs diet showed 
promising tumour prevention ability and 
remarkable tumour regression pattern observed in 
breast and colon cancer models. 
In vivo evaluation of nanotoxic nature of  FebLf 
NCs. 
Biocompatible, nil toxicity was observed. 
ϭϵϱ
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In vivo internalisation mechanisms of FebLf NCs 
in colon cancer - Caco2 cell line. 
Receptor mediated internalisation was observed. 
Receptors include ± LRP1, LRP2, ferroportin, 
ferritin ± heavy chain and ferritin ± light chain. 
Near infrared fluorescence live mice imaging of 
FebLf NCs in in vivo breast and colon cancer 
models to delineate multimodal nanotheranostic 
ability. 
Selective localization of FebLf NCs was observed 
at the tumour site, enabling continuous 
monitoring of  tumour regression patterns. 
Near infrared fluorescence ex vivo imaging 
analysis of mice organs in an in vivo breast and 
colon cancer models.  
Biodistribution of FebLf NCs was observed at 
tumour site, spleen, kidney, stomach and 
intestine. Sparse localization of FebLf NCs was 
observed at brain, liver. Other vital organs 
showed nil localization patterns. 
                              FebLf NCs exhibited multimodal onco nanotheranostic nature. 
Future directions of the research work: Delineation of multimodal imaging ability of FebLf NCs by 
employing MRI, PET,SPECT. The complete non toxic nature and immune responses of FebLf 
nanoformulation had been extensively investigated and represented in the previous findings. 
Interestingly, novel findings revealed that FebLf nanocarrier/nanocapsule had an impact on expression 
profile of wide range of interleukins (IL- 2,3,4,5,6,7,10,12,15,17,), granulocyte macrophage - colony 
stimulating factor, TGF-ȕ QLWULF R[LGH 12 )XWXUH ZRUN SHUVSHFWLYHV LQFOXGH GHVLJQLQJ RI
combinatorial FebLf immuno - nanotheranostic formulations for contemporaneous live cancer 
imaging and targeted drug delivery (Kanwar et al. 2014). Uncovering  multifunctional nanotheranostic 
nature with combinatorial strategies including photodynamic therapy, magnetic guided therapy and 
photoacoustic therapy.  
ϭϵϲ
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